Immunomodulation by NOD2/CARD15 and Vitamin D3 by Saraiva de Matos, Carina
   
 
Immunomodulation by NOD2/CARD15 
and Vitamin D3  
 
 
 
 
 
DISSERTATION ZUR ERLANGUNG DES 
DOKTORGRADES DER NATURWISSENSCHAFTEN (DR. RER. NAT.) 
DER FAKULTÄT FÜR BIOLOGIE UND VORKLINISCHE MEDIZIN  
DER UNIVERSITÄT REGENSBURG 
 
 
 
 
vorgelegt von 
Carina Saraiva de Matos 
aus Mortágua, Portugal 
im Jahr 2017
 
 
 
 
The present work was carried out from November 2013 to October 2017 at the Clinic and 
Polyclinic of Internal Medicine III at the University Hospital Regensburg. 
 
 
Die vorliegende Arbeit entstand im Zeitraum von November 2013 bis Oktober 2017 an der Klinik 
und Poliklinik für Innere Medizin III des Universitätsklinikums Regensburg. 
 
 
 
 
 
 
Das Promotionsgesuch wurde eingereicht am: 
27 Oktober 2017 
 
 
Die Arbeit wurde angeleitet von: 
Prof. Dr. Marina Kreutz 
 
 
 
 
Unterschrift: 
  ____________________________ 
 
 
 
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my parents 
Aos meus pais 
 
 I 
 
Table of Contents 
 
LIST OF FIGURES ............................................................................................................... IV 
LIST OF TABLES ............................................................................................................... VII 
LIST OF ABBREVIATIONS ............................................................................................... VIII 
1. INTRODUCTION ............................................................................................................. 1 
1.1. Hematopoietic stem cell transplantation .............................................................. 1 
1.2. Graft-versus-host disease (GvHD) ........................................................................ 1 
1.2.1. Acute GvHD (aGvHD) ................................................................................ 1 
1.2.2. Chronic GvHD (cGvHD) ............................................................................. 2 
1.3. Role of innate immune cell responses in GvHD .................................................. 3 
1.3.1. Importance of antigen-presenting cells (APCs) in GvHD ............................ 3 
1.3.1.1. Origin of dendritic cells (DCs) ................................................................. 4 
1.3.1.2. Tolerogenic dendritic cells ...................................................................... 5 
1.3.2. The role of pattern-recognition receptors in GvHD ..................................... 6 
1.3.3. NOD2 status and GvHD ............................................................................. 7 
1.3.4. Gut microbiome and GvHD ........................................................................ 8 
1.4. Role of the adaptive immune system in GvHD ................................................... 10 
1.4.1. B cells in GvHD .........................................................................................10 
1.4.2. Regulatory T cells (Tregs) in GvHD ...........................................................11 
1.5. Vitamin D .............................................................................................................. 14 
1.5.1. Vitamin D metabolism ...............................................................................14 
1.5.2. Vitamin D and immune function .................................................................16 
1.5.3. Vitamin D status and GvHD ......................................................................18 
2. RESEARCH GOALS AND OBJECTIVES .................................................................... 20 
3. MATERIAL ................................................................................................................... 21 
3.1. Equipment ............................................................................................................ 21 
3.2. Consumables ....................................................................................................... 22 
3.3. Media buffers and solutions ................................................................................ 23 
3.4. Enzymes, kits and reagents for molecular biology............................................ 24 
3.5. Chemicals for cell culture .................................................................................... 25 
3.6. Antibiotics ............................................................................................................ 25 
3.7. Oligonucleotides for qRT-PCR ............................................................................ 25 
3.8. Antibodies ............................................................................................................ 26 
3.8.1. Western blot antibodies .............................................................................26 
 II 
 
3.8.2. Flow cytometry antibodies .........................................................................26 
3.8.2.1. Anti-mouse antibodies ...........................................................................26 
3.8.3. Anti-human antibodies ..............................................................................27 
3.9. Mice ....................................................................................................................... 28 
3.10. Databases and software ...................................................................................... 29 
4. METHODS .................................................................................................................... 30 
4.1. Cell culture ........................................................................................................... 30 
4.1.1. Isolation and culture of human monocytes ................................................30 
4.1.2. Macrophage culture ..................................................................................31 
4.1.3. Dendritic cell culture ..................................................................................31 
4.1.4. Mixed lymphocyte reaction ........................................................................31 
4.1.5. Cytokine analysis from culture supernatant ...............................................32 
4.1.6. Enzymatic determination of lactate ............................................................32 
4.1.7. Analysis of the oxygen content in cultures .................................................32 
4.1.8. Sorting of CD4+25- T cells .........................................................................33 
4.1.9. Freezing and thawing of cells ....................................................................33 
4.1.10. Cell counting .............................................................................................33 
4.2. Flow cytometry ..................................................................................................... 33 
4.2.1. Compensation ...........................................................................................34 
4.2.2. Surface staining ........................................................................................34 
4.2.3. Intracellular staining ..................................................................................34 
4.2.4. Blood sample preparation for flow cytometry .............................................35 
4.3. Molecular biological methods ............................................................................. 35 
4.3.1. RNA isolation ............................................................................................35 
4.3.2. Polymerase chain reaction ........................................................................35 
4.3.3. DNA isolation ............................................................................................37 
4.4. Biochemical methods .......................................................................................... 38 
4.4.1. Protein isolation ........................................................................................38 
4.4.2. SDS polyacrylamide gel electrophoresis ...................................................40 
4.4.3. Western blot analysis ................................................................................41 
4.5. Mouse experiments .............................................................................................. 43 
4.6. Microbiota analysis .............................................................................................. 44 
4.7. Statistical analysis ............................................................................................... 44 
5. RESULTS ..................................................................................................................... 45 
5.1. Impact of NOD2 polymorphisms on the immune cell composition in 
peripheral blood of healthy donors ............................................................................... 45 
 III 
 
5.1.1. Impact of NOD2-/- on immune cell composition in mice ..............................48 
5.2. Impact of blood sampling and cell isolation method on the cell phenotype ... 49 
5.2.1. CD16 downregulation: Importance of the recognized epitope ...................51 
5.2.2. Effect of platelets and TGF-β on human monocytes ..................................52 
5.3. Impact of NOD2 on monocyte-derived macrophages ....................................59 
5.4. Impact of NOD2 on dendritic cell differentiation cultures ................................. 61 
5.4.1. Dendritic cell cultures of donors with NOD2 WT SNP8 and SNP12 and 13
 61 
5.4.2. Effect of the NOD2-ligand MDP on monocyte-derived dendritic cells ........64 
5.4.2.2. Cytokine profile of Mo-derived DC versus  MNC-derived DC .................66 
5.4.2.3. Oxygen consumption and lactate production of Mo-derived DC cultures
 67 
5.5. Impact of vitamin D3 on immune cells ................................................................ 70 
5.5.1. Effect of vitamin D3 on human monocytes ......................................................... 70 
5.5.2. Effect of Vitamin D3 on human T cells .......................................................71 
5.6. In vivo effects of vitamin D3 ................................................................................. 75 
5.6.1. Vitamin D3 sufficient versus deficient mouse model...................................75 
5.6.1.1. Impact of the serum 25(OH)D3 level on immune cell composition ..........77 
6. DISCUSSION & PERSPECTIVES ................................................................................ 83 
6.1. Impact of the NOD2 status on immune cell composition in human blood ....... 83 
6.1.1. Role of NOD2 in myeloid cell differentiation ..............................................84 
6.1.1.1. NOD2 status and dendritic cell differentiation/maturation .......................84 
6.1.1.2. NOD2 status and macrophage differentiation ........................................85 
6.1.2. Regulation of CD16 ...................................................................................86 
6.1.3. Role of NOD2 for monocyte activation ......................................................86 
6.1.3.1. Impact of NOD2 on NF-κB signalling .....................................................87 
6.1.4. Role of NOD2 ligands for cell activation and differentiation .......................88 
6.2. Role of vitamin D3 on immune regulation ........................................................... 90 
6.2.1. Effect of vitamin D3 on human T cells ........................................................91 
6.2.2. In vivo effects of vitamin D3 on mice ..........................................................93 
6.3. Impact of vitamin D3 on microbiota ..................................................................... 95 
6.4. Perspectives ......................................................................................................... 96 
7. SUMMARY ................................................................................................................... 99 
8. ZUSAMMENFASSUNG .............................................................................................. 101 
9. REFERENCES ............................................................................................................ 104 
PUBLICATIONS ................................................................................................................ 118 
ACKNOWLEDGMENT ....................................................................................................... 119 
 IV 
 
List of Figures 
 
Figure 1.1. The three phases of GvHD…………………………………………...……..........2 
Figure 1.2. Structure of NOD2/CARD15………………………………………………...…..…7 
Figure 1.3. Development of nTregs and iTregs…………..………………………………….11 
Figure 1.4. Vitamin D metabolism…………………………….…………………………........15 
Figure 1.5. Effects of 1,25(OH)2D3 in various immune cells………………………….…….17 
Figure 5.1. Impact of NOD2 SNP mutations on the blood cell composition of healthy 
donors…………………………………..……………………………………………..…...........46 
Figure 5.2. Amount of CD4+, and CD4+CD25+ and CD8 + T cells among living CD3+ cells 
in the blood of WT and donors with NOD2 variants…………………………………….….46 
Figure 5.3. Amount of myeloid and plasmacytoid dendritic cells among living lineage 
negative HLA-DR+ cells in the blood of WT, SNP8, 12 and 13 healthy donors…………47 
Figure 5.4. Amount of CD33+ cells among living leukocytes in the blood of WT, SNP8, 12 
and 13 healthy donors …………………………………………………………………….......48 
Figure 5.5. Impact of NOD2 expression on myeloid blood cells of WT and NOD2-/- 
mice.................................................................................................................................49 
Figure 5.6. Median fluorescence intensity (MFI) of CD14+16+ monocytes among living 
CD33+ cells in the blood of WT, SNP8, 12 and 13 healthy 
donors…………………………………………………………………………….…………….50 
Figure 5.7. Impact of the blood collection method on CD16 expression 
………………..…………………………………………………………………………………..51 
Figure 5.8. Relative CD1 expression on monocyte using different antibody clones……52 
Figure 5.9. Percentage of CD14+ CD16+ WT monocytes co-cultured with platelets or 
TGF-β………………………………………………………………………………………..…...53 
Figure 5.10. Percentage of CD14+CD16+monocytes stimulated with or without MDP, 
TGF-β or LPS…………………………..……………………………………………………….54 
Figure 5.11. Percentage of CD14+ monocytes stimulated with or without MDP, TGF-β or 
LPS………………………………………………………………………………….…….……..55 
Figure 5.12. Percentage of HLA-DR+ monocytes stimulated with or without MDP, TGF-β 
or LPS ……………………………………………………….……………………….…….......55 
 V 
 
Figure 5.13. Cytokine secretion in monocytes stimulated with or without MDP, TGF-β and 
LPS or LPS+MDP……..…………………………………………………………………….…57 
Figure 5.14. Effect of NOD2 mutations on iκBβ and phospho p38 
expression……......................................................................................................………58 
Figure 5.15. Expression of maturation markers in monocyte-derived macrophages from 
donors with NOD2 WT and NOD2 variants. …………………………………………........60 
Figure 5.16. SNP13 donors displayed an impaired DC maturation……………….…...…62 
Figure 5.17. IL-10 production is similar in cultures from WT and NOD2 SNP 
donors…….......................................................................................................................62 
Figure 5.18. SNP12 and 13 donors showed enhanced activation in classical 
DCs..................................................................................................................................63 
Figure 5.19. IL-10 and IL-12 production is impaired in cultures from NOD2 SNP 
donors……………………………………………………………………………………….......64 
Figure 5.20. MDP is incapable to induce the differentiation of human monocyte-derived 
dendritic cells (Mo-DCs).………………………………......................................................65 
Figure 5.21. Expression of tolerogenic DC markers after culture with LPS, MDP and 
1,25(OH)2D3………..........................................................................................................66 
Figure 5.22. IL10 and IL-12 secretion dendritic cells generated under different protocols. 
……………………………..…………………………………………………………………......67 
Figure 5.23. Oxygen consumption and lactate production of the Mo-derived DCs ……..68 
Figure 5.24. Functional analysis of the generated DCs ……………………………….......69 
Figure 5.25. Amount of FOXP3+ CD4+ cells after co-culturing with DCs matured either 
with MDP or LPS ……………………………………………………………………………….70 
Figure 5.26. NOD2 mRNA expression in human monocytes………............…………......71 
Figure 5.27. Amount of FoxP3+ cells and cell proliferation in CD4+ T cell cultures. 
…………………………………………………….………………………………….………......72 
Figure 5.28. . FOXP3 induction by 1,25(OH)2D3 and 25(OH)D3 in comparison to TGF-β 
…………………………………………………..……………………………………………......73 
Figure 5.29. FOXP3 mRNA expression is increased upon TGF-β + 1,25 (OH)2D3 
treatment …………………………………………...……………….………………………......73 
Figure 5.30. Amount of 1,25(OH)2D3 in the culture supernatant of human CD4+ T cells. 
…………………………………………….……………………………………………………....74 
 VI 
 
Figure 5.31. Cytokine profile of CD4+25- T cells stimulated with TGF-β, 25(OH)D3 or 
1,25(OH)2D3. 
………...............................................................................................................................75 
Figure 5.32. Serum vitamin D3 levels of BALB/c mice and CD1 mice at the age of 10 
weeks…………………………………………………………….…………….………..….......76 
Figure 5.33. Immune cell composition of BALB/c and CD-1 mice ………..……….…......77 
Figure 5.34. Analysis of immune cell subpopulations in the blood, spleen and bone 
marrow of BALB/c and CD-1 mice .......................................................................………79 
Figure 5.35. Analysis of immune cell subpopulations in the blood, spleen and bone 
marrow of BALB/c and CD-1 mice……………………………………..…………………….80 
Figure 5.36. Mice fed a vitamin D3 deficient diet have higher microbiota 
diversity…………………………………………………………………………………...…...…81 
Figure 5.37. The ten most abundant bacterial genera in mice stool samples..................82 
 
 VII 
 
List of Tables 
 
Table 1.1. Properties of both natural and induced regulatory T cells………………….….12 
Table 4.1. Elutriation parameters and cell types…………………………………………….29 
Table 4.2. Criteria for primer design……………………………………….………………….35 
Table 4.3. Reaction mix used in qRT-PCR……………………………….………………….36 
Table 4.4. Program used for qRT-PCR…………………….……………...………...……….36 
Table 4.5. Buffer A composition……………………….………………………………………37 
Table 4.6. Buffer B composition…………………………...…………………………………..38 
Table 4.7. Buffer C composition……………………………………...………………….........38 
Table 4.8. SDS sample buffer composition…………………………….…………………….38 
Table 4.9. SDS-PAGE stock solutions……………………………………………...………..39 
Table 4.10. SDS-PAGE gel mix solutions……………………….………………….………..39 
Table 4.11. Required buffers and solutions for SDS gel preparation……………….….....39 
Table 4.12. Western blot buffers………………………......................………………………41 
Table 4.13. Composition of ECL solutions…………………………….……………………..41 
 
 VIII 
 
List of Abbreviations 
 
aGvHD  acute Graft versus Host Disease 
ANOVA  Analysis of variance 
APCs  Antigen presenting cells 
APS  Ammonium persulfate 
BM  Bone Marrow 
CARD  Caspase Recruitment Domain 
cDNA  complementary DNA 
cGvHD  chronic Graft- versus -Host Disease 
CTLA4 Cytotoxic T-lymphocyte-associated Protein 4 
DAPI  4',6-diamidino-2-phenylindole 
DAMPs Danger associated molecular patterns 
Def. Deficient 
DNA Deoxyribonucleic acid 
DCs  Dendritic cells 
DMSO  Dimethyl sulfoxide 
dNTPs  2'-deoxyribonucleosid-5'-triphosphate 
dsDNA  Double stranded DNA 
ECL  Enhanced chemiluminescence 
ECP  Extracorporeal Photophoresis 
EDTA  Ethylene diamine tetra acetic acid 
ELISA  Enzyme-linked immunosorbent assay 
FCS  Fetal calf serum 
Foxp3  Forkhead Box Protein 3 
GI Gastro intestinal 
GM-CSF  Granulocyte -monocyte colony-stimulating factor 
GvHD  Graft versus Host Disease 
GvL  Graft versus Leukemia 
Gy  Gray 
HANK´s BSS Hank´s buffered saline solution 
HLA  Human Leukocyte Antigen 
HRP  Horse radish peroxidase 
HSCs  Hematopoietic Stem Cells 
HSCT  Hematopoietic Stem Cell Transplantation 
IDO  Indoleamine 2,3-dioxygenase 
 IX 
 
IFNγ  interferon gamma 
Ig  Immunoglobulin 
IL  Interleukin 
iTregs  induced Tregs 
IκB  Inhibitor of kappa B 
KDa Kilodalton  
LCs Langerhans cells 
LPS  Lipopolysaccharide 
MALDI-TOF matrix-assisted laser desorption/ionization-time-of-flight 
MDP Muramyl Dipeptide 
MDSC Myeloid-derived suppressor cells 
MHC  Major Histocompatibility Complex 
mRNA  messenger RNA 
NF-κB  Nuclear factor κB 
NK  Natural Killer 
NKT  Natural Killer T cell 
NOD2  Nucleotide oligomerization domain 2 
nTregs  natural Tregs 
PAMP  Pathogen associated molecular pattern 
PBS  Phosphate buffered saline 
PBSC  Peripheral Blood Stem Cells 
PCR  Polymerase chain reaction 
PRR  Pathogen recognition receptor 
qRT-PCR  Quantitative real-time PCR 
RNA  Ribonucleic acid 
RT  Room temperature 
rRNA  ribosomal RNA 
s.e.m  standard error of mean 
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SNP  Single nucleotide polymorphism 
Suf. Sufficient 
TBI  Total Body Irradiation 
TBS  Tris buffer saline 
TBST  TBS + Tween 20 
TCR  T Cell Receptor 
TGF  Transformation Growth Factor 
TLR  Toll Like Receptor 
 X 
 
TNF  Tumor Necrosis Factor 
Tregs  Regulatory T cells 
UV Ultraviolet 
 
 
 
Introduction 
1 
 
1. Introduction 
 
1.1. Hematopoietic stem cell transplantation 
Hematopoietic stem cell transplantation was originally conceived more than 60 years ago 
as a therapeutic option for irradiation injury. Later, this procedure was adopted as a 
method for treating several disorders, namely cancers and autoimmune diseases [1].  
There are different types of hematopoietic stem cell transplantation (HSCT): Autologous, 
where the patient´s own stem cells are transplanted; allogeneic, using stem cells from a 
donor and syngeneic, where cells from an identical twin are used [2]. 
One of the most common complications after allogeneic HSCT (aHSCT) is the 
development of Graft-versus-host disease (GvHD). 
1.2. Graft-versus-host disease (GvHD) 
GvHD is still the most common life-threatening complication associated with HSCT[3]. It 
was first observed in 1956 in a murine model, where Barnes et al. demonstrated that 
irradiated mice which were infused with allogeneic bone marrow and spleen cells, 
recovered from irradiation injury and marrow aplasia but additionally developed several 
complications like diarrhea, weight loss and skin changes, due to a “secondary disease”. 
This condition was later recognized as Graft-versus-host disease [4]. GvHD can be 
considered both acute and chronic, depending on the timing of its occurrence. 
1.2.1. Acute GvHD (aGvHD)  
Acute GvHD generally occurs before day 100 after HSCT, but may also occur later. It is a 
reaction of donor immune cells against host tissues and affects the skin, liver, and 
gastrointestinal tract [5]. 
The pathophysiology of aGvHD is often described as a three-step process where the 
innate and adaptive immune system interact (Figure 1.1). In the first step, tissue damage 
occurs as a result of conditioning, releasing danger signals which induce pro-
inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1β). 
This in turn leads to the activation of host antigen presenting cells (APCs). The activated 
APCs then stimulate donor T cells in the second step, also known as afferent phase. 
These T cell responses depend on the disparity between donor and recipient e.g. 
regarding human leucocyte antigen (HLA) or minor antigens. 
In the last phase, or efferent phase, both innate and adaptive immune cells work 
synergistically to exacerbate T cell induced inflammation. Microbial products like 
lipopolysaccharide (LPS) leak through the damaged epithelium and continue to stimulate 
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mononuclear cells (monocytes, macrophages) leading to the release of inflammatory 
cytokines. As a result, further destruction of epithelial cells occurs especially in the 
gastrointestinal (GI) tract [4, 6]. 
1.2.2. Chronic GvHD (cGvHD) 
Chronic GVHD was initially defined as “late” GvHD syndrome that appears more than 
100 days post-transplant, either as an extension of aGvHD (progressive onset GVHD), 
after a disease-free interval (quiescent cGvHD), or without preceding aGvHD (de novo 
cGvHD) [7]. 
The pathophysiology of cGvHD is poorly understood; therefore it remains one of the most 
significant complications of long-term survivors after aHSCT [8].  
The absence of reliable animal models hampers the experimental study of this condition, 
although in the last decades some theories attempt to explain the pathophysiology of 
cGVHD: (1) thymic damage and the defective negative selection of T cells, (2) regulatory 
T cell deficiencies, (3) auto-antibody production by aberrant B cells, and (4) the formation 
of profibrotic lesions [9]. 
 
Figure 1.1. The three phases of aGvHD, according to Ferrara et al [6]. In phase I, chemotherapy or 
radiotherapy as part of transplant conditioning causes host tissue damage and release of inflammatory cytokines 
such as TNF, IL-1β, and IL-6, with resulting priming of host antigen-presenting cells (APCs). In phase II, host 
APCs activate mature donor cells, which then proliferate and differentiate. Release of additional effector 
molecules, such as TNF and IL-1β, mediates additional tissue damage. Lipopolysaccharide (LPS) that has leaked 
through damaged intestinal mucosa triggers further TNF production. The TNF can damage the tissue directly by 
inducing necrosis and apoptosis in the skin and gastrointestinal tract through either TNF receptors or the Fas 
pathway. TNF plays a direct role in intestinal GVHD damage, which further amplifies the damage in the skin, liver, 
and lung in a “cytokine storm.” The process culminates in death of host cells through CD8
+
 cytotoxic T cell-
mediated apoptosis. 
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1.3. Role of innate immune cell responses in GvHD 
1.3.1. Importance of antigen-presenting cells (APCs) in GvHD 
Many cell types, including both hematopoietic and non-hematopoietic cells (e.g. 
endothelial cells), participate in the process of antigen presentation with distinct levels of 
efficiency. Hematopoietic APCs include B cells, monocytes, macrophages, as well as 
myeloid and plasmacytoid dendritic cells (pDCs). Besides antigen-presentation, APCs 
also are crucially involved in the production of (inflammatory) cytokines which regulate 
GvHD development [7]. 
Naïve B cells are absent from the skin and most mucosal sites, but instead they 
recirculate between blood and the secondary lymphoid organs. Here, they pick up 
antigens through specific B cell receptors for presentation on MHC class II and become 
competent APCs on interaction with CD40L+ CD4+ T cells [8].  
Monocytes and macrophages are important players in inflammation. Their role includes 
phagocytosis, elimination of bacteria and restoration of tissue homeostasis [9, 10]. To 
fulfill their tasks, they can adopt different functional phenotypes dependent on the 
respective microenvironment [10]. Monocytes infiltrate into tissues where the polarizing 
stimuli to which they respond, result in macrophage or DC differentiation. Distinct 
macrophage and DC subsets have also been described in vitro [10-13]. Classical or M1-
activated macrophages are anti-microbial, anti-tumorigenic and pro-inflammatory. This 
M1 phenotype plays a central role in chronic inflammation and autoimmunity. In contrast, 
alternative or M2 activation by IL-4 and/or IL-13 leads to differentiation of anti-
inflammatory macrophages [10]. It is believed however, that these M1 and M2 subtypes 
represent extremes of a continuum of activation states found in vivo [7]. Monocytes and 
macrophages can also act as APCs and stimulate a secondary T cell response, but 
initiate a primary immune response in a weaker degree, which is the main function of the 
specialized APCs known as DCs. Importantly, DCs possess the capacity to pick up 
antigens in peripheral tissues and traffic to secondary lymphoid organs [14]. Therefore, 
DCs are largely effective at priming naïve T cells, although the extent to which they do so 
is greatly dependent on their origin and activation history [15]. 
Mouse studies have demonstrated that CD4+ T cell-dependent (MHC-mismatched) 
aGvHD can be induced by either host or donor APCs [16-18]. Little is known about the 
role of DCs in cGvHD because of the lack of relevant mouse models. Both host and 
donor APCs have been implicated; skin cGvHD can be induced by either donor or host 
APCs, whereas donor APCs are dominant in intestinal cGvHD [19].  
Generally, T cells have been the primary focus in the development of GvHD, but given 
the important role of DCs in its pathogenesis, APCs also represent an important target. 
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DCs could be manipulated using multiple approaches in vivo or in vitro, and the 
generation of tolerogenic DCs (tDCs) could be an interesting approach to regulate 
immunity and suppress GvHD [20]. 
1.3.1.1. Origin of dendritic cells (DCs) 
DCs were first described in the mid-1970s by Ralph Steinman, who observed in the 
spleen a subpopulation of cells with a remarkable dendritic shape. It was soon 
appreciated that these cells existed in all lymphoid and most non-lymphoid tissues [21]. 
They are the most potent APC of the immune system and they are termed professional 
APC as a result of their exclusive ability to capture and to present antigens to naïve T 
cells. 
They are part of the myeloid lineage of hematopoietic cells and arise from a precursor 
that can also differentiate into monocytes [22]. 
Although they share many common features, DCs are a heterogeneous cell population. 
Various cytokines and transcription factors are known to be responsible for the 
development of DC subpopulations. Depending on the subpopulation and the maturation 
state of these cells, they are able to induce either a broad cytotoxic immune response or 
induce immune tolerance which is of great importance within the context of autoimmunity 
[15].  
Epithelial DCs, named Langerhans cells (LCs) are present exclusively in epithelial 
tissues (epidermis, mucosa) and they express receptors for antigen uptake, e.g. Fcγ and 
Fcε, as well as CD1a, a molecule involved in the presentation of glycolipids to T cells.  
Interstitial DCs, identified in the interstitium of most tissues, are characterized by the 
expression of CD68 and factor XIIIa, but lack LC markers. These cells display similarities 
with monocyte-derived DCs. 
Monocyte-derived DCs can be generated in vitro in the presence of IL-4 and granulocyte-
macrophage colony-stimulating factor (GM-CSF). Allegedly, in the course of inflammation 
in vivo, this type of differentiation occurs physiologically. Blood monocytes can also 
differentiate into DCs during transendothelial migration [23]. 
In the human blood, different DC subsets have been identified, namely myeloid dendritic 
cells (mDCs), characterized by the expression of HLA-DR and CD11c, and plasmacytoid 
dendritic cells (pDCs) which have a plasma cell-like morphology and lack CD11c 
expression [23]. 
Under normal (healthy) conditions, DCs exist in an immature or steady state and their 
main function is to maintain immune tolerance by keeping adaptive immune cells from 
attacking host cells that possess “self” antigens. However, if DCs encounter “non-self” 
entities in the periphery, they opsonize them, process their antigens for cross-
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presentation, migrate to the lymph nodes, and prime naïve T cells for the respective 
antigen. iDCs (immature DCs) exhibit continuous endocytic activity and therefore 
continuously present “self” antigens to T cells. Nevertheless, T cells are not polarized 
toward an effector state but are rather polarized to facilitate tolerance or 
immunosuppression. Such immunotolerance is accomplished due to the complete lack of 
stimulatory signals provided by the iDC [24]. On the other hand, when DCs encounter 
pathogens, they switch to a mature state exhibiting strong phenotypic and functional 
stimulation. Mature DCs are characterized by the high expression of costimulatory 
molecules, namely CD80, CD83 and CD86. The simultaneous presence of phenotypic 
maturation ligands and the appropriate cytokine profile of the DC (e.g. high IL-12 
secretion) helps to activate effector functions in interacting T cells, thus polarizing them 
for antigen-specific elimination of the “non-self” entity [24]. 
1.3.1.2. Tolerogenic dendritic cells 
Tolerogenic DCs are characterized by the downregulation of different costimulatory 
molecules such as CD80 and CD86 as well as the upregulation of inhibitory receptors 
like PDL-1, PDL-2, ILT3, ILT4 and TIM3. It is believed that ILT3 and ILT4 directly inhibit 
proliferation of T cells and drive FOXP3+ Treg expansion [25]. 
Tolerogenic DCs also exhibit a special cytokine profile. This type of DC produces higher 
amounts of IL-10 and reduced amounts of IL-12. As IL-12 is crucial for the induction of a 
Th1 response, tolerogenic DCs are more likely to induce the generation of Th2 cells or 
Tregs [26].  
Indoleamine 2, 3-dioxygenase (IDO), an immune checkpoint enzyme is also expressed 
by tolerogenic DCs. IDO metabolizes tryptophan to kynurenine and its expression by 
DCs has been implicated in the inhibition of T cell proliferation and survival. Furthermore, 
it has been reported that IDO expression by DCs promotes the development of Tregs 
[27].  
Tolerogenic DCs have the capability to induce long-lasting tolerance to transplanted 
allogeneic grafts and suppress the development of autoimmune diseases [28]. Hence, 
tolerogenic DCs represent a subtype of polarized DCs which inhibit immune activation. 
Diverse factors have been reported to support the generation of tolerogenic DCs with low 
antigen-presenting capability. These factors belong to different categories, such as 
cytokines (e.g. IL-10 and TGF-), vitamins (e.g. vitamin D) and drugs (e.g. 
dexamethasone or rapamycin) [29]. 
With their regulatory capacities tolerogenic DC seem to be a promising tool to mitigate 
GvHD 
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In fact, the suppression of DC function is under investigation in the prevention and 
treatment of human GvHD while ensuring the conservation of graft-versus-leukemia 
effects [19]. 
1.3.2. The role of pattern-recognition receptors in GvHD 
Specific receptors on innate immune cells, called pattern recognition receptors (PRRs), 
sense pathogen-associated molecular patterns (PAMPs), such as LPS and damage-
associated molecular patterns (DAMPs), like high mobility group box 1 (HMGB-1). 
Danger signalling is transmitted through PRRs when they bind PAMPs and DAMPs. 
Several signalling molecules, such as toll-like receptor (TLR), Nucleotide-binding 
oligomerization domain (NOD)-like receptor (NLR), and retinoic acid-inducible gene 1 
(RIG-1) signalling are recognized. 
TLRs are a family of PRRs and are expressed on a variety of cells derived from both 
hematopoietic and non-hematopoietic lineages [30]. There are several TLRs identified 
(TLR1-13) and they interact with different ligands. For example, LPS binds to TLR4 
whereas flagellin binds to TLR5.  
Another known PRR subtype refers to NLRs. These receptors are commonly expressed 
by immune cells and some non-immune cells. NOD1 and NOD2 are the most extensively 
investigated NLRs in GvHD. NOD1 and NOD2 recognize different kinds of peptidoglycan 
(PGN) fragments from the bacterial cell wall. NOD1 binds to diaminopimelate-containing 
N-acetyl glucosamine-N-acetylmuramic acid (GluNAc-MurNac) tripeptides from gram-
negative bacterial PGN, whereas NOD2 binds to muramyl dipeptide (MDP) that is 
produced by all bacteria [30]. 
Some studies have shown that TLR4 mutations lead to the reduction of GvHD risk in 
mice and humans [12, 13]. In a study using TLR4-knockout mice (TLR4-/-) as bone 
marrow and splenocyte cell graft donors or recipients, the occurrence of GvHD 
symptoms and mortality were delayed compared to wild-type (TLR4+/+) mice [12]. It has 
also been reported that TLR4 expression is upregulated in patients with cutaneous 
cGvHD [14]. Nevertheless, there are also both mice and human studies showing no 
significant impact of TLR4 mutations in the outcome of HSCT [31]. 
In the clinical setting, single nucleotide polymorphisms (SNPs) of the gene encoding 
NOD2 are associated with a higher GvHD incidence [32-34]. SNPs are defined as 
mutations with an allele frequency of at least 1% in a given population and can have 
modest biological effects [22]. NOD2 has been shown to have an inhibitory effect on 
GvHD by suppressing the function of APCs and favouring the generation of regulatory T 
cells (Tregs) [35]. 
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1.3.3. NOD2 status and GvHD 
The NOD2/CARD15 gene encodes the NOD2 protein that functions as a sensor for 
MDP. It takes part in the regulation of inflammatory responses through intracellular 
pathways involving nuclear factor κB (NF-κB) and IκB kinase [36]. 
The NOD2 protein (Figure 2) contains a series of carboxy-terminal leucine-rich repeats 
(LRR), as well as a central nucleotide-binding domain (NBD; also known as NOD 
domain). In addition, the amino-terminal domain contains tandem CARDs, which interact 
with receptor interacting protein 2 (RIP2) upon NOD2 stimulation [37]. Activation of RIP2 
leads to subsequent steps that ultimately result in activation attended by nuclear 
translocation of NF-B and transcription of its target genes [38]. 
The ligand sensing occurs at the LRR domain of NOD and the recognition of MDP is 
believed to trigger a conformational change in the protein, promoting a NBD-mediated 
oligomerization of NOD2 [39]. 
 
Figure 1.2. Structure of NOD2/CARD15 gene. NOD2 contains tandem N-terminal CARDs that interact with 
the CARD of receptor-interacting protein 2 (RIP2). NOD2 contains a central nucleotide-binding domain 
(NBD), which binds ATP and mediates NOD oligomerization and carboxy-terminal leucine-rich repeats 
(LRRs which are important for ligand sensing. Adapted from [39]. 
 
NOD2 was identified several years ago and is one of the well-studied members of the 
NLR family. Initially, NOD2 expression was reported to be relatively tissue specific and 
restricted to APCs such as monocytes, macrophages, DCs, and certain epithelial cells 
[40]. More recently, it has been reported that basal levels of NOD2 expression are 
usually quite low in other cell types (myeloblastic cells, dental pulp) but can be induced 
by a variety of inflammatory signals such as LPS), TNF-, interferon (IFN)- and 1,25-
dihydroxylvitamin D3  (1,25(OH)2D3) [40]. 
The association of SNPs of the NOD2 gene with a number of inflammatory pathologies, 
including Crohn´s disease (CD), and Blau syndrome, highlights its pivotal role in host-
pathogen interactions and the inflammatory response [41]. More than 10 years ago, 
SNPs in the NOD2 gene locus have been associated with GvHD [33, 34]. Holler et al. 
found an association between SNPs (alleles 8, 12, and 13) of the NOD2 gene in the 
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donor or host and a higher incidence of GvHD, as well as an increased transplant-related 
mortality. These results were partially confirmed by Elmaagacli et al [32] who found a 
relation between NOD2 status and outcome after allogeneic stem cell transplantation 
only if both recipient and donor carried NOD2 SNPs. Although there is still no consensus 
regarding the role of the NOD2 status with regard to the outcome of HSCT [42, 43], MDP 
sensing by hematopoietic cells seems to be of crucial importance for the intestinal 
immune homeostasis [44] and it appears that NOD2 SNPs of patients receiving aHSCT 
influence post-transplant immunity, even though the underlying mechanism is still not 
clear [45]. 
1.3.4. Gut microbiome and GvHD 
It is estimated that about one thousand microbial species live in symbiosis with the 
human gut [46]. These bacterial communities, collectively called microbiome, play an 
important role in the regulation of metabolic processes and also appear to be critical for 
the optimal function of the immune system [46]. Several studies have already 
demonstrated that particular species of microbiota can contribute to the induction of 
different immune cell types such as Foxp3+ regulatory T cells, suggesting a close 
relationship between the microbiome and the immune system [47].  
The gut microbiome is regulated by different mechanisms: On the one hand, the 
gastrointestinal epithelial barrier, in addition to its absorptive role, is involved in the 
regulation of microbial colonization and mucosal immune responses. On the other hand, 
specialized intestinal epithelial cells (IECs), such as the secretory goblet cells and 
Paneth cells, regulate bacterial species composition through the production of a mucous 
layer and the secretion of antimicrobial proteins, such as defensins. These antimicrobial 
peptides are produced by cells in the course of innate defence and serve as signals 
which initiate, mobilise, and amplify adaptive immune defences by the host. Defensins 
can be classified in two sub-families. Based on their tertiary structure, there are α- and β-
defensins. While human α-defensins are mostly expressed by neutrophils, β-defensins 
are secreted by epithelial cells of the skin and mucosae. Besides their anti-microbial 
activity, accumulating data arose in the past decade indicating that defensins have 
extended functions in human patho(physio)logy. Indeed, defensins appear as modulators 
of the adaptive immune system and angiogenesis, key mediators of wound healing and 
determinant players in male fertility [48]. 
In early studies, mice transplanted in germ-free conditions or treated with antibiotics 
developed significantly less GvHD, demonstrating a negative role for bacteria and the 
microbiome in the GvHD-related mortality [49, 50]. Also, human studies using 
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prophylactic gut decontamination demonstrated prevention in the development of aGvHD 
[51]. 
More recent studies indicate that the gut microbiome is altered after HSCT and the 
composition of the microbiome is important for transplantation outcome. Patients who 
develop GvHD have an altered microbiome, with loss of dominance of Clostridiales 
species replaced by a higher number of Lactobacillales or Enterobacteriales [47]. Results 
from a retrospective study showed that Clostridium difficile infection (CDI) is strongly 
associated with aGVHD and increased nonrelapse mortality in aHSCT patients [69]. 
Whether dysbiosis is just an epiphenomenon due to the use of antibiotics is still not clear 
but the loss of commensal bacteria correlates with GvHD severity and pathogenesis in 
human patients [52]. Furthermore, the importance of the microbiome in the setting of 
GvHD was demonstrated in animal studies [47], showing that the balance between 
specific gut bacteria plays a pivotal role in transplantation outcome. Namely, the 
expansion of Lactobacillales and loss of Clostridiales was found to be present in a GvHD 
mouse model [52]. 
The protective effect of commensal bacteria can be explained by the secretion of certain 
bacterial metabolites. In a study conducted by Reddy et al., the authors demonstrated 
that the bacterial metabolite butyrate is consistently decreased in the intestinal tissue 
after allogeneic stem cell transplantation. Butyrate is mainly produced by Clostridium, 
Eubacterium, and Butyrivibrio bacteria genera and it has been shown that butyrate 
improves intestinal epithelial barrier function, thereby mitigating GvHD [53]. Another 
possible mechanism connecting dysbiosis and GvHD is the ability of certain bacteria to 
promote T cell differentiation. For instances, Clostridiales bacteria have been reported to 
be upregulators of colonic regulatory T cells (Tregs) [54]. This may suggest that GvHD 
could deplete anti-inflammatory cell populations by reducing the abundance of 
Clostridiales. 
In line with the hypothesis that the intestinal microbial balance is of the outmost 
importance for the transplantation outcome, fecal microbiota transplantation (FMT) could 
be an option for transplantation patients. FMT refers to infusion of a fecal suspension 
from a healthy individual into the GI tract of a patient to restore “healthy” intestinal 
microbiota and cure disease [55]. In recent years, FMT has emerged as an effective 
method for the treatment of CDI. However, there is risk that fecal suspension could 
contain harmful bacteria, viruses, and parasites. An alternative solution to this problem is 
to screen the beneficial bacteria from stool and infuse these bacteria as a cocktail into 
the gastrointestinal tract [56].  
Although the importance of the gut microbiome in the regulation of the (intestinal) 
immune system is indisputable, further studies are needed to clarify the relation between 
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gut microbiome and complications after transplantation. These could pave the way for 
new therapeutic options for the prevention of GvHD. 
1.4. Role of the adaptive immune system in GvHD 
In GvHD pathophysiology, the interplay between innate and adaptive immune system is 
of utmost importance.  
After the initial response of the innate immune system to microbial products and 
molecules released by cellular damage, the adaptive immune response is initiated.  
Both donor CD4+ and CD8+ T cells have crucial roles in the pathophysiology of GvHD. 
Therefore, the most effective approach for GvHD prevention still is the depletion or 
suppression of donor T cells [57].  
However, recent animal studies suggest that B cells might also play an important role in 
the biology of GvHD [58]. Further evidence for the involvement of B cells in GvHD 
pathogenesis comes from reports of successful treatment of GvHD with B cell depletion 
therapies [59]. 
1.4.1. B cells in GvHD 
Little is known about the role of B cells in the pathogenesis of aGvHD. In mice, B cell 
depletion results in a decreased incidence of aGvHD [58]. Further support for a role of B 
cells in aGvHD comes from several recent clinical observations: Encouraged by reports 
of the effectiveness of B cell depletion in the treatment of cGvHD, Kamble et al treated 
patients with aGvHD, who were refractory to multiple immunosuppressive drugs, with 
rituximab, a chimeric monoclonal antibody directed against the B cell-specific CD20 
antigen. They reported that three patients who received rituximab showed a complete 
remission of aGvHD. Hence, B cell depletion might also be effective for the prevention of 
aGvHD. Rituximab administered as part of a myeloablative or nonmyeloablative 
conditioning regimen or given shortly before or after transplantation results in lower-than-
expected rates of GvHD [60]. 
Even though these results indicate that B cells are involved in the development of GvHD, 
most likely due to their role as APCs, other reports show that host B cells can also have 
protective effects as B cell-deficient mice experienced more severe aGvHD than wild-
type mice. In this experimental model IL-10 production by recipient B cells is responsible 
for the suppression of aGvHD [61]. 
The involvement of B cells in cGvHD seems to be more straightforward since both 
preclinical and clinical data suggest an important role of B cell dysregulation in cGvHD 
pathogenesis and treatment [35]. Post-transplant administration of rituximab appears to 
reduce the rate of cGVHD in preliminary studies [62]. 
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1.4.2. Regulatory T cells (Tregs) in GvHD  
Tregs are a subset of CD4+ T cells with immunosuppressive activity. They are 
characterized by the expression of the IL-2R α-chain (CD25) and the transcription factor 
FOXP3 [63]. However, identification of human Tregs is problematic since these and other 
markers (CD25, CTLA-4, CD127, FOXP3) seem to represent general T cell activation 
markers [74].   
Tregs are essential for the maintenance of self-tolerance, regulation of the peripheral T 
cell pool, and contribute to tolerance in solid organ transplantation and protection from 
GvHD lethality in bone marrow transplantation (BMT) models [64]. 
It is believed that there are two different subsets of CD4+ Treg cells. The natural 
occurring Tregs (nTregs) develop in the thymus. During negative selection, nTreg cells 
upregulate FOXP3 during self-antigen recognition [65]. nTreg cells are responsible for 
maintaining immune homeostasis and tolerance to self-antigen by inhibiting self-reactive 
T cells in the periphery. The other subset of CD4+ Tregs has been named “induced” 
Tregs (iTregs). These cells are generated in the periphery when conventional T cells are 
activated in the presence of TGF-β and IL-2 [66] (Figure 1.3).  
 
Figure 1.3. Development of nTregs and iTregs. Adapted from [66]. nTregs (top) differentiate from naïve 
conventional T cells to Foxp3+ Tregs in the thymus. In the periphery, natural Tregs express a number of cell 
surface markers, indicated in the box below the depiction of the natural Treg. However, none of these cell 
surface markers are unique to Tregs as they are also found on activated conventional T cells. Natural Tregs 
utilize the cytokines IL-10, IL-35 and TGFβ to exert their suppressive effects upon conventional T cells. TGFβ 
and IL-2 have also been shown to be important to the maintenance and fidelity of the Treg signature. iTregs 
(bottom) can be generated from conventional T cell precursors. Once in the periphery, naïve conventional T 
cells can be induced to become Foxp3− Tr1 cells or Foxp3+ Th3 cells via IL-10 and/or TGFβ secreted by 
APCs such as dendritic cells and macrophages. These induced Tregs share similar cell surface markers as 
natural Tregs. Foxp3+ induced Tregs can accumulate in the gut through upregulation of CCR9 and α4β7 via 
TGFβ and retinoic acid produced by CD103+ dendritic cells.  
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Induced Tregs can be also generated in vitro by activating naïve T cells with the proper 
culture conditions. T cells activated with either antigen or anti-CD3/28 beads in the 
presence of TGF-β and IL-2 are capable to up-regulate Foxp3, and also display other 
features used to characterize regulatory T cells, such as a suppressive function. 
The in vitro-generated iTregs are attractive in the clinical setting [67], since they can be 
generated in large numbers, facilitating the adoptive transfer of these cells into the 
recipients. 
The two Treg subsets differ in their main antigen specificities, in the T-cell receptor signal 
strength and also in the co-stimulatory requirements needed for their generation (Table 
1). Nonetheless, it is still not clear whether iTregs exist in vivo.  
 
Table 1.2. Properties of both natural regulatory T cells (nTregs) and induced regulatory T cells 
(iTregs). Adapted from [68].  
 nTregs iTregs (TGF-β+ IL-2) 
Principal antigen 
specificities 
Self Foreign 
Generation   
   IL-2 and TGFβ required No Yes 
   CD28-dependent Yes No 
   CTLA-4-dependent No Yes 
Maintenance   
   IL-2 and TGFβ required Yes Yes 
Stability   
   IL-6 can convert to Th17 
cells 
Yes No 
   Can block other cells from    
producing IL-17 
No Yes 
Suppression   
   IL-6 can block 
suppressive activity 
Yes No 
 
There is evidence that IL-6 is capable of converting nTregs to Th17 cells, while iTregs 
induced by IL-2 and TGF-β are resistant to this cytokine and retain their suppressive 
function at inflammatory sites. Thus, nTregs and iTregs may have different roles in the 
adaptive immune response [68]. 
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Since GvHD is characterized by the loss of tolerance and the occurrence of autoimmune 
manifestations, it seems reasonable to assume that Tregs may have a critical role in the 
pathophysiology of GvHD [67]. In fact, animal studies have already demonstrated that a 
deficiency in Tregs contribute to both aGvHD and cGvHD [69, 70]. 
Given the critical role of Tregs in maintaining tolerance, several groups postulated that 
the adoptive transfer of Tregs should ameliorate GvHD [70, 71]. The first study was 
performed in mice by Taylor et al. [70]. In this study, the authors depleted both CD4+ 
CD25+ T cells from the donor and recipient before transplantation and observed that the 
depletion of this cell population was associated with worsening of GvHD. In contrast, the 
adoptive transfer of CD4+ CD25+ nTreg cells along with the marrow graft resulted in the 
amelioration of disease. Hoffmann and co-workers [72] demonstrated that freshly 
isolated CD4+ CD25+ T cells from unprimed animals can rescue recipients from lethal 
GvHD induced by CD4+ CD25− T cells after allogeneic transplantation. That protection 
from lethality is partially dependent on IL-10 produced by transplanted CD4+ CD25+ T 
cells. 
The role of Tregs in GvHD mitigation has also been demonstrated in humans: Rezvani 
and colleagues demonstrated that a high number of CD4+ CD25+ FOXP3+ T cells in the 
donor graft were associated with a reduced risk of GvHD [73]. Also, they found that low 
nTreg counts early after aHSCT were associated with an increased risk of GvHD. 
Since one of the challenges in nTreg therapy is the reduced frequency of these cells in 
peripheral blood, there have been several attempts in order to expand this population. It 
is possible to expand nTreg cells through in vivo-stimulation of nTreg proliferation or 
through ex vivo-expansion [74] 
Based on the fact that nTregs express high levels of IL-2Rα, Kennedy-Nasser et al [75] 
treated 16 pediatric patients with ultralow doses of IL-2 three times per week, starting 
from day 7 or 30 after transplantation for 12 weeks, and they observed an increase in 
CD4+ CD25+ FOXP3+ Tregs from baseline. These cells were able to suppress 
alloreactive responses in vitro, indicating functionality.  
The first clinical trial using Tregs to suppress acute/chronic GvHD in patients was 
reported eight years ago. This “first-in-man-study” described the adoptive transfer of ex 
vivo-expanded CD4+ CD25+ CD127− Tregs in one patient with cGvHD and another with 
aGvHD after HSCT with an HLA-identical sibling donor [76] . The therapy resulted in 
significant alleviation of the symptoms and reduction of pharmacologic 
immunosuppression in the case of cGvHD, while in the case of grade IV aGvHD it only 
transiently improved the condition. Since then, several other studies have been 
conducted [77] including the use of umbilical cord blood as a source of Tregs for in vitro-
expansion [78]. 
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1.5. Vitamin D 
The classical, hormonal actions of vitamin D are related with calcium and bone 
homeostasis. Vitamin D enhances absorption of calcium in the small intestine and 
stimulates osteoclast differentiation and calcium reabsorption from bone. Furthermore, 
Vitamin D promotes mineralization of the collagen matrix [79]. 
Over the last decade it has become evident that the role of Vitamin D in human health is 
not limited to bone homeostasis. Several studies have already suggested that Vitamin D 
deficiency is associated with the development of cardiovascular diseases, various types 
of cancer and autoimmune disorders, such as type 1 diabetes mellitus (T1D), multiple 
sclerosis (MS) and inflammatory bowel disease (IBD) [80]. 
With the finding that the Vitamin D receptor (VDR) and enzymes important in Vitamin D 
metabolism such as 1-α-hydroxylase (CYP27B1) are expressed in different cell types like 
epithelial cells, and cells of the immune system, the interest of studying the impact of this 
hormone raised, particularly in the field of human immunology. 
1.5.1. Vitamin D metabolism 
There are three possible sources of vitamin D: nutritional, UVB-dependent endogenous 
production and supplements. 
In humans, the main source is through UVB exposure. Only a small part is derived from 
the diet. There are very few natural products that can be used as vitamin D source. 
These include fatty fish such as salmon, sardines and cod liver oil [79]. 
Due to its dependence on UVB exposure, vitamin D levels can fluctuate depending on 
the season of the year, latitude, skin pigmentation and lifestyle [79]. 
In the human skin, cholecalciferol is synthesized from 7-dihydrocholesterol by ultraviolet 
irradiation (Figure 1.4). 
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Figure 1.4. Vitamin D metabolism. Cholecalciferol is synthesized from 7-dihydrocholesterol by UV 
irradiation, or can be obtained in small amounts from the diet. In the liver, cholecalciferol is hydroxylated to 
calcidiol 25(OH)D3 through the action of CYP2R1. Once in the kidney, 25(OH)D3 is further converted into its 
active form, 1,25(OH)2D3. 
 
Cholecalciferol is biologically inactive. It binds to transport proteins such as vitamin D 
binding proteins or albumin and enters the circulation. In the liver cholecalciferol is 
hydroxylated, a process catalysed by the enzymes CYPR1 and CYP27A1, resulting in 
the production of the inactive form 25-hydroxyvitamin D3 (25(OH)D3), which represents 
the main circulating form of vitamin D. This form is also the most stable and is used as a 
parameter to define one person’s vitamin D status [79, 81]. 
In the kidney, 25(OH)D3 is further converted to the biologically active form of vitamin D, 
calcitriol (1,25(OH)2D3) by the action of the enzyme 1-α-hydroxylase (CYP27B1). 
Calcitriol levels are regulated in a renal negative feedback loop, including the inhibition of 
CYP27B1 by high calcitriol levels and stimulation of CYP24A1 (24-hydroxylase), an 
enzyme that metabolizes calcitriol to calcitroic acid, the inactive, water soluble form, 
which is then excreted in the bile. Although the circulation levels of 1,25(OH)2D3 levels 
are mainly determined by renal CYP27B1, other cell types such as immune cells which 
express this enzyme are also capable of converting 25(OH)D3 into its biologically active 
form. The production of 1,25(OH)2D3 by macrophages and dendritic cells may lead to 
high local concentrations of 1,25(OH)2D3 which are assumed to be important for 
immunomodulation [81]. 
 
 
 
Introduction 
16 
 
1.5.2. Vitamin D and immune function 
Early evidence for the importance of vitamin D for the immune system dates from the 19th 
century. Cod liver oil was used as a treatment for infections such as consumption, a 
condition these days known as tuberculosis. Tuberculosis patients were also sent to 
sanatoriums, where therapy included sunlight exposure. It was believed that sun 
exposure directly kills Mycobacterium tuberculosis bacteria [79]. In the meantime we 
know that the effect of both, sunlight and cod liver oil, is due to vitamin D. 
M. tuberculosis is a strong inducer of CYP27B1 and VDR in monocytes and 
macrophages after pathogen recognition by toll-like receptors. 1,25(OH)2D3 in turn can 
induce antimicrobial peptides such as cathelicidin and β-defensins [92] [79]. 
Human cathelicidin (LL37) is produced as a precursor protein called hCAP18, which 
upon cleavage releases LL37. Further processing can occur in the skin which results in 
the release of shorter peptides. hCAP18 is widely expressed in the immune system and 
also in a variety of epithelial cells. Beside tuberculosis, low 25(OH)D3 serum levels have 
been associated with various infectious diseases, such as influenza, chronic obstructive 
pulmonary disease and allergic asthma and were found to be significantly lower in 
critically ill septic patients. It has also been shown that low 25(OH)D3 serum levels 
correlates with decreased concentrations of antimicrobial peptides such as cathelicidin 
[82].  
Taken together, these findings support the idea that the vitamin D status regulates 
antimicrobial protein levels that are critical for the control of infection. 
Besides its effect on antimicrobial protein regulation, vitamin D also has other effects on 
the activation of immune cells [83]. In the hematopoietic system, VDR is expressed in 
various hematopoietic precursors as well as in monocytes, thymocytes and activated B 
and T cells [80]. Some studies with VDR-knock-out (VDR-KO) mice show that these 
animals produce normal number and proportion of blood cells, demonstrating that vitamin 
D signalling is not necessary for the differentiation of the hematopoietic cell repertoire 
[84]. Although the number of cells is not changed, it has been shown that there are 
changes in the cytokine profile in VDR-KO mice that may affect T-helper (Th) immune 
responses indicating that 1,25(OH)2D3 may regulate immune cell function [84]. 
Nevertheless there are studies stating that VDR also seems to be critical for the 
development of invariant natural killer T (iNKT) cells, a subset of T cells with a regulatory 
role in autoimmunity and infection [85]. Cantorna and co-workers have demonstrated that 
CD8+ T cells and iNKT cells are targets for vitamin D [85]. VDR-KO mice have significant 
less iNKT cells, and the few iNKT cells present in the periphery are functionally defective. 
Like iNKT cells, there are also less CD8αα/TCRαβ precursors in the thymus of VDR-KO 
animals. CD8αα T cells are mainly present in the gut, where they have a role in 
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preserving tolerance and suppress inflammation [85]. Taken together, these results show 
that VDR expression is compulsory for the development of both iNKT and CD8αα/TCRαβ 
cells. 
 
Dendritic cells differentiated in the presence of vitamin D remain in an immature-like 
tolerogenic state. This can be accessed by the cytokine profile of these cells. Pro-
inflammatory cytokines like IL-12 and TNF are reduced and anti-inflammatory cytokines 
like IL-10 are increased. Due to their maturation status, these tolerogenic DCs (tDCs) are 
less capable of stimulating T cell proliferation and cytokine production of pro-
inflammatory T cells, whereas they induce the differentiation of regulatory T cells. 
It was demonstrated that 1,25(OH)2D3 promotes the anti-inflammatory M2 phenotype of 
macrophages and is capable to induce the differentiation of monocytes into 
macrophages in vitro [86]. 
Although the effect of 1,25(OH)2D3 on B cells is still not completely understood, several 
reports suggest that vitamin D reduces the proliferation of B cells, induces their apoptosis 
and inhibits immunoglobulin class switching [87]. There is also evidence that vitamin D 
decreases antibody production [83]. 
For a long time it was believed that the effect of vitamin D on T cells was indirect and 
mediated exclusively by antigen-presenting cells. However, it has become clear now that 
upon activation, T cells upregulate the VDR, making this cell type another important 
target for vitamin D.  
Figure 1.5. Effects of 1,25(OH)2D3 on various immune cells. Adapted from [80]. 
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Vitamin D treatment has been shown to have an impact on different T cell subtypes., 
namely by inducing regulatory T cells [88]. When 1,25(OH)2D3 is added to T cells, it 
inhibits the differentiation of pro-inflammatory Th1 cells by suppressing IFN-γ and 
favouring Th2 response. In VDR KO, the Th1 response is also impaired.  
1.5.3. Vitamin D status and GvHD 
In an optimal stem cell transplantation scenario, the donor immune system would destroy 
the malignant cells without harming the healthy recipient tissues. In order to prevent or 
treat GvHD, immune suppressive medication is required, which is crucial to (re)balance 
the immune response in patients. 
Since vitamin D has already been evidenced as an important immunomodulatory 
hormone, this suggests a possible significance in the outcome of HSCT [77]. 
In fact, the relationship between vitamin D serum levels and GvHD outcome has already 
been investigated by a number of groups [89-92]. 
Kreutz et al. reported an analysis of 25(OH)D3 and 1,25(OH)2D3 serum levels in 48 
patients undergoing allogeneic bone marrow transplantation (BMT) and found a decline 
in both metabolite levels in the course of transplantation [89]. 
In a different study, Glotzbecker and colleagues demonstrated that vitamin D deficiency 
before HSCT is associated with an increased risk of cGVHD [90].  
VDR genes are polymorphic in the human population and their variants have also been a 
subject of investigation in patients undergoing HSCT [93-95]. 
Cho and co-workers hypothesized that polymorphisms of the VDR gene could affect 
clinical outcomes of allogeneic HSCT [96]. Three VDR gene polymorphisms (BsmI G>A, 
ApaI G>T, and TaqI T>C) were genotyped in 147 patients who underwent HLA-matched 
sibling aHSCT. Frequencies of infection, GvHD, overall survival (OS), and disease-free 
survival (DFS) were compared according to genotypes and haplotypes. In this study they 
found a correlation between polymorphisms at the TaqI cleavage site, where 
heterozygous patients had better DFS and OS than TT homozygote patients.  
Also, they found that recipients having two copies of the “A” allele for the ApaI 
polymorphism had lower rates of aGvHD and infection. Homozygosity of the “A” allele is 
associated with higher VDR activity and in a study performed by Middleton et al. [95] a 
similar effect was reported: a solid trend toward reduced aGvHD in recipients with the AA 
genotype.  
Bogunia-Kubik and co-workers also published a study regarding VDR polymorphisms 
and HSCT, but included an analysis of patients receiving cells from unrelated donors. 
Here, they found an association between the FF genotype (associated with higher VDR 
activity) and the outcome after HSCT. If both donor and recipient had the FF genotype, 
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the recipient experienced higher risk of GvHD development. Interestingly, GvHD risk 
based on VDR polymorphisms depends on whether they are present in the donor or 
recipient.  
So far, data suggest that both VDR and vitamin D may play a role in immune 
reconstitution and immune surveillance in transplant patients. Prospective studies are 
needed to investigate the effects of vitamin D supplementation, e.g. with 1,25(OH)2D3 
analogues, on HSCT outcome [97]. In HSCT recipients, supplementation could promote 
better immune function in the reconstituted immune system and help to prevent the 
deleterious effects of GvHD.  
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2. Research Goals and Objectives 
GvHD is still the most common major life-threatening complication associated with 
allogeneic hematopoietic stem cell transplantation (aHSCT). Previous data demonstrate 
that single nucleotide polymorphisms of the NOD2/CARD15 receptor are associated with 
increased risk of GvHD. Furthermore, vitamin D has emerged as a central player in the 
immune system, with its deficiency being implicated in the pathogenesis of several 
diseases, including the development of GvHD. 
The aims of this dissertation were to clarify the role of NOD2 status for the regulation of 
the immune response, namely by studying the immune cell composition in peripheral 
blood of healthy donors differing in their NOD2 status. Also, the effects of muramyl 
dipeptide (MDP), the natural ligand of NOD2, were studied in monocyte/MNC-derived 
dendritic cell cultures. 
Moreover, the effect of vitamin D on human T cells with particular interest in the 
generation of inducible regulatory T cells was investigated in vitro. In parallel, the in vivo-
effects of vitamin D levels were also studied, using an animal model of vitamin D 
sufficiency versus deficiency to examine the impact of vitamin D in the immune cell 
composition of blood, spleen and bone marrow of the mice. Additionally, the impact of 
vitamin D levels on murine gut microbiota was analysed. 
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3. Material 
3.1. Equipment 
 
Autoclave  Technomara, Fernwald, Germany 
Balance LP1200S Sartorius, Göttingen, Germany 
Bioanalyzer 2100 Agilent Technologies, Böblingen, Germany 
Biofuge fresco Heraeus, Osterode, Germany 
CASY Cell Counter Innovatis/Roche, Basel, Switzerland 
Centrifuge Megafuge 3.0R Heraeus, Osterode, Germany 
Centrifuge Sigma 2 Sartorius, Göttingen, Germany 
Electrophoresis equipment  Biometra, Göttingen, Germany 
Electrophoresis equipment (PFGE) Biostep, Jahnsdorf, Germany 
ELISA plate reader MWG Biotech, Ebersberg, Germany 
EVOS Cell Imaging System Life Technologies, Carlsbad, CA, USA 
FACS Calibur flow cytometer BD Biosciences, Franklin Lakes, NJ, USA 
Forceps Aesculap, Tuttlingen, Germany 
Heat sealer Eppendorf, Hamburg, Germany 
Hemocytometer Marienfeld, Lauda-Königshofen, Germany 
Incubators  Heraeus, Hanau, Germany 
Laminar Flow Cabinet Clean Air Telstar, Woerden, The Netherlands 
LSR II flow cytometer Becton Dickinson, Heidelberg, Germany 
LSR Fortessa Becton Dickinson, Heidelberg, Germany 
Microscopes Zeiss, Jena, Germany 
Multifuge 3S-R Heraeus, Osterode, Germany 
Multipipettor Multipette plus Eppendorf, Hamburg, Germany 
NanoDrop 1000 Thermo Fisher Scientific, Schwerte, Germany 
PCR Thermocycler PTC-200 MJ-Research/Biometra, Oldendorf, Germany 
pH Meter  Knick, Berlin, Germany 
pH Meter, portable Hanna Instruments, Kehl am Rhein, Germany 
Picofuge Heraeus, Osterode, Germany 
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Pipetboy Integra Biosciences, Fernwald, Germany 
Pipettes Gilson, Milddleton, WI, USA 
Pulsed field gel electrophoresis  GE Healthcare, Chalfont St Giles, UK 
Realplex Mastercycler epGradient S Eppendorf, Hamburg, Germany 
Rocking plattform HS250 IKA Labortechnik, Staufen, Germany 
Rotilabo® mini centrifuge Carl Roth, Karlsruhe, Germany 
SenSorDish- Reader PreSens, Regensburg 
Sonifier 250  Branson, Danbury, USA 
Sonorex Ultrasonic Bath Branson, Danbury, CT, USA 
Speed Vac Thermo Fisher Scientific, Hudson, NH, USA 
Thermomixer  Eppendorf, Hamburg, Germany 
Vortexer Scientific Industries Ink., Bohemia, NY, USA 
Water purification system  Millipore, Eschborn, Germany 
Waterbath Julabo, Seelstadt, Germany 
 
3.2. Consumables 
 
Cell culture flasks Costar, Cambridge, MA, USA 
Cell culture plates Eppendorf, Hamburg, Germany 
Cell culture plates, cell repellent Greiner Bio-One, Kremsmünster, Austria 
Cell scrapers Sarstedt, Nümbrecht, Germany 
Cell strainer (70 µm, 100 µm) Falcon, Heidelberg, Germany 
Combitips for Eppendorf multipette Eppendorf, Hamburg, Germany 
Cryo tubes  Corning, Corning, NY, USA 
ep dualfilter T.I.P.S® Eppendorf, Hamburg, Germany 
Heat sealing film  Eppendorf, Hamburg, Germany 
HyperfilmTM ECL GE Healthcare, Chalfont St Giles, UK 
Micro test tubes (0.5 ml, 1.5 ml, 2 ml)  Eppendorf, Hamburg, Germany 
Micropore filters Sartorius, Göttingen, Germany 
Microtiter plates (6, 12, 24, 96 wells) Costar, Cambridge, MA, USA 
Microtiter plates for ELISA Costar, Cambridge, MA, USA 
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OxoDishes (24 well) PreSens, Regensburg, Germany 
PCR plate Twin.tec 96 well Eppendorf, Hamburg, Germany 
Petri dish Falcon, Heidelberg, Germany 
Pipette tips Eppendorf, Hamburg, Germany 
Plastic pipettes Costar, Cambridge, MA, USA 
Polystyrene test tubes Falcon, Heidelberg, Germany 
Polystyrene test tubes with cell strainer cap Corning, Corning, NY, USA 
Scalpels (No. 10), disposable Feather, Osaka, Japan 
Syringe Filters, sterile Sartorius, Göttingen, Germany 
Syringes and needles Becton Dickinson, Heidelberg, Germany 
Teflon foils Heraeus, Hanau, Germany 
Tissue culture dish Falcon, Heidelberg, Germany 
Tubes (5 ml, 15 ml, 50 ml, 225 ml)  Falcon, Heidelberg, Germany 
Whatman® Chromatography Paper Sigma-Aldrich, St. Louis, MO, USA 
 
3.3. Media buffers and solutions 
 
2-Mercaptoethanol Gibco/Life Technologies, Carlsbad, CA, USA 
Acrylamide Carl Roth, Karlsruhe, Germany 
APS Merck Millipore, Billerica, MA, USA 
Aqua Braun, Melsungen, Germany 
Bovine serum albumine Sigma-Aldrich, St. Louis, MO, USA 
CasyTON Roche, Basel, Switzerland 
DMSO Sigma-Aldrich, St. Louis, MO, USA 
FACS clean BD Biosciences, Franklin Lakes, NJ, USA 
FACS flow BD Biosciences, Franklin Lakes, NJ, USA 
FACS rinse BD Biosciences, Franklin Lakes, NJ, USA 
Fetal calf serum Gibco/Life Technologies, Carlsbad, CA, USA 
Hydrogen peroxide Merck, Darmstadt, Germany 
Hydrochloride acid Carl Roth, Karlsruhe, Germany 
Isopropanol Braun, Melsungen, Germany aun 
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L-Alanyl-L-Glutamine Merck Millipore, Billerica, MA, USA 
Methanol Thermo Fisher Scientific, Waltham, MA, 
USA 
Nuclease-free water Gibco/Life Technologies, Carlsbad, CA, USA 
PBS Sigma-Aldrich, St. Louis, MO, USA 
RPMI 1640 Gibco/Life Technologies, Carlsbad, CA, USA 
TEMED Sigma-Aldrich, St. Louis, MO, USA 
Tween 20 Sigma-Aldrich, St. Louis, MO, USA 
 
3.4. Enzymes, kits and reagents for molecular biology 
 
Agilent RNA 6000 Nano Kit Agilent Technologies, Santa Clara, CA, 
USA 
BDTM Comp Beads BD Biosciences, Franklin Lakes, NJ, USA 
Bio-Rad DC protein assay Bio-Rad, Munich, Germany 
CD4 Microbeads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Collagenase IV Worthington, Lakewood, NJ, USA 
DAPI Sigma-Aldrich, St. Louis, MO, USA 
Dynabeads Human T-Activator CD3/CD28 ThermoFisher, Massachusetts, USA 
DNeasy Blood & Tissue Kit Qiagen, Hilden, Germany 
dNTPs Roche diagnostics, Mannheim, Germany 
DuoSet ELISA Kits R&D Systems, Minneapolis, MN, USA 
FcR-Blocking reagent mouse Miltenyi Biotec, Bergisch Gladbach, 
Germany 
FoxP3 transciption factor staining buffer 
set 
eBioscience, San Diego, CA, USA 
GM-CSF Berlex, Seattle, USA 
Human interkeukin 2 (IL-2) Promokine, Heidelberg, Germany 
Human interkeukin 4 (IL-4) Promokine, Heidelberg, Germany 
M-MLV Reverse Transcriptase Promega, Madison, WI, USA 
Proteinase K Roche, Mannheim, Germany 
QuantiFast SYBR® green PCR Kit Qiagen, Hilden, Germany 
Material 
25 
 
Random Decamers Ambion/Life Technologies, Carlsbad, 
CA,USA 
RNAlaterTM Qiagen, Hilden, Germany 
RNase-free DNase Set Qiagen, Hilden, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
SDS Sigma-Aldrich, St. Louis, MO, USA 
 
3.5. Chemicals for cell culture 
 
Lipopolysaccharide (LPS) Enzo Life Sciences, Farmingdale, NY, USA 
Muramyl dipeptide (MDP) InVivogen, Toulouse, France 
25-hydroxyvitamin D3 (25(OH)D3) Sigma-Aldrich, St. Louis, MO, USA 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) Biozol, Eching, Germany 
 
3.6. Antibiotics 
Penicillin and streptomycin for primary cell culture were purchased from Gibco Life 
Technologies, Carlsbad, California, USA. 
3.7. Oligonucleotides for qRT-PCR 
Primers were designed using UCSC genome browser and PerlPrimer software. 
Unmodified, HPLC-purified oligonucleotides were purchased from Eurofins MWG Operon 
(Ebersberg, Germany). 
Gene Primer sequence (sense and antisense) 
FoxP3 (mouse) 5´CCCATCCCCAGGAGTCTTGC 3´ 
5´ACCATGACTAGGGGCACTGTA 3´ 
18S (mouse) 5'-ACCGATTGGATGGTTTAGTGAG-3' 
5'-CCTACGGAAACCTTGTTACGAC-3' 
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3.8. Antibodies 
3.8.1. Western blot antibodies 
 
Antibodies Species Dilution 
Molecular 
weight 
Manufacturer 
iKB Rabbit 1:1000 45 kDa Santa Cruz Biotechnology, 
Dallas, 
TX, USA 
Sigma-Aldrich, St. Louis, MO, 
USA 
Phospho-p38 Rabbit 1:1000 43 kDa 
β-Actin Rabbit 1:2000 42 kDa 
Rabbit-HRP Goat 
 
1:2500 Dako, Glostrup, Denmark 
 
3.8.2. Flow cytometry antibodies 
3.8.2.1. Anti-mouse antibodies 
 
Specificity Isotype   Conjugation Clone  Manufacturer 
Biotin Mouse IgG1 PerCP Bio3-18E7 Miltenyi Biotec 
CD4 Rat IgG2a κ   FITC RM4-5 eBioscience 
CD8 Rat IgG2b κ   APC-Cy7 53-6.7 Biolegend 
CD11b Rat IgG2b κ   Pe-Cy7 M1/70 BD 
CD19 Rat IgG2a κ   PE 6 D5 Biolegend 
CD25 Rat IgG1 λ Pe-Cy7 PC 61.5 eBioscience 
FoxP3 Rat IgG2a κ   FITC FJK-16s eBioscience 
Gr1 Rat IgG2b κ   APC RB6-8C5 BD 
Helios Hamster IgG PE 22F6 Biolegend 
H2kb Mouse IgGa κ   Biotin AF6-88.5 Biolegend 
NK1.1 Mouse IgGa κ   BV421 PK136 Biolegend 
TCRβ Hamster IgG APC-Cy7 H57-597 Biolegend 
 
 
 
 
 
Material 
27 
 
3.8.3. Anti-human antibodies 
 
Specificity Isotype   Conjugation Clone  Manufacturer 
CD1a Mouse IgG1,ƙ PE SFCI19Thy1A8 
Beckman 
Coulter 
CD3 Mouse IgG1,ƙ FITC SK7 BD 
CD4 Mouse IgG1,ƙ PE RPA-T4 BD 
CD8 Mouse IgG1,ƙ APC-H7 SK1 BD 
CD11c Mouse IgG1,ƙ PerCP BU15 Abnova 
CD14 
Mouse 
IgG2a,ƙ 
Horizon 450 M5E2 BD 
CD14 
Mouse 
IgG2b,ƙ 
PE MϕP9 BD 
CD15 Mouse IgG1,ƙ Pacific Blue W6D3 Biolegend 
CD16 Mouse IgG1,ƙ APC 3G8 Biolegend 
CD16 Mouse IgG1,ƙ APC B73.1 Biolegend 
CD16 Mouse IgG1,ƙ APC VEP Miltenyi Biotec 
CD16 Mouse IgG1,ƙ APC REA423 Miltenyi Biotec 
CD16b Mouse IgG1,ƙ APC REA589 Miltenyi Biotec 
CD19 Mouse IgG1,ƙ FITC HIB19 eBioscience 
CD19 Mouse IgG1,ƙ PerCP SJ25C1 BD 
CD21 Mouse IgG1,ƙ APC B-ly4 BD 
CD25 Mouse IgG1,ƙ Pe-Cy7 M-A251 BD 
CD25 Mouse IgG1,ƙ APC 2A3 BD 
CD32 Mouse IgG1,ƙ PE FUN-2 Biolegend 
CD33 Mouse IgG1,ƙ PE WM53 Biolegend 
CD39 
Mouse 
IgG2b,ƙ 
PE TU66 BD 
CD45 Mouse IgG1,ƙ PerCP 2D1 Biolegend 
CD45RA 
Mouse 
IgG2b,ƙ 
Pe-Cy7 HI100 Biolegend 
CD56 
Mouse 
IgG2a,ƙ 
FITC MEM188 eBioscience 
CD62P Mouse IgG1,ƙ PE Ak4 Biolegend 
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CD73 Mouse IgG1,ƙ FITC AD2 BD 
CD80 Mouse IgG1,ƙ FITC BB1 BD 
CD83 Mouse IgG1,ƙ FITC HB15a 
Beckman 
Coulter 
CD85j (ILT2) 
Mouse 
IgG2b,ƙ 
Pe-Cy7 GI/75 Biolegend 
CD85k (ILT3) Mouse IgG1,ƙ APC ZM4.1 Biolegend 
CD86 Mouse IgG1,ƙ APC 2331(FUN-1) BD 
CD127 Mouse IgG1,ƙ BV 510 HIL-7R-M21 BD 
CD197 (CCR7) 
Mouse 
IgG2a,ƙ 
FITC 150503 BD 
CD209 (DC-
Sign) 
Mouse 
IgG2b,ƙ 
PE 120507 R&D 
CD273(PD-L2) Rat IgG2a, κ APC TY25 Biolegend 
CD274(PD-L1) 
Mouse 
IgG2b,ƙ 
Pe-Cy7 29E.2A3 Biolegend 
CD366(TIM3) Mouse IgG1,ƙ Pe-Cy7 F38-2E2 Biolegend 
CX3R1 Rat IgG2b,ƙ Pe-Cy7 2A9-1 Biolegend 
HLA-DR 
Mouse 
IgG2a,ƙ 
APC-H7 G46-6 BD 
IgD 
Mouse 
IgG2a,ƙ 
PE IA6-2 BD 
IgM Mouse IgG1,ƙ FITC G-20-127 BD 
Lin Cocktail Mouse IgG1,ƙ FITC L27 BD 
 
3.9. Mice 
 
Strain Provider 
BALB/c Charles River Laboratories 
CD-1 
Provided by the Central Animal Facility 
University Hospital Regensburg 
C57BL/6  Provided by Dr. Petra Hoffmann, University 
Hospital Regensburg NOD2-/- 
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3.10. Databases and software 
The following databases and software tools were used to design experiments and 
process data. 
CellQuest Pro BD, Heidelberg, Germany 
EndNote X7 Thomson Reuters, New York, NY, USA 
ExonMine http://www.imm.fm.ul.pt/exonmine/ 
FACSDiva BD, Heidelberg, Germany 
FlowJo version 9.5.3 FlowJo,LLC, Ashland, OR, USA 
GraphPad Prism version 5.02 GraphPad Software, La Jolla, CA, USA 
ImageLab version 4.0 Bio-Rad, Munich, Germany 
Microsoft Excel 2003/2007/2010 Microsoft Deutschland GmbH 
PerlPrimer version 1.1.14 http://perlprimer.sourceforge.net/ 
PubMed http://www.ncbi.nlm.nih.gov/entrez 
SenSorDish-Reader Software PreSens, Regensburg, Germany 
USCS Genome Browser http://www.genome.ucsc.edu 
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4. Methods 
4.1. Cell culture 
4.1.1. Isolation and culture of human monocytes 
4.1.1.1. Isolation of human monocytes 
Peripheral blood mononuclear cells (PBMCs) were separated by leukapheresis of 
healthy volunteer donors, followed by density gradient centrifugation over 
Ficoll/Hypaque. Monocytes were then isolated from mononuclear cells (MNCs) by 
counterflow centrifugation elutriation. Elutriation was performed using a J6M-E centrifuge 
equipped with a JU 5.0 elutriation rotor and a 50 ml flow chamber (Beckman, Munich, 
Germany). After system sterilization with 6% H2O2 for 20 minutes, the system was 
washed with PBS. Following calibration at 2500 rpm and 4 °C with Hank’s BSS, MNCs 
were loaded into the system at the flow rate determined after calibration. 
Fractions were collected according to the right flow rate (see table 4.1). The last fraction 
collected represented the monocytes, the largest cells within the MNCs. The monocyte 
yield was donor dependent, normally ranging from 10 to 20%. The purity of the monocyte 
fraction was then determined by flow cytometry and varied from 85 to 95%. 
 
Table 4.1. Elutriation parameters and cell types 
Fraction Volume (ml) Flow rate (ml/min) Main cells isolated 
Ia 1000 52 Platelets 
Ib 1000 57 
B and T lymphocytes, NK cells 
IIa 1000 64 
IIb 500 74 
IIc 400 82 
IId 400 92 
III 800 130 Monocytes 
 
4.1.1.2. Culture and stimulation of human monocytes 
For the TGF-β experiments, the isolated monocytes were plated (2x106 cells/ml), in 6-
well plates with a cell-repellent surface (Greiner BioOne, Kremsmünster, Austria) in 
RPMI 1640 supplemented with 2% AB serum, 2 mmol/l L-Glutamin (Biochrom, Berlin), 50 
U/ml Penicillin and 50 µg/ml Streptomycin (both Gibco, Darmstadt) . 
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Cells were stimulated overnight with TGF-β, LPS, MDP or combination of the 
substances. 
For the platelet co-culture, monocytes (2x106 cells/ml) were co-incubated overnight with 
platelets (20x106) isolated from elutriation fraction Ia. 
4.1.2. Macrophage culture 
Macrophages were obtained by culturing monocytes at a density of 1x106/ml in RPMI 
medium supplemented with 2% AB serum in teflon bags for 7 days. After this period, the 
cells were harvested by placing the teflon bag in the fridge for 30 minutes and after 
gently rubbing the bag. The cells were decanted to a falcon tube. Afterwards, the 
collected cells were analysed for cell viability and surface markers by means of flow 
cytometry.  
4.1.3. Dendritic cell culture 
For the “classical” protocol, immature monocyte-derived dendritic cells (iDCs) were 
generated by culturing 10x106 elutriated monocytes in 15 ml (0,67x106 cells/ml) RPMI 
1640 medium supplemented with 10% FCS, 2 mol/l L-glutamine, 50 U/ml penicillin and 
50 µg/ml streptomycin, 144 U/ml IL-4 and 280 U/ml GM-CSF. Cells were incubated for 5 
days at 37°C with 5% CO2 and 95% relative humidity. On day 5, iDCs were stimulated 
with 100 ng/ml LPS, 100 ng/ml MDP or a combination of both substances for 48 hours. 
On day 7, mature dendritic cells were harvested. 
When the “fast” protocol was applied, iDCs were generated by culturing 10x106 elutriated 
monocytes in 15 ml (0,67x106 cells/ml) RPMI 1640 medium supplemented with 10% 
FCS, 2 mol/l L-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin 114 U/ml IL-4 and 
225 U/ml GM-CSF. Alternatively, 40x106 MNCs/15 ml (2,8x106/ml) were incubated for 24 
hours at 37°C with 5% CO2 and 95% relative humidity, and then stimulated for 48 hours 
with the same stimuli used in the “classical” protocol. 
When generating MNC-DC in 96-well plates, the fast protocol was applied, culturing 
1x106 MNC/100 µl/well. 
4.1.4. Mixed lymphocyte reaction 
10,000 DCs were cocultured with 100,000 allogeneic T lymphocytes, isolated from 
elutriation´s IIb fraction, in RPMI containing 5% AB serum, L-glutamine (2 mmol/L), 
penicillin (50 U/mL), and streptomycin (50 mg/mL). Cells were cultured in round bottom 
96-well plates, in a final volume of 200 µl (100 µl T lymphocytes + 100 µl DCs). On day 5, 
supernatants were harvested and frozen at -20°C until analysis. On day 7, cells were 
harvested, counted and analyzed by flow cytometry. 
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For the vitamin D3 experiments, T cells (isolated from elutriation’s IIb fraction either by 
magnetic bead sorting (CD4+ cells) or FACS sorting (CD4+CD25-T cells) were cocultured 
with Dynabeads Human T-Activator CD3/CD28 (0,1 bead/cell or 1 bead/cell), in RPMI 
medium containing 2% AB serum, 100U/ml IL-2, L-glutamine (2 mmol/L), penicillin (50 
U/mL), and streptomycin (50 mg/mL) for 3 or 4 days. Afterwards, cells were harvested, 
counted and analyzed by means of flow cytometry. Cells were further cultured and 
analyzed at the indicated periods of time. 
4.1.5. Cytokine analysis from culture supernatant 
After harvesting the cells, the supernatants were frozen and cytokines present in culture 
supernatants were measured by means of sandwich ELISA. The capture antibody is 
attached to a solid phase (microtiter plate). After blocking unspecific binding-sites, the 
sample is added and the antigen of interest will bind. Afterwards, the plate was washed 
and the detection antibody added, recognizing the antigen of interest. The next step 
involves the addition of an enzyme-linked secondary antibody that will bind to the 
detection antibody. Finally, the substrate is added, and is enzymatically converted to a 
detectable form. The fluorescence is measured using a microtiter plate reader and the 
concentration of the antigen is quantified using a standard curve. 
4.1.6. Enzymatic determination of lactate 
To determine lactate concentrations, supernatants were harvested and frozen at -20°C 
until analysis. For the measurement, an ADVIA 1650 analyser was used at the 
Department of Clinical Chemistry (University Hospital Regensburg, Germany). 
4.1.7. Analysis of the oxygen content in cultures 
Oxygen content of cell cultures was measured with using the SensorDish-Reader system 
(PreSens, Regensburg). This system allows a non-invasive measurement of O2 content 
in the culture, using 24-well plates that contain a sensor spot at the bottom of each well. 
The sensor spot contains a luminescent dye that is excited by the SensorDish Reader 
placed below the multidish, and its luminescence lifetime is detected non-invasively 
through the transparent bottom. The luminescence of the dye depends on the oxygen 
partial pressure, as molecular oxygen quenches/deactivates the luminescent indicator. 
Measured values are afterwards converted by the software with the help of the stored 
calibration data. 
For the analysis of the oxygen content of DC cultures (section 5.3.1.3), monocytes 
(1x106) or MNC (2x106) were seeded in 24-well OxoDishes and incubated at 37°C for 24 
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hours. Afterwards, cells were stimulated with LPS, MDP (100 ng/ml) or combination and 
placed onto the SensorDish Reader for 48 hours. 
4.1.8. Sorting of CD4+25- T cells 
Peripheral blood mononuclear cells (PBMCs) were separated by leukapheresis of 
healthy volunteer donors, followed by density gradient centrifugation over 
Ficoll/Hypaque. Afterwards, CD4+ cells were separated using CD4+ T cell isolation kit 
from Miltenyi Biotec. For some experiments (section 5.5.1) the resulting population was 
further separated to obtain CD4+CD25- T cells by FACS with a FACSAria sorter. 
4.1.9. Freezing and thawing of cells 
For freezing, circa 40 million cells were resuspended in 1 ml RPMI medium. Freezing 
medium (80% FCS and 20% DMSO) was added in a 1:1-ratio and slow-frozen in cryo-
freezing vials for short term storage at -80°C in an isopropanol-filled container (Nalgene) 
for 24 hours. For long term storage, the samples were then transferred to liquid nitrogen 
(-196°C). 
Frozen cells were thawed at room temperature and directly added to serum containing 
medium. After centrifugation, the cells were resuspended in fresh medium. 
4.1.10. Cell counting 
Cell number and viability were determined using the CASY system, an electric field multi-
channel cell counting system. This system quantifies cells passing a measuring pore 
where cells are exposed to a low voltage electrical field. Based on the resistance signal 
generated, cells can be differentiated, since dying or dead cells have a lower resistance 
due to their higher membrane permeability, whereas living cells generate high resistance 
signals due to their intact membrane structure.  
4.2. Flow cytometry 
Flow cytometry is a technique that allows detection, counting and sorting of individual 
cells. Cell components are stained with fluorochrome-labeled antibodies and then excited 
by a laser to emit light at different wavelengths. This technique measures various 
characteristics of single particles flowing individually in a stream of fluid. The scattering of 
light in different angles can discriminate cells regarding differences in size (forward 
scatter, FSC) and granularity (side scatter, SSC), while fluorescence from the labeled 
antibodies allows the identification of various cell surface and cytoplasmic antigens. This 
approach makes flow cytometry a powerful tool for cell analysis in a short period of time, 
giving both qualitative and quantitative information about complex populations[98]. 
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Different fluorochrome-conjugate antibodies against the antigens of interest were used in 
6-colour measurements performed using a BD LSR II cytometer, equipped with a red, 
blue, violet and UV laser. The staining procedure was performed on ice to preserve cell 
viability. 
Dead cells were excluded by 4',6-diamidino-2-phenylindole (DAPI), a DNA-binding dye 
that enters cells with damaged membranes. 
Analysis of the generated flow cytometry data was performed with the FlowJo software. 
4.2.1. Compensation 
All fluorochromes possess their particular excitation and emission spectra. The excitation 
spectra refer to the range of light wavelength that adds energy to a fluorochrome, 
causing it to emit light in another wavelength, the emission spectrum. In a flow cytometer 
there are bandpass filters that select the right ranges of excitation and emission 
wavelengths. However, when more than one marker is expressed in a single cell, their 
emission spectra may overlap, giving false results. This is called spillover and occurs 
whenever the fluorescence emission of one fluorochrome is detected in a detector 
designed to measure signal from another fluorochrome. To avoid this, a process called 
compensation is required, allowing the correction of the detected spillover [99]. 
BD compbeads were used to determine compensation values, according to 
manufacturer’s instructions. To determine cell autofluorescence, unstained cells were 
used.  
4.2.2. Surface staining 
For surface staining of antigens, 0,5-1x106 million cells were placed in flow cytometry 
tubes and centrifuged at 525 g at 4°C for 4 minutes with 1 ml flow cytometry buffer. 
Afterwards, the cells were incubated with the proper antibody amount for 30 minutes at 
4°C in the dark. Next, cells were centrifuged twice with 1 ml of flow cytometry wash buffer 
and the pellet was resuspended in 300 µl flow cytometry buffer. 
The cells were measured on the same day, after adding 10% of DAPI for discrimination 
between living and dead ones. 
4.2.3. Intracellular staining 
For the intracellular staining of antigens, cells had to be permeabilized, using the 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience), following manufacturer’s 
instructions. Briefly, 0.5 ml of FIX/Perm diluent (diluted 1:4) was added to the cells, 
vortexed and incubated for 45 minutes at 4°C. The cells were then centrifuged three 
times with Perm solution (diluted 1:10 with H2O) and the pellet was incubated with the 
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proper antibody amount for 30 minutes at 4°C. After the incubation time, the cells were 
washed twice with 1 ml of Perm solution and one time with flow cytometry buffer. In the 
end, the pellet was resuspended in 300 µl of flow cytometry buffer and the data acquired 
at the flow cytometer.  
4.2.4. Blood sample preparation for flow cytometry 
The erythrocytes of 1 ml of blood collected from heparin, hirudin, EDTA and citrate tubes 
were lysed using 20 ml ACK lysis buffer (0.155 M NH4Cl, 0.1 M KHCO3 and 0.1 mM 
EDTA, diluted 1:6 with H2O) for 5 minutes at room temperature. The reaction was 
stopped by adding 25 ml RPMI medium and cells were centrifuged. The procedure was 
repeated about 2 times, until the pellet was colourless. Cell pellets were resuspended in 
1-50 ml medium (volume dependent on pellet size) and filtered via 100 µm cell strainers. 
Alternatively, PBMCs from the collected blood were separated by density gradient 
centrifugation over Ficoll/Hypaque. 
4.3. Molecular biological methods 
4.3.1. RNA isolation 
For RNA isolation, cells were harvested, centrifuged at 350 g for 7 minutes, the dry pellet 
resuspended in RLT Buffer containing 1% 2-Mercaptoethanol and then sheared 10 times 
using a 1 ml syringe. Procedures were performed on ice and RNA lysates were frozen at 
-80°C for storage. The subsequent isolation of total cellular RNA was performed using 
the RNAeasy Mini Kit, according to manufacturer´s instructions (QUIAGEN). RNA 
concentration was determined using a NanoDrop 1000 spectrophotometer. 
4.3.2. Polymerase chain reaction 
Polymerase chain reaction (PCR) is a technique used in molecular biology that aims the 
amplification of DNA fragments using a DNA template, a DNA polymerase and 
sequence-specific oligonucleotide primers which flank the DNA fragment of interest. 
Here, real-time quantitative PCR (RT-qPCR) was used in order to quantify the 
expression level of specific genes. Therefore, total cellular RNA had to be converted into 
copy DNA (cDNA) by reverse transcription. 
4.3.2.1. Reverse transcription 
In order to determine gene expression levels, total RNA was transcribed into cDNA using 
a reverse transcriptase from Moloney Murine Leukemia (M-MLV), random decamer 
primers and 2’-deoxyribonucleosid-5’-triphosphates (dNTPs). The reaction was 
performed in a PCR thermocycler by adjusting the volume of 1 µg of total RNA to 13 µl 
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nuclease-free ddH20, mixing 1 µl random decamers (Promega) and 1 µl dNTPs (10 mM) 
on ice. Secondary structures of RNA were dissolved by 5 minutes incubation in the 
thermocycler at 65°C followed by immediate incubation on ice for 1 minute. After mixing 
with 4 μl M-MLV buffer (5x; Promega), samples were incubated at 42°C for 2 min. 
Reverse transcription started upon addition of 1 μl M-MLV (50 min, 42°C) and was 
stopped by heat inactivation of the enzyme (15 min, 70°C). cDNA samples were stored at 
-20°C. 
4.3.2.2. Primer design 
The specific primers used to detect the gene of interest by means of RT-qPCR were 
designed using PerlPrimer software and the USCS genome browser obeying the criteria 
presented in table 4.2.  
Table 4.2. Criteria for primer design 
GC content 40-60% 
Melting temperature (Tm) 65-68°C 
Primer lenght 20-28 bp 
Amplicon size 70-150 bp 
Position On 2 adjacent exons 
 
4.3.2.3. Real-time quantitative PCR 
Real-time quantitative polymerase chain reaction (RT-qPCR) is a technique that allows 
gene expression quantification using a DNA-binding dye that intercalates double-
stranded DNA causing more fluorescence when bound. An increase in DNA product 
during PCR therefore leads to an increase in fluorescence intensity measured at each 
cycle. The higher the initial number of DNA molecules in the sample, the faster the 
fluorescence will increase during the PCR cycles. This means that if a sample contains 
more targets, the fluorescence will be detected in earlier cycles. The cycle in which 
fluorescence can be detected is termed quantitation cycle (Cq) and is the basic result of 
RT-qPCR: lower Cq values mean higher initial copy numbers of the target. In the present 
work, the QuantiFast SYBR Green (manufacturer) was used. The reactions were 
prepared in 96-well PCR plates at a volume of 10 µl/well with a reaction mix illustrated in 
table 4.3. All samples were pipetted in triplicates and a positive control, used for the 
generation of a standard curve was pipetted in duplicates. 
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Table 4.3. Reaction mix used in RT-qPCR 
QuantiFast SYBR Green-mix 5µl 
cDNA (1:10 in H2OUSB) 1 µl 
Sense primer 0.5 µl 
Antisense primer 0.5 µl 
H2OUSB 3 µl 
 
After plate preparation, the RT-qPCR was performed in a Realplex Mastercycler 
EpGradient S according to the program depicted in table 4.4. 
 
Table 4.4. Program used for RT-qPCR 
Process Temperature Duration 
Initial denaturation 95°C 5 min 
Denaturation 95°C 8 sec 
45 cycles 
Annealing/elongation 60°C 20 sec 
Melting curve 
95°C 15 sec 
65°C 15 sec 
 65-95°C  10 min 
 
Specific amplification of the expected PCR product was controlled by the pattern of the 
melting curve. By means of the slope of the standard curve and the y-axis intercept, the 
amount of cDNA was calculated by the Realplex software. The amount of messenger 
RNA (mRNA) which corresponds to the calculated amount of cDNA was finally 
normalized to that of 18S rRNA. 
4.3.3. DNA isolation 
For the NOD2 SNP analysis, PBMCs were isolated and preserved in liquid nitrogen until 
analysis. Subsequently, genomic DNA was extracted using the DNeasy Blood & Tissue 
Kit from Quiagen, according to manufacturer´s instructions. 
4.3.3.1. Allelic discrimination of the NOD2/CARD gene 
Single nucleotide polymorphisms R702W, G908R, and (3020insC/L1007fsinsC ) also 
known as SNP8, 12, and 13  of the NOD2 gene were determined by a Taqman protocol 
(performed by Heike Bremm, AG Holler, Internal Medicine III, University Hospital 
Regensburg), as previously described [33]. Alternatively, samples were analysed using a 
Sequenom MassARRAY iPLEX platform (performed by AG Rehli, Internal Medicine III, 
Methods 
38 
 
University Hospital Regensburg). The assay consists of an initial locus-specific PCR 
reaction, followed by single base extension using mass-modified dideoxynucleotide 
terminators of an oligonucleotide primer which anneals immediately upstream of the 
polymorphic site of interest. Using Matrix Assisted Laser Desorption Ionization- Time-of-
Flight (MALDI-TOF) mass spectrometry, the distinct mass of the extended primer 
identifies the SNP allele [100]. 
4.4. Biochemical methods 
4.4.1. Protein isolation 
For protein isolation, monocytes were isolated as described in section 4.1.1.  
2x106 cells were seeded in 6-well plates and stimulated for 30 minutes. Afterwards, 
plates were transferred to ice, the cells harvested and centrifuged at 1300 rpm for 7 
minutes at 4°C. Possible remaining cells in the 6-well plates were obtained by washing 
the wells with ice cold PBS. For later determination of protein phosphorylation 500 µl of 
freshly prepared pre-equilibration buffer (buffer B) which contains cytoplasmic extraction 
buffer (CEB) (also called buffer A in this setting) was added to the cell pellet whereas 500 
µl of buffer was added to the culture plates to obtain any remaining cells. Cells were 
incubated in buffer for 4 min on ice and collected. Lysates were centrifuged and the 
supernatant carefully discarded. Subsequently, 60 µl of freshly prepared lysis buffer 
(buffer C) was added to the cell pellets and incubated for 10 min on ice. Afterwards, 60 µl 
of SDS buffer was added to the cell lysate and transferred to a 95°C heater for 10 min to 
denature the secondary protein structure. The obtained protein lysates were aliquoted, 
and stored at -80°C. The required buffers and solutions are presented in the tables 
bellow. 
 
Table 4.5. Buffer A composition 
Reagents  Final concentration  Final volume 
Tris/HCl (pH 7,9)  10 mM  1 ml 
KCl  60 mM  447 mg 
EDTA  1 mM  37 mg 
ddH2O   ad 100 ml 
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Table 4.6. Buffer B composition 
Reagents  
Stock 
concentration  
Final concentration  Final volume 
EDTA  500 mM  1.5 mM 3 µl 
Dithiothreitol  100 mM  1 mM 10 µl 
EGTA  200 mM  1 mM 5 µl 
β- Glycerophosphate  1 M  50 mM 50 µl 
Sodium fluoride  1 M  50 Mm 50 µl 
Sodium 
pyrophosphate  
250 mM  25 Mm 100 µl 
Sodium orthovanadate  200 mM  1 mM 5 µl 
Leupeptin  1 mg/ml  2 µg/ml 2 µl 
Pepstatin A  1 mg/ml  2 µg/ml 2 µl 
Aprotinine  2 mg/ml  2 µg/ml 1 µl 
Buffer A   
 
772 µl 
ddH2O  
  
ad 1000 µl 
 
 
Table 4.7. Buffer C composition 
Reagents  
Stock 
concentration  
Final concentration  Final volume 
Nonidet P40  10%  0.4%  40 µl 
Chymostatin  20 mg/ml  100 μg/ml  5 µl 
Bestatin  5 mg/ml  10 μg/ml  2 µl 
E64  3 mg/ml  3 μg/ml  1 µl 
1,10-Phenanthrolin  0.1mg/ml  1 mM  1 µl 
Buffer B   
 
951 µl 
ddH2O  
 
ad 1000 µl 
 
 
Table 4.8. SDS sample buffer composition 
Reagents  Final concentration  Final volume 
Glycerine  20 %  10 ml 
Tris buffer (pH 6.8)  125 mM  5 ml 
Sodium dodecyl sulfate  4 %  2 g 
2-Mercaptoethanol  10 %  5 ml 
Bromophenol Blue  0.02 %  10 mg 
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4.4.2. SDS polyacrylamide gel electrophoresis  
Protein samples obtained from section 4.4.1 were separated using a discontinuous gel 
system which is composed of a stacking and a separation gel mainly consisting of 
acrylamide (AA). Separation gel of 10% and stacking gel of 5% were prepared freshly as 
mentioned in table 4.9. In order to achieve complete polymerization, ammonimum 
persulfate (APS) was added acting as a free radical initiator and N, N, N’, N’-
tetramethylenedianime (TEMED) was added to catalyse the gel polymerization as 
mentioned in Table 4.10. 
Table 4.9. SDS-PAGE stock solutions 
Gel stock solution  Separation gel  Stacking gel 
Final AA concentration  10%  5% 
Stacking gel buffer  -  25 ml 
Separating gel buffer  25 ml  - 
SDS (10%)  1 ml  1 ml 
Acrylamide (AA) (30%)  33 ml  16,7 ml 
Millipore water  Adjust to 100 ml Adjust? 
 
 
Table 4.10-.SDS-PAGE gel mix solutions 
 Separation gel  Stacking gel 
Separating gel stock solution  6 ml  - 
Stacking gel stock solution  -  2.5 ml 
TEMED  6 µl  2.5 µl 
APS (10%)  30 µl  20 µl 
 
Table 4.11. Required buffers and solutions for SDS gel preparation 
Solutions  
Final 
concentration 
Weight Constituents 
Separating gel buffer  1.5 M 90.83 g Tris/HCl pH 8.8 
Stacking gel buffer  0.5 M 30 g Tris/HCl pH 6.8 
Sodium dodecyl sulfate  10% 10 g SDS 
APS  10% 1 g APS 
Laemmli buffer (5X)  40 mM 15 g Tris 
Glycine  0.95 M 21 g 
 
SDS 0.5% 15 g 
 
 
Methods 
41 
 
To perform electrophoresis, the SDS gel was placed in the electrophoresis chamber and 
bathed in electrode buffer (1X). After carefully removing the comb, wells were rinsed with 
electrode buffer and loaded with equal volumes protein lysates (Chapter 4.4.1). 
Additionally, one well was loaded with 5 µl Kaleidoscope Prestained Standard 
(manufacturer) as molecular weight standard. Voltage of 80-100 V was applied and as 
soon as the samples reached the running gel, voltage was increased to 120-130 V. 
Electrophoresis was stopped at the time point when the lowest band of the protein 
marker reached the lower bottom of the gel. 
4.4.3. Western blot analysis 
Proteins separated by SDS-PAGE were transferred to a PVDF (Polyvinyl difluoride) 
membrane using a three-buffer semi-dry system. To transfer the proteins from the gel to 
the membrane, a PVDF membrane was cut into the size of the gel. The membrane was 
then soaked in 70% isopropanol and transferred to anode buffer B. Afterwards, three 
pieces of filter paper, of the size of the membrane, were soaked in anode buffer A, and 
placed on the semi-dry electro-blotting system. Three more filter papers were soaked in 
anode buffer B and placed on top of first three papers. Air bubbles were gently removed. 
With the help of forceps the membrane was placed over the filter paper. The SDS gel 
was carefully removed from the glass plate, immersed in buffer B for 10 s and placed on 
top of the membrane. Another 3 layers of filter paper soaked in buffer C were laid on top 
of the gel. The system was closed with the upper part of the semi-dry transfer cell 
(cathode) and transfer of the proteins onto the PVDF membrane was carried out at 11 V 
for 1 h at room temperature (RT). 
In a second step, the proteins on the membrane were subjected to immunostaining. Each 
step was performed with shaking for maximum accessibility of reagents. To minimize 
non-specific binding, the membrane was incubated in blocking buffer over night at 4°C. 
Afterwards, the membrane was swirled in a dilution of primary antibody in blocking buffer 
(Chapter 3.8.1) for 1.5 h at RT. Then, the membrane was washed three times in Tris-
buffered saline and Tween 20 (TBST) buffer for 10 minutes, before incubation with a 
dilution of a secondary antibody in blocking buffer (Chapter 3.8.1), specific to the isotype 
of the primary antibody for 1 hour at RT. The membrane was washed again three times 
in TBST buffer for 10 minutes, and proteins were visualized on an imaging film using a 
luminol-based enhanced chemiluminescence (ECL) solution (Table 4.10).  
All the proteins of interest were normalized to the reference gene, β-actin, meaning that 
the previous antibody had to be stripped off. For this, membrane was washed three times 
for 10 min followed by stripping off the old signal with Reblot solution (1:1 diluted; 
manufacturer) for 15 min at RT. The membrane was then washed three times and 
Methods 
42 
 
preceded with blocking, washing, and primary and secondary antibody procedure. 
Stripping was performed every time when more than one antibody was to be bound on 
the same membrane and these antibodies are isolated from the same species. Images 
were processed and analysed using Image Lab software. 
 
Table 4.12. Western blot buffers 
Buffers  Components 
Buffer A  
0.3 M (36.3 g) Tris/HCl (pH 10.4) 
20% (200 ml) Methanol 
Add Millipore water to 1000 ml 
Buffer B  
25 mM (3.03 g) Tris/HCl (pH 10.4) 
20% (200 ml) Methanol 
Add Millipore water to 1000 ml 
Buffer C  
4 mM (5.2 g) Caproic acid (pH 7.6) 
20% (200 ml) Methanol 
Add Millipore water to 1000 ml 
TBS buffer (2X)  
20 mM (9.16 g) Tris/HCl (pH 7.4) 
150 mM (35.1 g) NaCl 
Add Millipore water to 2000 ml 
TBST buffer  
1X (500 ml) TBS (2X) 
0.1% (1 ml) Tween 20 
Add Millipore water to 1000 ml 
Blocking buffer  
5% (5 g) Non-fat dry milk 
Add 100 ml TBST buffer 
 
 
Table 4.13. Composition of ECL solutions 
Solutions  Components 
ECL solution A  
250 mM (100 mg) Luminol  
Add 2 ml of Millipore water 
ECL solution B  
90 mM (14.8 mg) p-Coumaric acid 
Add 1 ml DMSO 
ECL mix  
2 ml ECL solution A 
0.89 ml ECL solution B 
20 ml Tris/HCl (pH 8.5, 1 M)  
Add 200 ml ddH2O 
Stored away from sunlight. 
ECL working solution  5 ml ECL mix + 1.5 µl 30% H2O2 
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4.5. Mouse experiments 
All mouse experiments were conducted according to the regulations of the government of 
Upper Palatinate, Regensburg, Germany and in cooperation with AG Hoffmann/Edinger 
(Internal Medicine III, University Hospital Regensburg, Germany). Female BALB/c mice 
and C57BL/6 mice at the age of 3 weeks were purchased from Charles River 
Laboratories. CD-1 mice were gently provided by the Central Animal Facility, University 
Hospital Regensburg. 
4.5.1. Vitamin D3 deficient versus sufficient mouse model 
In order to generate a model differing in serum Vitamin D3 levels, BALB/c or CD-1 mice 
at the age of 3 weeks were fed with special Vitamin D3-deficient (<100 U/Kg) or sufficient 
(1500 U/Kg) diets (Ssniff GmbH). Serum 25(OH)D3 levels were measured by means of 
liquid chromatography high-resolution tandem mass spectrometry by the Clinical 
Chemistry Department, University Hospital Regensburg. 
4.5.1.1. Preparation of murine tissue for flow cytometry analysis 
For flow cytometry analyses, tissues of mice had to be processed to single-cell 
suspensions. In order to maintain cell viability, tissues dissected from mice were 
collected in ice-cold PBS and tissue preparation was performed on ice. 
Spleens were processed to single-cell suspensions by scratching out cells with curved 
forceps in a petri dish containing medium. Afterwards, they were filtered via 100 µm-cell 
strainers and centrifuged. Erythrocytes in single-cell suspensions were lysed with 2 ml 
ACK (Ammonium-Chloride-Potassium) lysis buffer (0.155 M NH4Cl, 0.1 M KHCO3 and 
0.1 mM EDTA, diluted 1:6 with H2O) for 3 minutes at room temperature. The reaction 
was stopped by adding 10 ml medium and cells were centrifuged. Cell pellets were 
resuspended in 1-50 ml medium (volume dependent on pellet size) and filtered via 100 
µm-cell strainers. After counting the cells with a CASY cell counter, 0.5-1 x 106 cells were 
stained for flow cytometry analysis. 
Bone marrow was collected flashing the cells out of the bone with medium with the help 
of a syringe. Afterwards, the collected cells were pressed into a 100 µm-cell strainer, 
centrifuged and the erythrocytes lysed like described above. 
4.5.1.2. Preparation of blood samples 
Blood of mice was collected from the tail vein in heparin tubes. 2-3 drops of blood were 
lysed with 1 ml ACK lysis buffer (Chapter 4.4.2.2) for 5 minutes at room temperature. The 
reaction was stopped by adding 2 ml flow cytometry buffer (PBS containing 2% FCS). 
After centrifugation, supernatants were carefully aspired, leaving ~50 µl to avoid 
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disturbing the pellet and ACK lysis was repeated until the pellet was colourless. At last, 
the pellet was resuspended in 1 ml of flow cytometry buffer for subsequent flow 
cytometry analysis. 
4.6. Microbiota analysis 
In recent years, significant advances in “deep-sequencing technologies” made possible 
the identification and characterization of the intestinal microbial content. The most 
common tool used for taxonomic characterization of microbial communities is the 16S 
ribosomal DNA sequencing. This gene has both highly conserved and variable regions. 
By amplifying regions of the gene using primers against the conserved regions, one can 
generate a population of bar-coded sequences that contain the region internal to those 
primers, which is highly variable. These regions can then be sequenced and classified 
based on the similarity to a reference database [51, 101]. 
For the microbiota analysis, stool samples of the mice were collected and frozen at -20°C 
until analysis. The gut microbiota composition of the mice was analyzed by means of 16 
rDNA PCR analysis (Dr. Andreas Hiergeist, AG Gessner, Institute of Microbiology and 
Hygiene, University Hospital Regensburg) as previously described [102]. 
4.7. Statistical analysis 
Results represent the median or mean and standard error of the mean (s.e.m.). 
Comparison between two groups was performed using Mann-Whitney U test or with 
Wilcoxon signed rank test (non-normal distributed data). When analysing more than two 
groups, non-normal distributed data was analysed with Kruskal-Wallis test followed by 
Dunns post-test. In case of normal- distributed data one-way ANOVA was used followed 
by Tuckey´s post-test. P-values of < 0.05 were considered statistically significant. All 
calculations were performed using the GraphPad Prism software. 
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5. Results 
5.1. Impact of NOD2 polymorphisms on the immune cell 
composition in peripheral blood of healthy donors 
NOD2/CARD15, the intracellular pathogen-recognition receptor recognizing bacterial 
muramyl dipeptide (MDP), has gained substantial interest, as single nucleotide 
polymorphisms (SNPs) of this receptor have been identified as a risk factor for Crohn´s 
disease and Graft-versus-Host disease (GvHD) [33, 38] . These data suggest that MDP 
sensing by hematopoietic cells is of crucial importance for the immune homeostasis in 
target organs of GvHD, especially in the gastrointestinal tract and/or skin. 
We were interested whether differences in the blood cell composition would be present in 
individuals carrying the respective SNPs (8, 12 and 13) in the NOD2 receptor. 
These mutations affect the C-terminal portion of the NOD protein. While SNP8 and 
SNP12 lead to amino acid substitutions, SNP13 represents a frameshift insertion. Both 
SNP12 and 13 mutations are located at the leucin-rich repeat (LRR), the region for ligand 
recognition, while the SNP8 mutation is located in the region between NOD and in close 
proximity to LRR [45].  
Blood samples from healthy donors without NOD2 mutation (WT) and donors carrying 
NOD2 SNP8, 12 and/or 13 NOD2 heterozygous mutations were collected into heparin 
containing tubes; the PMNCs were isolated by ficoll density gradient centrifugation and 
cryopreserved for future analysis.  
Seven-color flow cytometry was performed using standard protocols for cell surface 
staining to establish the frequencies of different cell populations. The percentage of T 
cells was determined by CD3 staining. B cells were determined via the percentage of 
CD19+ cells, myeloid cells by CD33 staining and NK cells by excluding the CD3+ cells 
and gating on CD16+/CD56dim cells. 
As observed in figure 5.1, no differences were found regarding the percentages of T and 
B cells. However, a significant lower percentage of CD33+ myeloid cells was found in 
individuals bearing any of the NOD2 SNPs. Regarding NK cells, we observed a trend 
towards an increase in this population in SNP donors. Next, a more detailed analysis of 
the populations was performed, and specific cell sub-populations were analyzed.  
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For the characterization of T lymphocyte populations, cells were stained for CD4, the 
marker for T helper cells, CD8, the marker for cytotoxic T cells, and CD25, a marker for T 
cell activation, also used for the identification of regulatory T cells (Tregs), since Tregs 
express constitutively high levels of CD25. 
In line with the preserved amount of CD3+ cells, no differences were found regarding the 
amount of specific T cell subtypes, as a similar percentage of CD4+,CD25+ and CD8+ 
cells was observed in both WT and SNP donors. 
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Figure 5.1. Impact of NOD2 SNP mutations on the blood composition of healthy donors. Percentage of 
CD3
+
 T cells (A), CD33
+
 myeloid cells (B), CD19
+ 
B cells (C) and CD16
+
CD56
dim 
NK cells (D) among living 
DAPI
- 
leukocytes. Each symbol represents an individual donor. Statistical analysis was performed with Mann 
Whitney U test. (** p ≤ 0.01, n.s.: not significant). 
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Figure 5.2. Amount of CD4
+, 
and CD4
+
CD25 (A) and CD8 
+ 
(B) T cells among living CD3
+ 
cells in 
the blood of WT and donors with NOD2 variants. Each symbol represents an individual donor and 
horizontal lines indicate the median. Statistical analysis was performed with Mann Whitney test. n.s.: 
not significant) 
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The dendritic cell populations present in blood were also analysed (Figure 5.3). The 
amount of plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) were determined by 
staining the cells with a lineage cocktail (CD3, CD14, CD19, CD20, CD56) to exclude T 
cells, B cells, monocytes and NK cells. After gating on HLA-DR+ cells, CD11c and 
CD123 were used to further discriminate the DC populations. mDCs were identified as 
lineage negative cells with high expression of CD11c and no expression of CD123, 
whereas pDCs express CD123 and have no CD11c expression.  
We observed a significantly reduced amount of mDCs (CD11c+, CD123-) in the SNP 
donors compared with WT. We also found a trend towards an increase in pDC frequency 
in SNP donors (CD11c-, CD123+) compared to WT, however, this effect was not 
statistically significant.  
 
 
As the number of CD33+ cells was significantly reduced, we were interested whether 
CD33+ subpopulations were influenced by the NOD2 SNPs. Therefore, we excluded cells 
positive for CD3, CD56 or CD19 and investigated CD33 expression as well as CD14 and 
CD16, markers characterizing subpopulations of monocytes. As shown in figure 5.4 A, 
we identified two CD33+ populations differing in the amount of CD33 expression (“low” – 
figure 5.4.B, “high” - figure 5.4.C). SNP donors showed a reduction in the CD33 “high” 
population compared to WT (Figure 5.4 C). Further analysis of this CD33 “high” 
population demonstrated an increase in CD16 expression on monocytes (Figure 5.4 D). 
Interestingly, donors with SNP8 showed comparable expression levels to WT donors, 
while donors with SNP12 or 13 showed increased expression levels. 
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Figure 5.3. Amount of myeloid (A) and plasmacytoid (B) dendritic cells among living lineage negative 
HLA-DR
+
 cells in the blood of WT, SNP8, 12 and 13 healthy donors. Each symbol represents an 
individual donor and horizontal lines indicate the median. Statistical analysis was performed with Mann 
Whitney U test (** p ≤ 0.01, n.s.: not significant). 
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5.1.1. Impact of NOD2-/- on immune cell composition in mice 
The number of donors carrying SNPs in NOD2 is rather limited. In the duration of the 
present work, 10% of the donors were carriers of SNP8, 4% of SNP12 and 5% were 
SNP13 carriers. Therefore, we investigated whether a mouse model lacking NOD2 would 
be an appropriate model reflecting the situation in humans carrying NOD2 SNPs. 
However, this model did not reflect the human findings, as the differences found in the 
myeloid compartment were not observed in mice lacking NOD2 expression (Figure 5.5). 
For this reason, all further experiments were performed with human samples.  
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Figure 5.4. Amount of CD33
+
 cells among living leukocytes in the blood of WT, SNP8, 12 and 13 
healthy donors. (A) gating strategy and representative image of a WT and SNP13 donor; (B)- amount of 
CD33 “high”; (C) Amount of CD33 “low”; (D) mean fluorescence intensity (MFI) of CD16 expression on 
monocytes, gated on CD33 “high”. Each symbol represents an individual donor and horizontal lines indicate 
the median. Statistical analysis was performed with Mann-Whitney U test (B and C) and Kruskal–Wallis test 
(D) (* p ≤ 0.05, ** p ≤ 0.01, n.s.: not significant).  
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5.2. Impact of blood sampling and cell isolation method on the cell 
phenotype 
In the previous experiments, blood collected with heparin tubes followed by ficoll 
separation was used. Due to the low yield of cells, the number of analysis was limited. As 
we observed a significant difference in donors with NOD2 SNPs regarding the myeloid 
compartment, we decided to study this cell population in more detail. Consequently, to 
obtain larger cell numbers, leukapheresis volunteers were screened for NOD2 
polymorphisms. Surprisingly, we could not reproduce the increased CD16 expression on 
monocytes with NOD2 SNPs using PMNCs from leukapheresis products. In fact, a trend 
towards an even lower expression of CD16 in donors carrying the SNP12 or 13 was 
observed.  
Figure 5.5. Impact of NOD2 expression on myeloid blood cells of WT and NOD2
-/-
 mice. Amount of total 
myeloid cells (CD11b
+
) (A) ,total amount of monocytes (Ly6C
+
) (B) and amount of CD11b
+
Gr1
+
myeloid-
derived suppressor cells (MDSC) (C) in the blood of WT and NOD2
-/- 
mice. Each symbol represents an 
individual donor and horizontal lines indicate the median. Statistical analysis was performed with Mann-
Whitney U test (n.s.: not significant). 
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Based on these conflicting data, we wondered whether the isolation method has an 
impact on CD16 expression. In the first set of experiments cells were collected using 
heparin as anti-coagulant agent; in the second set of experiments cells were obtained via 
leukapheresis products which uses citrate as anti-coagulant. In order to investigate a 
possible effect of the anti-coagulant on the monocyte phenotype, cells from the same 
donor were collected using different methods. Blood was withdrawn using tubes coated 
with different anti-coagulants (heparin, citrate, hirudin) before leukapheresis (always with 
citrate) from each donor. All samples were further separated by ficoll to isolate MNCs, 
which were stained for CD16 expression. Moreover, MNCs from the leukapheresis 
products were further separated by elutriation to obtain pure monocytes and also stained 
for CD16 expression, to control whether the elutriation process itself has an impact on 
the cell phenotype. 
As shown in figure 5.7, the collection method had a strong impact on the cell phenotype, 
as we observed a significant decrease in CD16 expression in cells collected by 
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Figure 5.6. Median fluorescence intensity (MFI) of CD14
+
16
+
 monocytes among living CD33
+ 
cells in 
the blood of WT, SNP8, 12 and 13 healthy donors. MNCs were collected from leukapheresis products 
followed by ficoll separation. Each symbol represents an individual donor and horizontal lines indicate the 
median. Statistical analysis was performed with Kruskal–Wallis test (n.s.: not significant). 
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leukapheresis. However, citrate alone had no significant impact on CD16 expression, 
showing that the decreased expression observed in leukapheresis products is possibly 
due to the preparation procedure itself but not due to the use of citrate. Elutriated 
monocytes also showed a lower CD16 expression, comparable to mononuclear cells 
from leukapheresis products before the elutriation, demonstrating that the elutriation 
procedure did not further modulate CD16 expression. 
 
5.2.1. CD16 downregulation: Importance of the recognized epitope 
The FcγRIII (CD16) is a low-affinity receptor for monomeric IgG. This glycoprotein of 50 
to 70 kD is expressed on neutrophils, natural killer cells, eosinophils, macrophages and 
monocytes. The CD16 expressed on natural killer cells and macrophages (CD16A) has a 
classical polypeptide membrane anchor, whereas the neutrophil CD16 (CD16B) is 
glycosyl-phosphatidyl inositol (GPI)-anchored [103]. 
The antibody used in the previous experiments was produced by the hybridoma cell 
clone 3G8, which should recognize both A and B isoforms of CD16. Next, we aimed to 
investigate if the observed difference in CD16 expression between the different 
preparation procedures was epitope-specific. Therefore, in addition to the previously 
used 3G8 antibody, also two other antibodies directed against both CD16 isoforms (A 
and B) from different clones, B73.1 and VEP13 were used. It is known that the epitope 
recognized by clone B73.1 is in the first membrane distal Ig-like domain of the CD16 
molecule, which is different from that of clones 3G8 and VEP13. 
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Figure 5.7. Impact of the blood collection method on CD16 expression. Blood was drawn either in the 
presence of heparin (n=6), hirudin (n=2), citrate (n=2) or EDTA (n=1). The same donor donated blood cells for 
the leukapheresis product. All blood samples were separated by ficoll. Elutriated monocytes separated from 
leukapheresis products are also shown (n=4).Shown is the median fluorescence intensity (MFI) of CD16. 
Each dot represents one individual donor. Statistical analysis was performed with Kruskal–Wallis test (** p ≤ 
0.01, *** p ≤ 0.001).
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Donor-matched blood from healthy volunteers was drawn using heparin tubes and 
erythrocytes were lysed using ACK lysis buffer. Alternatively, the same donors’ MNCs 
were obtained from ficoll separation after leukapheresis, as already described. 
Results demonstrated that the downregulation of CD16 expression in monocytes 
collected by leukapheresis was significant when stained with the 3G8 clone and the 
VEP13 clone but not when CD16 was measured using the B73.1 clone (Figure 5.8). 
Therefore, it seems that the observed decreased expression of CD16 detected with 3G8 
and also with VEP13 represents a downregulation of specific epitopes whereas other 
epitopes (detected by B73.1) are preserved. 
 
Interestingly, Passacquale et al. reported of an interaction between platelets and 
monocytes which they found to up-regulate CD16 expression in monocytes [104]. These 
monocyte-platelet aggregates are calcium-dependent and therefore calcium chelators 
such as citrate or EDTA could lead to a disruption of these aggregates, thereby reducing 
the amount of CD16+ monocytes. On the other hand, heparin as anti-coagulant could 
preserve the interaction of platelets and monocytes.  
5.2.2. Effect of platelets and TGF-β on human monocytes 
Because platelets are a major source of TGB-β in circulation [105], it was hypothesized 
that the up-regulation of CD16 in monocytes would also occur in monocytes treated with 
TGF-β. 
To prove that platelets and TGF-β are capable to induce the expression of CD16, 
monocytes were isolated by elutriation and co-cultured with platelets or with TGF-β in the 
presence or absence of MDP (the natural ligand of NOD2) for 24 hours. After this period, 
cells were harvested and stained for CD33, CD14, CD16 (3G8 clone) and CD62P, a 
Figure 5.8. Relative CD16 expression on monocytes using different antibody clones. Cells were 
collected either with heparin tubes (orange) or by leukapheresis, using citrate as an anti-coagulant (green) 
and stained with different CD 16 antibodies. Shown is the CD16 MFI. Each dot represents one individual 
donor and horizontal lines indicate the median. Statistical analysis was performed with Wilcoxon signed rank 
test (* p ≤ 0.05, n.s.: not significant). 
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marker for activated platelets. Co-expression of CD62P and CD14 demonstrated 
monocyte-platelet aggregates (Figure 5.9 A). Although a significant up-regulation was not 
detected, we observed a clear trend towards an increase of CD16+ monocytes in the 
presence of platelets and TGF-β, especially upon MDP treatment (Figure 5.9 B). 
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Figure 5.9. Percentage of CD16
+
 WT monocytes co-cultured with platelets or TGF-β. 2 x10
6 
Monocytes 
were cultured in 2 ml RPMI media supplemented with 2% AB serum. After 24 hours, the cells were 
harvested, washed and stained with fluorochrome-conjugated monoclonal antibodies (A). Shown is the 
median of CD14
+ 
CD16
+ 
cells.
 
Each dot represents an individual donor. (n=3) (B) Statistical analysis was 
performed with Kruskal–Wallis test (n.s.: not significant).  
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Next, CD16 expression was investigated in monocytes from NOD2 SNP-bearing donors 
under the same conditions. For this purpose, frozen cells from WT, SNP8, 12 and 13 
donors were cultured for 24 hours with or without TGF-β, LPS or MDP. Cell staining 
before starting the culture (day 0) revealed a low level of CD16 expression (Figure 5.10).  
Donors carrying a SNP12 or SNP13 (SNP12/13) had a slightly higher percentage of 
CD16+ cells, compared to WT and SNP8 donors after 24 hours incubation without any 
treatment. MDP stimulation had no impact on CD16. TGF-β stimulation was able to up-
regulate CD16 in all monocytes. The strongest effect of TGF, however, was observed in 
monocytes from SNP12/13 donors. Upon LPS treatment, we observed a lower 
expression of CD16 in donors with NOD2 SNP12/13 (Figure 5.10).  
These results indicate that the higher CD16 expression of donors with NOD2 SNP12/13 
found in mononuclear cells collected with heparin tubes but not in cells from 
leukapheresis products can be partially recovered after culturing the cells for 24 hours in 
vitro. Furthermore, TGF-β up-regulates CD16 independently of the NOD2 status. 
Nevertheless donors with NOD2 SNP12/13 were more susceptible to this effect since 
they exhibited a significantly higher expression of CD16. Interestingly, LPS counteracted 
the up-regulation of CD16 independently of the NOD2 status. However, more donors 
have to be included in the analysis to confirm the observed effects. 
 
As a control we analysed whether other typical monocyte antigens such as CD14 (Figure 
5.11) are also altered in cultured monocytes under the different treatments. Here no 
significant differences were observed between the treatments independent of the NOD2 
Figure 5.10. Percentage of CD14
+
CD16
+
monocytes stimulated with or without MDP, TGF-β or LPS. 2 
x10
6 
frozen monocytes were cultured in 2 ml RPMI medium supplemented with 2% AB serum and stimulated 
with the indicated substances. After 24 hours, cells were harvested, washed and stained with fluorochrome-
conjugated monoclonal antibodies. Shown is the median of CD16
+
 positive cells. Each dot represents an 
individual donor. Statistical analysis was performed with Kruskal-Wallis test. Due to the low number of SNP8 
donors, they were not included in statistical analysis (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.)  
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status, although a trend could be observed towards a down-regulation of CD14 upon 
LPS stimulation.  
 
 
In addition, HLA-DR expression was analysed on monocytes. HLA-DR is an important 
surface marker regarding antigen presentation. Monocyte culture or MDP treatment did 
not influence HLA-DR expression on monocytes independent of the NOD2 status (Figure 
5.12). 
TGF-β down-regulated HLA-DR expression however this effect was only significant for 
donors with NOD2 SNPs 12/13. 
Figure 5.12. Percentage of HLA-DR
+
 monocytes stimulated with or without MDP, TGF-β or LPS. 
2x10
6 
frozen monocytes were cultured in 2 ml RPMI medium supplemented with 2% AB serum and 
stimulated with the indicated substances. After 24 hours, the cells were harvested, washed and stained 
with fluorochrome-conjugated monoclonal antibodies. Each dot represents an individual donor. Shown is 
the median of HLA-DR
+
 positive cells. Statistical analysis was performed with Kruskal-Wallis test (* p ≤ 
0.05). 
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Figure 5.11. CD14
 
expression on monocytes stimulated with or without MDP, TGF-β or LPS. 2 x10
6 
frozen monocytes were cultured in 2 ml RPMI medium supplemented with 2% AB serum and stimulated 
with the indicated substances. After 24 hours, cells were harvested, washed and stained with 
fluorochrome-conjugated monoclonal antibodies. Each dot represents an individual donor. Shown is the 
median of CD14
+
 positive cells. Statistical analysis was performed with Kruskal-Wallis test (n.s.: not 
significant). Due to the low number of SNP8 donors, they were not included for statistical analysis. 
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In summary, the phenotype with regard to surface markers of monocytes from donors 
with NOD2 SNP12 or 13 was altered. Cells expressed similar amounts of CD14 but 
increased levels of CD16. Furthermore, monocytes with NOD2 SNP12 or 13 were more 
susceptible to TGF-β treatment, which up-regulated CD16 but down-regulated HLA-DR 
expression compared to donors with WT NOD2. Next, the functional impact of the NOD2 
status was determined in monocytes by means of analysis of cytokine expression. 
5.2.2.1. Cytokine profile of monocytes with different NOD2 variants 
The cytokine secretion was analysed by means of ELISA in supernatants of the previous 
cultures used for surface marker analyses (Figures 5.10-5.12). The levels of IL1-β, IL-6 
and IL-8 and TNF were determined.  
We observed that WT and NOD2 SNP donors produced similar amounts of IL-6 
independent of the stimulus. Although not significant, in WT individuals IL-6 production 
was diminished upon incubation with the combination of LPS and MDP compared to 
incubation with LPS alone. This effect, however, was not observed in the NOD2 SNP 
donors. Furthermore, non-stimulated monocytes (control) showed increased IL-6 
production compared with WT (Figure 5.13 A). 
Although IL-8 secretion was slightly decreased in donors carrying the NOD2 SNPs in all 
treatments, statistical significance was only reached in the presence of MDP in donors 
with NOD2 SNP12 or 13 compared to WT donors. This is in line with some reports that 
already described that IL-8 levels are decreased in patients with NOD2 SNPs [106]. 
TNF secretion (Figure 5.13C) was not significantly altered between WT and NOD2 SNP 
donors, with LPS treatment or LPS and MDP combination being able to up-regulate 
cytokine production independent of the NOD2 status. 
Although a trend towards a decrease in IL-1β secretion is observed in donors bearing the 
NOD12/13 mutation in control, MDP and TGF-β treatment this was not significant. Upon 
LPS or LPS in combination with MDP treatment, a significant up-regulation of IL1-β was 
observed, independent of the NOD2 status (Figure 5.13D) 
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5.2.2.2. Regulation of IκBβ and phospho p38 expression in monocytes with 
different NOD2 variants 
It is known that NOD2 activation triggers different signalling pathways including the NF-
κB pathway. Upon stimulation with pro-inflammatory cytokines such as TNF, IL-1β or 
bacterial stimuli, IκBα/β is phosphorylated, polyubiquitinated, then degraded by the 26S 
proteasome, allowing NF-κB to translocate to the nucleus and activate its target genes 
[107]. In order to investigate if monocytes from donors with NOD2 WT or NOD2 SNPs 
exhibit differences regarding this pathway, IκB protein was analysed by western blot. 
Both MDP and LPS were able to reduce IkBb expression in the WT donor. Interestingly, 
we found an almost undetectable level of IκB expression in non-stimulated cells of the 
donor with a combined SNP8+13 mutations compared to the WT donor suggesting a 
constitutively active NF-κB pathway. In line with this finding, this donor had a constitutive 
high production of IL-6 (Figure 5.14 C). The analysed donor harbouring the SNP13 alone 
revealed a similar behaviour to the WT, possibly indicating that the presence of 2 
different mutations (SNP8+13) represents a special phenotype with stronger 
consequences in terms of cell signalling. These results have to be confirmed with more 
donors harbouring NOD2 SNPs. 
Figure 5.13. Amount of IL-6 (A) , IL-8 (B), TNF (C) and IL1-β (D) secretion in monocytes stimulated 
with or without MDP, TGF-β and LPS or LPS+MDP. Statistical analysis was performed with Kruskal-Wallis 
test (*p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). WTn= 5, SNP8 n=2, SNP12/13 n=6 Due to the low number of 
SNP8 donors, they were not included for statistical analysis. 
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The activation of phospho-p38 MAP Kinase was also analysed in WT, SNP8+13 and 
SNP13 (Figure 5.14C). A high variance was detected in the two analysed NOD2 WT in 
the control group. One donor showed only p38 activation upon stimulation whereas the 
other presented a strong activation of p38 in the control. The analysed SNP8+13 appears 
to activate this pathway with all the applied stimuli, whereas for the SNP13 donor no 
significant differences were detected regarding p38 activation. 
A. 
B. 
Figure 5.14. Effect of NOD2 mutations on iκBβ and phospho p38 expression. Monocytes were 
stimulated for 30 minutes with the indicated stimuli. Phospho-protein lysates were collected and western blot 
was performed to analyse iκBβ expression (A and B) Representative blot is shown on A and densiometric 
analysis in shown on B. On C is shown representative blots for P-p38 and on D the densiometric analysis WT 
n≥2, SNP8 n=1 SNP13+8 n=1; SNP13 n=1.  
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5.3. Impact of NOD2 on monocyte-derived macrophages 
Macrophages (and their precursors, monocytes) are the 'big eaters' of the immune 
system. These cells are present virtually in all tissues. They differentiate from circulating 
blood monocytes which migrate into tissues in the steady state or in response to 
inflammation. Macrophages are remarkably plastic and can change their phenotype 
depending on the environmental signals they receive. Through their ability to clear 
pathogens and instruct other immune cells, these cells have a central role in protecting 
the host but can also contribute to the pathogenesis of inflammatory diseases [13]. 
It is generally accepted that CD14++ classical monocytes leave the bone marrow and 
differentiate into CD14++CD16+ intermediate monocytes and sequentially to 
CD14+CD16++ non-classical monocytes in the peripheral blood circulation [108].  
Due to the observation of an increased amount of CD14++CD16+ monocytes in donors 
with NOD2 SNP12 and SNP13, we hypothesised that the differentiation of macrophages 
and/or dendritic cells could be impaired, leading to the accumulation of “mature” 
monocytes in the blood circulation. Since macrophages normally express high levels of 
CD16 as a differentiation marker, this cell type appear to be a promising cell population 
to study the CD16 regulation in NOD2 mutated donors. For that reason, monocytes were 
cultured from donors with NOD2 WT and SNP13 in teflon bags with AB-serum for 7 days. 
After this period cells were harvested and stained for macrophage markers. Data 
analysis demonstrated no significant impact of the NOD2 SNP13 mutation on 
macrophage maturation indicating that the maturation of macrophages is not disturbed 
by the presence of NOD2 SNP13. Nevertheless, a decreased expression in CD16 was 
detected on the analysed NOD2 SNP13 donor. Since a great variation between donors 
sharing the same NOD2 genotype was identified, no significant conclusion can be taken 
from these experiments. The number of viable cells (Figure 5.15 B) was the same in the 
analysed WT and SNP donors. Nonetheless, data should be confirmed with other donors 
carrying the NOD2 SNP12/13 mutation. 
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Figure 5.15. Expression of maturation markers in monocyte-derived macrophages from donors 
with NOD2 WT and NOD2 variants. Macrophages were cultured as mentioned before. Cells were 
harvested, washed, and stained with the indicated fluorochrome-conjugated monoclonal antibodies. 
Samples were analysed by flow cytometry. Representative FSC and SSC (A) cell viability (B) 
representative histograms (C) summary of the preformed experiments (D). Shown is the median 
fluorescence intensity (MFI) (isotype subtracted). Cell viability was determined by a cell analyzer (CASY 
system). 
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5.4. Impact of NOD2 on dendritic cell differentiation cultures 
Due to the observed reduction of myeloid dendritic cells in the blood of donors with 
NOD2 SNP12 and 13, the maturation of dendritic cells under different culture conditions 
was analysed. 
Although DCs have the ability to induce a T cell response, they can also exhibit 
tolerogenic properties that might be exploited in the prevention and treatment of e.g. 
GvHD. Tolerogenic DC are characterized by a semi-mature phenotype with low 
expression of co-stimulatory B7 molecules. They mainly secrete immunosuppressive 
mediators, such as IL-10, and lack the production of pro-inflammatory cytokines such as 
IL-12 [109]. 
5.4.1. Dendritic cell cultures of donors with NOD2 WT SNP8 and SNP12 and 13  
Based on the findings that NOD2 SNP donors have alterations in their myeloid cell 
compartment and show a reduced amount of mDCs in peripheral blood (chapter 5.1) we 
hypothesized that the in vitro generation of dendritic cells would also be affected in 
cultures from NOD2 SNP-bearing donors. Due to limited numbers of cells with NOD2 
SNPs in heparin-drawn blood samples and more physiological culture conditions we 
used a protocol for DC generation starting from MNCs instead of purified monocytes 
[110].  
Mononuclear cells (consisting of a mixture of monocytes and lymphocytes) were 
separated from heparin-drawn blood by ficoll. The isolated cells were cultured in 96-well 
plates (1x106 in 100 µl) in RPMI medium supplemented with 10% FCS for 24 hours. After 
this period the cells were stimulated with or without LPS or MDP for 24 hours. 
Dendritic cell maturation markers such as CD80, CD83 and CD86 were significantly up-
regulated by LPS in cultures from donors with WT NOD2 but not in cultures from donors 
harbouring a NOD2 SNP13 mutation indicating that dendritic cell maturation is impaired 
in these cells. MDP had only a slightly positive effect on dendritic cell maturation. 
Regarding HLA-DR expression, no significant differences were found independent of the 
NOD2 status or stimulus (Figure 5.16). 
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Figure 5.17. IL-10 production is similar in cultures from WT and NOD2 SNP donors. DCs were 
cultured as previously described. The supernatants were harvested and IL-10 production analysed by 
means of ELISA.  Shown is the mean of 3 experiments + SEM. Statistical analysis was performed with 
Kruskal-Wallis test (* p ≤ 0.05). 
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Culture supernatants were harvested and analysed by means of ELISA. IL-12 production 
was not detected in any of the cultures (data not shown). IL-10 analysis revealed that 
cells were able to produce this cytokine but no difference was found between cell 
cultures from donors with NOD2 WT and NOD2 SNP 13 (Figure 5.17). 
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Figure 5.16. SNP13 donors displayed an impaired DC maturation. MNCs were cultured in 96 well plates 
in RPMI supplemented with 10% FCS, IL-4 and GM-CSF for 24 hours. After this period, cells were stimulated 
with or without LPS or MDP for additional 48 hours. Shown is the mean of the median fluorescence intensity 
(MFI) (isotype subtracted) + SEM (n=3). Statistical analysis was performed with Kruskal-Wallis test (* p ≤ 
0.05, ** p ≤ 0.01, n.s.: not significant n.e: not expressed). 
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To confirm the data obtained from these MNC-DC cultures, monocytes of WT and NOD2 
SNP-bearing donors were isolated via elutriation to generate DCs using the “classical” 
protocol for DC generation. Therefore monocytes were cultured for 5 days in RPMI 
medium supplemented with 10% FCS, IL-4 and GM-CSF. Afterwards, cells were 
stimulated for 48 hours with LPS or MDP. Surprisingly, and contrary to our findings on 
fast MNC-DC, we found that classical DCs generated from monocytes with NOD2 SNPs 
expressed higher amounts of CD86 and CD83 upon LPS stimulation compared with WT, 
indicating an enhanced maturation level of these cells (Figure 5.18). The number of 
viable cells was not significantly differrent in WT or SNP donors (Figure 5.18 B). 
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Figure 5.18. SNP12 and 13 donors showed enhanced activation in classical DCs. Monocytes were 
cultured in flasks in RPMI supplemented with 10% FCS, IL-4 and GM-CSF for 5 days. After this period, cells 
were stimulated with or without LPS or MDP for additional 48 hours. Shown is one representatice FSC/SSC 
(A) Cell viability (B) the mean of the median fluorescence intensity (MFI) (C-F) (isotype subtracted) relative to 
unstimulated cells + SEM (n=3). Statistical analysis was performed with Kruskal-Wallis test (*** p ≤ 0.001, n.s.: 
not significant).Cell viability was determined with a cell analyser (CASY system). 
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Culture supernatants were harvested and analysed by means of ELISA. Although not 
significant, we observed a strong reduction in cytokine production in monocyte- derived 
DCs generated from SNP12 or 13 donors compared with WT (Figure 5.19). 
5.4.2. Effect of the NOD2-ligand MDP on monocyte-derived dendritic cells 
MDP had only little effect on dendritic cell maturation in the previous experiments (Fig. 
5.16, Fig. 5.18). We wondered whether this limited capacity to induce maturation is due 
to the used differentiation protocol or whether it was donor-related. Therefore, the 
different protocols were applied to the same donor. Here, it was analysed whether MDP 
can influence dendritic cell maturation in WT donors using different dendritic cell 
differentiation protocols. Classical DC (cDC) protocols using monocytes (Mo-DCs) and 
fast DC (fDC) protocols using mononuclear cells (MNC-DC) or monocytes were 
compared for the generation of dendritic cells. The classical protocol was performed has 
described above (5.4.1) Alternatively, for the fast protocol, monocytes or mononuclear 
cells were cultured for 24 hours and then stimulated for another 48 hours. Cells were 
stained and analysed by means of flow cytometry. Supernatants were harvested, frozen 
and cytokine production was analysed by ELISA. In contrast to LPS, MDP was incapable 
to induce the maturation of human monocyte-derived dendritic cells (Figure 5.19 A-D), as 
MDP failed to up-regulate DC maturation-related markers such as CD80, CD83, CD86 
and HLA-DR, independent of the applied protocol. Regarding the LPS treatment, 
differences in the expression of the maturation markers were observed between the 
different protocols, however, the differences were not statistically significant. As MDP 
failed to induce differentiation of dendritic cells, we hypothesised that MDP could induce 
a semi-mature more tolerogenic phenotype in DCs.  
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 Figure 5.19. IL-10 and IL-12 production is impaired in cultures from NOD2 SNP donors. DCs were 
cultured as previously described following the classical protocol. The supernatants were harvested and IL-
10 and IL-12 production analysed by means of ELISA.  Shown is the mean of 3 experiments + SEM. 
Statistical analysis was performed with Kruskal-Wallis test . n.s: not-significant; n.d- not detected.  
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5.4.2.1. Impact of MDP on tolerogenic marker expression in DC cultures 
It is well-known that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) can induce tolerogenic 
dendritic cells [111]. Therefore, 1,25(OH)2D3 was used as a positive control for the 
generation of tolerogenic DC. Monocytes were cultured using the fast protocol and 
stimulated with or without LPS, MDP and 1,25(OH)2D3. Typical markers for tolerogenic 
cells were analysed such as ILT2, ILT3 and also PD-L1 and PD-L2, which are co-
inhibitory molecules crucial for the down-regulation of T-cell response and maintenance 
of immune homeostasis. 
Data analysis revealed a significant up-regulation of PD-L1 and PD-L2 in DCs stimulated 
with LPS (Figure 5.21 A and B).  
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Figure 5.20. MDP is incapable to induce the differentiation of human monocyte-derived dendritic 
cells (Mo-DCs). Mo-DCs or MNC-DCs were generated under 3 different protocols differing in the initial 
culture period or initial cell population. For Fast Mo-DC, 10x10
6
 monocytes were cultured for 24 hours. 
Classical DCs were culture at the same density for 5 days. MNC-DC were generated using 40x10
6
 cultured 
for 24 hours. Afterwards, all cultures were stimulated for 48 hours and analysed by flow cytometry. Shown is 
the mean of the median fluorescence intensity (MFI) (isotype subtracted) relative to unstimulated DC + SEM 
(n≥3). Statistical analysis was performed with Kruskal-Wallis test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, n.s.: 
not significant). 
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No differences in the expression of immunoglobulin like transcript 2 (ILT2) were found 
under all the tested conditions (Figure 5.21 A-D). However, ILT3 was significantly 
increased on DCs stimulated with 1,25(OH)2D3. (Figure 5.21 D). MDP stimulation had a 
similar effect, although not significant (Figure 5.21 D). 
5.4.2.2. Cytokine profile of Mo-derived DC versus  MNC-derived DC 
The balance between IL-10 and IL-12 secretion can also determine the T cell response 
as tolerogenic dendritic cells secrete more IL-10, polarizing the T cell towards a more 
regulatory phenotype. 
To further characterize the generated dendritic cell populations, the supernatants of the 
cultures were analysed by means of ELISA (Figure 5.22). Comparable to the surface 
marker analyses, only LPS but not MDP was capable to stimulate cytokine secretion in 
dendritic cells. This effect was partially dependent on the used differentiation protocol. 
Dendritic cells generated from mononuclear cells produced more IL-10 and less IL-12 
what indicate that these cells possibly exhibit a more tolerogenic phenotype.  
Figure 5.21. Expression of tolerogenic DC markers after culture with LPS, MDP and 1,25(OH2D3. 
fDC were cultured as previously described and stimulated with or without LPS (100 ng/mL), MDP (100 
ng/mL),) and 1,25 (OH)2D3 (5x10
-9
 M). After 48 h cells were harvested, washed, and stained with the 
indicated fluorochrome-conjugated monoclonal antibodies for PDL1 (A), PDL2 (B), ILT2 (C) and ILT3 (D) 
.Samples were analysed by flow cytometry. Shown is the mean of the median fluorescence intensity (MFI) 
(isotype subtracted). Data are means + SEM (n=3). Statistical analysis was performed with Kruskal-Wallis 
test (* p ≤ 0.05, ** p ≤ 0.01, n.s.: not significant). 
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Taking together these results suggest that the presence of lymphocytes in the culture 
and the duration of the protocol can influence the dendritic cell cytokine secretion profile. 
5.4.2.3. Oxygen consumption and lactate production of Mo-derived DC 
cultures 
The metabolic phenotype has also been implicated in the activation and differentiation of 
dendritic cells. Stimulation by LPS is known to induce glycolysis and this “glycolytic 
switch” seems to be important for cell activation and differentiation [112]. Therefore, we 
investigated whether MDP could alter the metabolic characteristics of dendritic cells. 
Cells were seeded in 24-well SDR SensorDish Reader plates for 24 hours. Afterwards, 
cells were stimulated with or without LPS or MDP and placed in the SensorDish Reader 
for 48 hours to measure oxygen consumption. As expected, LPS reduced respiration in 
donor 1 and 2 but not in donor 3 (Figure 5.23 A-C). MDP also lowered respiration in 
donor 1 and 2 but to a lower extent. In addition, lactate was determined in the 
supernatant of the different cell cultures as readout for glycolysis. In line with the reduced 
respiration LPS and MDP slightly stimulated glycolysis, however, differences were not 
significant (Figure 5.23D). 
Figure 5.22. IL10 and IL-12 secretion dendritic cells generated under different protocols. After 48 
hours supernatants were harvest and the amount of IL-10(A) and IL-12 (B) were determined by ELISA.  
Data are means + SEM (n ≥4). Statistical analysis was performed with Kruskal-Wallis test (* p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001 n.s.: not significant; n.d- not detected). 
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5.4.2.4. T cell stimulatory capacity of fast DC versus classical DC 
To determine the T cell stimulatory capacity of the DCs generated under different 
protocols, we performed mixed lymphocyte reactions (MLRs) where 10,000 DCs 
(classical or fast) (previously matured with or without LPS and MDP) were cultured for 5 
days with 100,000 allogeneic T cells and the proliferation of the cultures was analysed. In 
line with the high expression of maturation markers and high capacity for IL-12 secretion, 
both classical and fast LPS-DC strongly induced proliferation of T lymphocytes, but MDP-
DC were incapable to induce T cell proliferation (Figure 5.24).  
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Figure 5.23. Oxygen consumption and lactate production of the Mo-derived DCs were seeded in 24 well 
SDR SensorDish plates for 24 hours. Afterwards, cells were stimulated with or without LPS or MDP and 
placed on the SensorDish Reader for 48 hours. For the lactate analysis, supernatants were harvested and 
lactate determined as described in Chapter 4. Data are means + SEM. N=3. Statistical analysis was 
performed with Kruskal-Wallis test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001) (n.s.: not significant). 
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5.4.2.5. Generation of regulatory T cells in the MLR 
Regulatory T cells are a population of T cells with immunosuppressive activity and can 
be identified by high levels of CD25 and the expression of the transcription factor 
FOXP3. This cell population is of great importance in maintaining peripheral tolerance 
[66]. Regulatory T cells can be induced e.g. via culturing naïve T cells with tolerogenic 
DCs. To analyse the lymphocyte populations after culturing dendritic cells with allogeneic 
T cells, cells were harvested, stained for CD4, CD25 and FOXP3 and analysed by 
means of flow cytometry. Co-culturing T cells with iDCs differentiated applying the fast 
protocol or the classical protocol did not result in any difference in FOXP3+ T cells (Figure 
5.25). Immature DCs and MDP-stimulated DCs resulted in similar numbers of FOXP3+ 
cells whereas cultures with LPS-stimulated DCs had reduced numbers of FOXP3+ cells 
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Figure 5.24. Functional analysis of the generated DCs 
Monocyte derived-DC generated under different protocols were stimulated for 48 hours with or without LPS 
(100 ng/mL) or MDP (100 ng/mL) under different protocols. DCs were harvested and washed.10,000 DCs 
(cDCs or fDCs) were co-cultured with allogeneic T lymphocytes.L. alone refers to the unstimulated 
lymphocyte culture. After five days, the proliferation rate of T cells was analysed. Shown are means + SEM 
(n = 3). Statistical analysis was performed using Kruskal-Wallis test. (* p ≤ 0.05). 
Results 
70 
 
 
5.5. Impact of vitamin D3 on immune cells 
5.5.1. Effect of vitamin D3 on human monocytes 
5.5.1.1. Vitamin D3 and NOD2 interplay 
Beside NOD2 polymorphisms, vitamin D3 receptor gene polymorphisms have also been 
associated with GvHD [96]. Furthermore, it was already demonstrated that vitamin D3 
deficiency is a common phenomenon in allogeneic transplant patients and may also be 
involved in the pathogenesis of GvHD [89]. Although at the first glance NOD2 and 
vitamin D3 appear to be completely independent factors, they seem to be linked since the 
active metabolite of vitamin D3, 1,25(OH)2D3, stimulates the expression of the pattern 
recognition receptor NOD2/CARD15 on monocytes [113]. 
In order to investigate whether physiological concentrations of 25(OH)D3 and 
1,25(OH)2D3 are also capable to induce NOD2 mRNA expression, human monocytes 
were incubated for 24 hours with or without vitamin D3 and stimulated for additional 24 
hours with or without LPS, MDP and combination. Next, total cellular mRNA was isolated 
and gene expression was analysed by means of real-time quantitative PCR (RT-qPCR). 
Although not significant, a trend towards an up-regulation of NOD2 mRNA expression by 
25-hydroxyvitamin D3 (25(OH)D3) and 1,25(OH)2D3 (Figure 5.23) was observed under all 
treatments, with the exception of the combined treatment with LPS and MDP.  
Figure 5.25. Amount of FOXP3
+
 CD4
+
 cells after co-culturing with DCs matured either with MDP 
ord LPS Monocyte derived-DC, differentiated applying the classical or fast protocol,  were stimulated for 
48 h with or without LPS (100 ng/mL) or MDP (100 ng/mL). Cells were harvested and washed.10,000 
DCs (cDCs or fDCs) were co-cultured with allogeneic T lymphocytes in the absence of LPS or MDP. After 
five days, the proliferation rate of T cells was analysed and the cells stained for CD4 and Foxp3. Data are 
means + SEM (n = 3). Statistical analysis was performed using Kruskal-Wallis test. (n.s. not significant). 
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5.5.2.  Effect of Vitamin D3 on human T cells 
5.5.2.1. FoxP3 induction by 25(OH)D3 in human CD4
+ T cells 
The tolerogenic effects of vitamin D3 on myeloid cells have already been extensively 
studied [111, 114, 115]. It is widely accepted that 1,25(OH)2D3 has an indirect DC-
mediated effect on T cells [116]. 1,25(OH)2D3-treated DCs are capable to induce FOXP3 
expression in T cells, a marker for regulatory T cells. However, little is known about the 
direct impact of 25(OH)D3 and 1,25(OH)2D3 on FOXP3 expression in T cells. 
Furthermore, the majority of these studies use high, non-physiological concentrations of 
vitamin D3. Here, the impact of 25(OH)D3 , the most important serum metabolite due to its 
stability, was investigated. CD4+T cells were isolated from human PBMCs using 
magnetic bead separation and stimulated with anti-CD3/CD28 T cell expander beads 
(TCE) in different ratios (1 bead/T cell or 1 bead /10 T cells) in the presence or absence 
of 25(OH)D3 for 3 days. After this period, cells were harvested, counted and stained for 
FOXP3. Data analysis showed an increase in FOXP3 expression in the presence of 
25(OH)D3 independent of the number of stimulator beads, demonstrating that 
physiological concentrations of the vitamin D3 precursor are able to induce a regulatory 
phenotype in T cells independent of the presence of DCs (Fig. 26). A lower level of 
stimulation with 0.1 bead/T cell led to a significantly decreased T cell proliferation 
independent of 25(OH)D3. 
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Figure 5.26. NOD2 mRNA expression in human monocytes. Human monocytes were incubated with or 
without 25(OH)D3 (5x10
-8
 M) or 1,25(OH)2D3, (5x10
-9
 M) for 24 hours. Afterwards, cells were further 
stimulated with LPS (100ng/ml), MDP (100 ng/ml) or the combination for another 24 hours. Subsequently, 
cells were lysed, RNA was isolated and NOD2 mRNA analysed by means of qRT-PCR. Data are means ± 
SEM (n =3). Statistical analysis was performed with Kruskal-Wallis test (n.s.:not-significant).  
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5.5.2.2. FoxP3 induction by Vitamin D3 in naïve CD4
+ T cells 
In the previous experiments, an increase in FOXP3 expression was found in the 
presence of 25(OH)D3. However, the initial culture contained not only naïve CD25
-T cells 
but also CD25+ T cells, meaning that the observed increase in FOXP3+ cells could be 
due to the expansion of a pre-existing population of regulatory T cells. To overcome this, 
cells were FACS sorted for CD4+CD25- T cells (kindly performed by AG 
Hoffmann/Edinger, Department of Internal Medicine III, University Hospital Regensburg) 
to assure that the observed results represent an induction of CD25 and FOXP3.  
In this set of experiments, the impact of both forms of vitamin D3, the precursor, 
(25(OH)D3) and the active form (1,25(OH)2D3),  were studied in naïve CD4
+ T cells. TGF-
β, a well-known stimulus for FOXP3 induction was used as a positive control [117]. 
Analysis revealed that all stimuli added to the cultures were able to significantly up-
regulate FOXP3 expression (Figure 5.27), independently of the presence of DC. A 
significant up-regulation of FOXP3 was also found in the presence of 25(OH)D3 indicating 
either a direct induction of FOXP3+ T cells by the vitamin D3 precursor or the 
hydroxylation of 25(OH)D3 to 1,25(OH)2D3 by T cells. 
 
 
 
 
 
 
 
Figure 5.27. Amount of FOXP3+ cells (A) and cell proliferation (B) in CD4
+
 T cell cultures. 0,5x10
6
 cells 
were cultured in 24 well plates in the presence or absence of 25(OH)D
3
 and stimulated with different TCE 
bead: cell ratios (1 bead:1 cell or 1 bead: 10 cells) . The amount of FOXP3
+ 
cells was analysed by flow 
cytometry. Each dot represents one individual donor. Shown is the mean (n=6). Statistical analysis was 
performed with repeated measures ANOVA (* p ≤ 0.05). 
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FOXP3 expression was also analysed on the mRNA level by means of qRT-PCR (Figure 
5.29). Surprisingly, a significant increase of FOXP3 m RNA was only found for the TGF-β 
and 1,25(OH)2D3 combination. 
 
 
Figure 5.29. FOXP3 mRNA expression is increased upon TGF-β + 1,25 (OH)2D3 treatment. Cells were 
cultured with the indicated stimuli for 4 days. Afterwards, cells were lysed, RNA was isolated and FoxP3 
mRNA analysed by means of qRT-PCR. Data are means + SEM (n ≥2). Statistical analysis was performed 
with Kruskal-Wallis test (* p ≤ 0.05). 
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Figure 5.28. FOXP3 induction by 1,25(OH)2D3 and 25(OH)D3 in comparison to TGF-β,. Naïve CD4+ T 
cells  were stimulated with TGF-β (10 ng/ml), 25(OH)D3 (5x10
-8
 M) and 1,25(OH)2D3, (5x10
-9
 M) in 24 well 
plates for 4 days in the presence of TCE beads ( 1 bead/cell). The amount of FOXP3
+ 
cells was analysed by 
flow cytometry. Data are means ± SEM (n ≥ 5). Statistical analysis was performed with one-way ANOVA (* p 
≤ 0.05, *** p ≤ 0.001). 
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Figure 5.30. Amount of 1,25(OH)2D3 in the culture supernatant of human CD4+ T cells. Cells were 
cultured for 4 days in the presence of 25(OH)D3 and TCE beads. After the culture period, supernatants 
were harvested and the amount of 1,25(OH)2D3 determined by using a radioimmunoassay according to the 
manufacturer’s instructions (Immunodiagnostic Systems). Data are means + SEM (n ≥ 4). Statistical 
analysis was performed with one-way ANOVA (* p ≤ 0.05, ** p ≤ 0.01,). 
There is some evidence that T cells also express CYP27B1, the enzyme catalysing the 
hydroxylation of 25(OH)D3 to 1,25(OH)2D3. However, data on the production of 
1,25(OH)2D3 from 25(OH)D3 by T cells are inconsistent [118-120]. 
Since the expression of CYP27B1 in T cell cultures suggest that the cells are perhaps 
able to produce 1,25(OH)2D3, culture supernatants were harvested after 4 days and 
analysed for the level of 1,25(OH)2D3. An increase in 1,25(OH)2D3 was found in the 
presence of 50 nM 25(OH)D3 and significantly higher levels of 1,25(OH)2D3 were 
detected upon incubation of T cells with 100 nM 25(OH)D3. (Figure 5.30).  
 
5.5.2.2.1. Cytokine secretion by T cells in the presence of vitamin D3 
The effect of 1,25(OH)2D3 on T cell responses is not limited to the induction of regulatory 
T cells. It is discussed that 1,25(OH)2D3 inhibits the Th1 and Th17 
response[79].Therefore, the secretion of soluble CTLA-4 and other cytokines in T cell 
cultures were analyzed in the presence or absence of 25(OH)D3 or 1,25(OH)2D3 after 4 
days stimulation with TCE. A significant increase in the secretion of soluble CTLA-4 was 
detected in the presence of TGF-β in combination with 1,25(OH)2D3 (Figure 5.31 A), as 
well an increase in IL-10 production (Figure 5.31 B). Although not significant, the 
stimulation of CD4+CD25- T cells in the presence of 25(OH)D3 lead to the down-
regulation of IL-17 (Figure 5.31 C) and IFN-γ secretion (Figure. 5.31 D), indicating that 
also other T cell populations than FOXP3+ T cells might be influenced by 25(OH)D3.  
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Figure 5.31. Cytokine profile of CD4
+
25
-
 T cells stimulated with TGF-β, 25(OH)D3 or 1,25(OH)2D3. Cells 
were cultured with the indicated stimuli for 4 days. Afterwards, supernatants were harvested and cytokines 
measured by means of ELISA. Amount of soluble CTLA-4 (A),IL-10 (B), IL-17 (C) and IFN (D) in culture 
supernatant. Data are means + SEM (n ≥3). Statistical analysis was performed with one-way ANOVA (A and 
B) or Kruskal-Wallis test (C and D). (* p ≤ 0.05, ** p ≤ 0.01). 
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5.6. In vivo effects of vitamin D3 
Based on our own in vitro data and the available information regarding vitamin D3 effects 
on the immune system, we decided to establish a model of vitamin D3 sufficiency versus 
deficiency in order to investigate vitamin D3 modulation of the immune system in vivo. 
5.6.1. Vitamin D3 sufficient versus deficient mouse model 
Vitamin D3 levels are strictly regulated and relatively stable. Therefore, it is necessary to 
use young mice directly after weaning to generate mice with low 25(OH)D3 levels. Two 
independent experiments were conducted, using 3 weeks old female BALB/c mice 
purchased from Charles River Laboratories. Mice were fed with a special vitamin D3-
deficient (<100 U/Kg) or vitamin D3-sufficient (1500 U/Kg) diet (Ssniff GmbH). Serum 
25(OH)D3 levels were measured by means of liquid chromatography high-resolution 
tandem mass spectrometry in the Department of Clinical Chemistry (Figure 5.32). 
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In a third experiment we used an outbred mouse model (CD-1) which should more 
closely mimic the situation in patients. Outbred mice have unpredictable genotypes and 
therefore are expected to have a diverse population of phenotypes [121].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding BALB/c mice in both experiments (1 and 2), significantly lower values of 
serum 25(OH)D3 were obtained in mice receiving the vitamin D3 deficient diet (mean 41.9 
nM (suf.) vs. 12.2 nM (def.) for experiment 1 and 66.6 nM vs. 17.2 nM in experiment 2). 
In the case of outbred CD-1 mice, we also observed a significant difference in the 
25(OH)D3 serum levels in mice receiving different diets. Here, a mean of 81.18 nM 
25(OH)D3 was detected in the serum of vitamin D3-sufficient diet mice compared with 
21.60 nM 25(OH)D3 for the vitamin D3-deficient diet. 
Due to the different vitamin D3 levels in animals fed with the vitamin D3-sufficient diet in 
experiments 1 and 2, data were analyzed separately. 
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Figure 5.32. Serum vitamin D3 levels of BALB/c mice (experiments 1 and 2) and CD1 mice 
(experiment 3) at the age of 10 weeks. Mice were fed with vitamin D3 deficient diet (pink), or with vitamin 
D3 sufficient (green). Blood samples were collected from the animal´s tail vein in three independent 
experiments. The blood was centrifuged and the serum collected and frozen until analysis. Each symbol 
represents an individual mouse. Statistical analysis was performed with one-way ANOVA (* p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001. n.s not significant). 
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5.6.1.1. Impact of the serum 25(OH)D3 level on immune cell composition 
5.6.1.1.1. Impact on the main cell populations 
To investigate the impact of serum vitamin D3 levels on the immune cell composition, 
mice were sacrificed at the age of 17-18 weeks and their blood, spleen and bone marrow 
were examined by flow cytometry. 
 
 
 
Figure 5.33. Immune cell composition of BALB/c and CD-1 mice. (A-C) Quantification of myeloid cells 
(A), B-Cells (B) and T Cells (C) among living mononuclear cells in the blood of healthy BALB/c and CD-1 mice 
fed with different Vitamin D3 diets. (D-F). Quantification of myeloid cells (D), B-Cells (E) and T Cells (F) in 
spleen cells as described in (A-C). (G-I) Quantification of myeloid cells (G), B-Cells (H) and T Cells (I) in bone 
marrow cells as described in (A-C). Each symbol represents an individual mouse and horizontal lines indicate 
the median. Statistical analysis was performed with Kruskal-Wallis test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
n.s not significant). 
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Regarding the myeloid compartment, mice with high or low serum 25(OH)D3 level 
exhibited no significant differences in the amount of CD11b+ cells in the blood and 
spleen, irrespective of the used mouse strain. Concerning B cells, (Figure 5.33 B,E,H) we 
also found no significant difference in CD19+ cells between mice with high or low serum 
25(OH)D3 levels. Only CD-1 mice with low 25(OH)D3 levels showed fewer CD19
+ B cells 
in the spleen. Overall more differences were found between the different mouse 
experiments than between mice fed vitamin D3 sufficient vs. deficient diets. The only 
immune cell population with relative differences related to vitamin D3 levels seems to be 
the T cell population (Figure 5.33 C,F,I). Here, increased levels of T cells were found in 
mice with higher 25(OH)D3 levels in bone marrow in experiment 2 and 3. 
5.6.1.1.2. Impact of 25(OH)D3 serum level on immune cell sub-populations 
Although differences in the main immune cell populations were hardly detected between 
mice receiving a vitamin D3 sufficient vs. deficient diet, effects on sub-populations cannot 
be excluded. To better characterize the immune cell composition of the mice, different 
immune cell sub-populations were analyzed by means of flow cytometry. 
Regarding the myeloid compartment, we observed an increase in myeloid-derived 
suppressor cells (MDSC, CD11b+Gr+) in the blood and bone marrow (significant only 
experiment in experiments 2 and 3 ) but not in the spleen of mice fed with sufficient 
levels of vitamin D3 in experiments 1 and 2 (Figures 5.34 A and D). 
Concerning CD8+ T cells (Figures 5.34 C, F and I), an increase in this population was 
detected in CD-1 mice in the spleen and bone marrow of mice fed with sufficient levels of 
vitamin D3. No vitamin D3-related differences in the number of CD4
+ T cells were 
detected in blood, spleen and bone marrow (Figures 5.34 B, E and H). 
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Since a positive relation between vitamin D3 levels and CD4
+ CD25+ Foxp3+ Tregs is 
described in patients and we found a positive effect of vitamin D3 on the induction of 
Foxp3+ cells in vitro, this cell population was also analyzed in the blood, spleen and bone 
marrow of mice. In BALB/c mice vitamin D3 levels did not significantly influence the Treg 
population whereas in CD-1 mice high vitamin D3 levels even down-regulated regulatory 
T cells in the blood. Helios is a transcription factor expressed in a subset of Foxp3+ 
Tregs. It has been proposed that Helios is a marker of thymic derived Treg (tTreg). Other 
studies have suggested that Helios is primarily a marker of T cell activation [122]. Only in 
CD-1 mice Foxp3+Helios+ cells were significantly suppressed in the blood of mice with 
sufficient vitamin D3 levels (Figure 5.34 B). In contrast, CD4
+Foxp3- Helios+ cells were 
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Figure 5.34. Analysis of immune cell subpopulations in the blood, spleen and bone marrow of 
BALB/c and CD-1 mice. Quantification of MDSC(A, D, G), CD4
+
 T cells (B, E,H) and CD8 
+
 T Cells (C.F,I) 
among living mononuclear cells healthy BALB/c and CD-1 mice fed with different vitamin D3 diets. Each 
symbol represents an individual mouse and horizontal lines indicate the median. Statistical analysis was 
performed with Kruskal-Wallis test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. n.s not significant). 
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enriched in the bone marrow of BALB/c mice with sufficient vitamin D3 (experiment 2) 
levels and a trend was also observed in the blood (experiments 2 and 3). 
 
 
 
 
 
 
Figure 5.34. Analysis of subpopulations in the blood, spleen and bone marrow of BALB/c and CD-1 mice. 
Quantification of CD4
+
Foxp3
+
 T cells (A, D, G), CD4
+
 Foxp3
+
Helios
+
 T cells (B, E,H) and CD4
+
 Foxp3
-
Helios
+
 T 
cells (C.F,I) among living mononuclear cells healthy BALB/c and CD-1 mice fed with different vitamin D3 diets. 
Each symbol represents an individual mouse and horizontal lines indicate the median. Statistical analysis was 
performed with Kruskal-Wallis test(* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. n.s not significant). 
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5.6.1.2. Impact of 25(OH)D3 serum level on gut microbiota 
The role of microbiota in health and disease has been acknowledged in recent years, 
and several studies suggest an important interplay between the microbiome and the 
immune response [123-125]. 
In particular, dysbiosis, an imbalance in microbiota composition, is postulated to be a key 
factor in human diseases, such as inflammatory bowel disease and GvHD [47, 126, 127].  
 
As several studies also suggest an impact of vitamin D3-related SNPs and vitamin D3 
serum status on the microbiota composition [123], we hypothesized that mice fed under 
different vitamin D3 diets would exhibit a different gut microbiota composition. In order to 
analyze gut microbiota composition of the mice, stool samples were collected and 
analyzed by means of 16S ribosomal DNA (rDNA) PCR analysis (in collaboration with Dr. 
Hiergeist and Prof. Dr. Dr. André Gessner, Institute for Medical Microbiology and 
Hygiene, University Hospital Regensburg). 
Surprisingly, higher microbial diversity was found in mice receiving the vitamin D3-
deficient diet (Figure 5.35 A-C). The relative abundance of microbiota genera was also 
found to be significantly different in mice receiving the vitamin D3-deficient or -sufficient 
Figure 5.35. Mice fed a vitamin D3 deficient diet have higher microbiota diversity. The microbiota of mice 
fed with Vitamin D3 sufficient and deficient diet were determined by 16rDNA sequencing. The microbial 
diversity was analysed and shown as Observed Operational Taxonomic Unit (OTU) (A), Shannon Index (B), 
Simpson´s Index (C) and the difference between the two groups by principal component analysis (D). 
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diets. Mice fed with one diet grouped nicely, as shown in the principal component 
analysis (Figure 5.35D).  
The most striking difference separating the two groups were the high levels of 
Akkermansia microbes in the mice fed with a vitamin D3-sufficient diet compared to mice 
fed with a vitamin D3-deficient diet (Figure 5.36). On the other hand, mice receiving the 
vitamin D3-deficient diet showed increased numbers of other microbial genera, namely 
Anaerotruncus, Bacteroides and Oscillibacter. Taken together, these data demonstrate 
that vitamin D3 plays a role in the composition of the gut microbiota, with low levels of 
vitamin D3 completely abolishing presence of Akkermansia in the murine intestine. 
 
 
Figure 5.36. The ten most abundant bacterial genera in stool samples. The microbiota of mice fed with 
vitamin D3 sufficient or deficient diet was determined by 16rDNA sequencing diet.(n=4/group).  
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6. Discussion & Perspectives 
6.1. Impact of the NOD2 status on immune cell composition in 
human blood 
Nucleotide-binding oligomerization domain containing 2 (NOD2) is an intracellular pattern 
recognition receptor involved in detection of bacteria [37] and single nucleotide 
polymorphisms (SNPs) of NOD2 have been linked to several inflammatory disorders, 
such as Crohn’s disease (CD), Blau syndrome , early-onset sarcoidosis and Graft-
versus-Host disease (GvHD) [128]. These findings indicate that this receptor is of crucial 
importance for maintaining immune cell homeostasis, especially in the gastrointestinal 
tract.  
Although it is known that NOD2 is expressed in different cell types such as paneth cells 
[129], epithelial cells [130] and keratinocytes [131], it is widely accepted that the highest 
NOD2 expression is found in myeloid cells. Several publications describe alterations in 
the function and differentiation of myeloid cells with SNPs of NOD2 most in patients with 
Crohn's disease [132-134]. However, to our knowledge nothing is known about changes 
in the immune cell composition in healthy persons or patients with NOD2 SNPs. 
Furthermore, there is also limited knowledge about functional aspects of these mutations 
in healthy donors. This may be related to the fact that the frequency of NOD2 mutations 
such as SNP13 is relatively rare (ca 5 % of healthy donors carry the mutation) and it is 
difficult to obtain sufficient samples for analyses. 
Analysing the blood cell composition of healthy donors bearing NOD2 SNPs 8, 12 and 
13, we detected only significant changes in the myeloid compartment. Since this blood 
cell population is the one with highest expression of this intracellular receptor, it seems 
reasonable that the most striking differences were found in monocytes and dendritic cells 
(DCs).  
Flow cytometry analysis of mononuclear cells separated from blood samples collected 
with heparin tubes revealed that donors bearing NOD2 SNP12 and SNP13 had less 
CD33+ cells, a common myeloid marker, indicating that NOD2 could be involved in the 
regulation of haematopoiesis. In further studies it would be interesting to analyse 
neutrophil counts in blood, as neutrophils represent the main myeloid blood cell 
population.  
Additionally, we detected an increased CD16 expression on monocytes in the blood of 
NOD2 SNP12- and SNP13-bearing donors, compared to WT and SNP8 donors. Also, 
myeloid DCs were reduced in SNP donors compared with WT, further supporting the 
evidence for changes in the myeloid compartment of these donors. 
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Recently, it has been demonstrated that NOD1 is involved in the steady-state survival 
and turnover of circulating neutrophils and inflammatory monocytes in mice [135]. 
Therefore, it is seems possible that other microbial sensors, such as NOD2, are also 
involved in the regulation of the myeloid compartment. Based on these results we 
wondered whether mice with NOD2 knock-out (KO) would also have differences in the 
blood composition of myeloid cells. Unfortunately, we did not find differences in the 
number of myeloid subpopulations in the blood of these mice. However, human 
monocyte markers like CD14 or CD16 are not expressed in murine monocytes [136], 
which could partially explain the different results in the murine and human system. As it 
was not possible to transfer our data to the murine system, we continued to analyse 
human cells. 
6.1.1. Role of NOD2 in myeloid cell differentiation 
In addition to the finding that NOD2 SNP donors have less CD33+ myeloid cells, a more 
detailed analysis of this population revealed an increased mean fluorescence intensity 
(MFI) of CD16 on monocytes isolated from blood collected with heparin tubes.  
In humans, three subsets of monocytes have been identified based on the expression of 
CD14 and CD16 [137]. The subset of “classical” blood monocytes expresses CD14 (LPS 
co-receptor) and shows no expression of the low-affinity Fcγ-receptor CD16. This subset 
is the most abundant of the three and normally represents about 90% of all blood 
monocytes. The “intermediate” monocytes are characterized by a high expression of both 
CD14 and CD16. The “nonclassical” subset of monocytes is characterized by low 
expression of CD14 and high CD16 expression [137].   
It has been suggested that the monocytes expressing different levels of CD14 and CD16 
represent a continuum in monocyte differentiation [138]. Intermediate CD14+CD16+ 
monocytes derive from classical CD14+CD16- and nonclassical CD14-CD16+ monocytes. 
Based on this, one can speculate that the observed increase in CD14+CD16+ monocytes 
is due to a block in cell differentiation, with more cells accumulating in this state. 
CD14+CD16+ monocytes also show differences regarding their adhesion to the 
endothelium. This monocyte subpopulation adheres stronger compared with their 
CD14+CD16- counterparts [139]. 
6.1.1.1. NOD2 status and dendritic cell differentiation/maturation 
Based on our data with blood monocytes suggesting an impact of NOD2 SNPs on 
myeloid differentiation, we further analysed monocyte to DC and monocyte to 
macrophage differentiation. Although our analysis on mononuclear cell DC (MNC-DC) 
clearly demonstrates a defect in LPS-induced DC maturation and cytokine production, 
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other reports suggest that the presence of NOD2 polymorphisms only affect the 
phenotype of DCs stimulated with MDP but not LPS. However, in our hands MDP was 
not able to induce maturation of DCs independent of the NOD2 status. Nevertheless, 
other studies [137, 138, 139] used cells derived from Crohn´s disease patients, which is 
not comparable with our experiments as we used cells from healthy donors. Monocytes 
from Crohn’s disease patients may be in a “pre-stimulated” state.  
Contradictory to our findings in MNC-DC, DCs generated from monocytes (Mo-DCs) and 
stimulated with LPS expressed higher CD83 and CD86 levels upon maturation with LPS, 
indicating a stronger activation status of these cells. This finding is in line with a study 
from Sánchez-Schmitz G. et al [140]. In this study, the authors found that DCs generated 
from CD16+ monocytes expressed higher levels of CD86, CD11a and CD11c, and 
showed lower expression of CD1a and CD32 compared to mo-DCs generated from 
CD16- monocytes. As we were able to demonstrate an increased amount of CD16+ 
monocytes in NOD2 SNP-bearing donors, this population could be responsible for the 
high activation status of the generated mo-DCs. Furthermore, Ventura and colleagues 
[141] also found that DCs obtained from Crohn’s disease patients with NOD2 mutations 
display an activated phenotype characterized by high CD86 expression. 
6.1.1.2. NOD2 status and macrophage differentiation  
NOD2 is also highly expressed in macrophages [142]. Although the majority of studies 
regarding NOD2 and antigen-presentig cells (APCs) make use of DCs, the effects of 
NOD2 SNPs in macrophages were also investigated.  
In the present work few experiments were conducted studying monocyte to macrophage 
differentiation. Due to the big variation detected in the analysed macrophages, even from 
donors with the same NOD2 genotype, it is difficult to take conclusions regarding the 
impact of NOD2 status on macrophages differentiation. More donors need to be included 
in the analysis.  
In a murine model, Murray et al [143] demonstrated that bone marrow-derived 
macrophages from NOD2-/- mice behaved in a similar way as macrophages from 
wildtype (WT) NOD2 mice, with the exception of extracellular-signal-regulated kinase 
(ERK) phosphorylation, that appeared to be slightly delayed when the cells were 
stimulated through toll-like receptor (TLR) 9 and TLR4. Nevertheless, cytokine production 
seemed to be unaffected. Other studies described that macrophages from Nod2-/- mice 
generated to express the disease-associated SNP13 Nod2 variant exhibit increased 
factor nuclear kappa B (NF-κB) activation and interleukin (IL)-1β secretion when 
stimulated with muramyldipeptide (MDP), suggesting that this common mutation acts as 
a gain-of-function mutation in this model [140]. However, unlike this Nod2-/- mouse 
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model, monocytes from patients or healthy individuals homozygous for the L1007insC 
mutation (SNP13) display a marked defect in NF-κB activation and IL-1β production in 
response to MDP [106].  
6.1.2. Regulation of CD16 
When analysing CD14/CD16 expression on elutriated human monocytes, we found that 
the difference in CD16 expression was no longer detectable. Further analyses revealed 
that CD16 expression was down-regulated on monocytes dependent on the cell 
preparation technique. Interestingly, the differences in CD16 expression between 
monocytes from WT donors and donors with SNP12 or SNP13 were again detectable 
after culturing the cells for 24 hours without stimulation indicating that NOD2 SNP12 or 
SNP13 play a role in the regulation of CD16 in human monocytes.  
Upon TGF-β stimulation CD16 was up-regulated independent of the NOD2 status. 
Nevertheless, the highest number of CD16+ cells was again detected in monocytes 
isolated from donors with NOD2 SNP12/13. In the course of inflammation TGF-β is often 
present in high amounts [141], and could induce this CD14/CD16 monocyte population 
especially in monocytes from donors with NOD2 SNP12 and SNP13. Platelets are an 
important source of TGF-β and are able to up-regulate CD16 [104, 142]. It is discussed 
that platelet-monocyte aggregates are present in human blood under physiological 
conditions [143]. This could also up-regulate CD16 expression especially in donors with 
NOD2 SNPs which seem to be more sensitive to the effects of TGF-β.   
6.1.3. Role of NOD2 for monocyte activation  
The intermediate population of CD14/CD16+ monocytes has been identified as a major 
pro-inflammatory cell population [123]. They exhibit a distinct cytokine secretion pattern, 
with low IL-10 production and high levels of IL-1β, tumor necrosis factor (TNF) and IL-12. 
Moreover, it has been shown that these monocytes are more efficient antigen-presenting 
cells than its classical counterparts [144]. Based on these observations it has been 
proposed that intermediate monocytes play an important role in the pathogenesis of 
inflammatory disorders, such as in patients with active chronic disease [124]. Based on 
these data and our finding of an increased population of CD14/CD16+ monocytes in 
donors with NOD2 SNPs, we studied cytokine section in monocytes with or without 
NOD2 SNPs. As expected, cytokine secretion was affected in relation to the NOD2 
status. 
No significant differences were found in IL-6, IL-1β and TNF secretion, but in line with the 
literature [106] a decrease in IL-8 secretion was detected in NOD2 SNP 12/13 donors 
compared with WT donors. IL-8 is known to be one of the most potent chemoattractant 
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molecules that, among several other functions, is responsible for guiding neutrophils 
through the tissue matrix until they reach sites of injury [145]. A decrease in IL-8 
secretion could lead to a delayed bacterial clearance in case of infection, possibly due to 
a reduced number of neutrophils in the site of infection. 
6.1.3.1. Impact of NOD2 on NF-κB signalling 
After ligand binding, the NOD2 protein associates with a serine/threonine kinase called 
receptor-interacting protein 2 (RIP2) which in turn interacts with the regulatory subunit of 
the Iκκ complex. This leads to phosphorylation and degradation of IκBα and nuclear 
translocation of NF-κB. NF-κB is known to induce the expression of pro-inflammatory 
cytokines and other factors. Variants of the NOD2/CARD15 gene show an impaired 
activation of NF-κB in vitro in transfection experiments human embryonic kidney (HEK) 
293T cells [146]. 
SNP13 is a frameshift mutation with the most drastic loss-of-function phenotype of all the 
three NOD2 SNPs. This SNP is normally associated with a markedly reduced NF-κB 
activation, while SNP8 and 12 normally respond better to bacterial stimulation than 
SNP13. Nevertheless, the ability to activate this pathway is still significantly reduced in all 
of the three variants [147]. 
Surprisingly, we detected a constitutive low Iκb level in the cells from a donor with 
combined NOD2 SNP 8+13 indicating increased activity rather than an incapability to 
activate NFκ-B. In line, donors with NOD2 SNP12 or SNP13 showed more spontaneous 
IL-6 production in non-stimulated monocytes compared with WT. Further analyses have 
to prove whether decreased IκB levels are also found in other SNP13 donors.  
After bacterial stimulation with MDP or LPS, no difference was found in NF-κB activation 
between LPS and MDP, or between WT and SNP8 or SNP12. This result is in sharp 
contrast to data from transfection experiments with NOD2 SNPs [146]. Since we 
analysed only 3 donors our results have to be confirmed with more donor samples. 
However, it is possible that overexpression of mutated forms of NOD2 in tumor cell lines 
as done by Ogura et al. may not reflect the physiologic situation. Our donors have 
heterozygous mutations which mean that one WT allele is still present in the cell and this 
is the case in most published data on NOD2 SNPs in patient cells.  
Based on the decreased IL-8 secretion in donor cells with NOD2 SNPs, one would 
expect a decrease in the activation of this signalling pathway. On the other hand, the 
secretion of IL-6, IL-1β and TNF was not altered in donors with NOD2 mutation. This 
indicates that the observed decrease in IL-8 secretion is not entirely dependent on the 
NF-κB pathway. NOD2 activation not only activates the NF-κB pathway but also mitogen-
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activated protein (MAP) kinases such as ERK1/2 and c-Jun N-terminal kinases (JNK) 
[148], it would be interesting to determine these pathways in more detail in future studies.  
Regarding Crohn´s disease or GvHD, it is discussed that NF-κB activation in epithelial 
cells is important for gut homeostasis [149]. Mice with an epithelial-specific deletion of 
Iκκβ showed a reduced expression of lymphopoietin and fail to develop a pathogen-
specific Th2 response [150]. Further evidence also points to an important role of NF-κB 
for intestinal epithelial integrity and the interaction between the mucosal immune system 
and gut microflora: In a mouse model of epithelial cell-specific inhibition of NF-κB through 
a deletion of Iκκ subunits essential for NF-κB activation, severe chronic intestinal 
inflammation occurred associated with increased apoptosis of colonic epithelial cells, 
impaired expression of antimicrobial peptides and translocation of bacteria into the 
mucosa [151]. Therefore, NOD2 mutations in epithelial cells rather than in myeloid cells 
could play an important role for Crohn´s disease and intestinal GvHD.    
6.1.4. Role of NOD2 ligands for cell activation and differentiation  
DCs are the most effective APCs in the activation of naïve T cells and therefore essential 
for the initiation of a primary immune response. They represent a bridge between innate 
and adaptive immunity [152].  
Under steady state conditions DCs exist in an immature “tolerogenic” state. Upon 
microbial encounter they become activated and are now capable to stimulate T cells. The 
microbial products are normally recognized by TLRs and other microbial sensors [22], 
like the NOD-like sensors. Here, we compared the efficacy of possible NOD2 ligands 
such as MDP and LPS on DC maturation.  
Although DCs express the NOD2 receptor, our analysis of the effect of MDP on Mo-
derived DCs revealed that this molecule was unable to induce the maturation of DCs. 
Although several protocols were used for the generation of DCs, MDP was not able to 
successfully induce maturation. However, when the short time protocol using MNCs as a 
starting population was applied we detected a trend towards an increase of some of 
maturation-related markers, indicating that possibly lymphocytes are also targets of MDP 
stimulation and may support DC differentiation. There is evidence from the literature that 
NOD2 is also expressed and relevant in T cells. MDP stimulates NF-κB in human 
FOXP3+ T cells and protects cells from apoptosis. This effect is not evident in T cells 
isolated from patients with NOD2 polymorphisms [153]. 
Since MDP failed to induce maturation, one hypothesis would be that MDP could actively 
induce a tolerogenic state in DCs. After analysing tolerogenic markers we only observed 
a trend towards an up-regulation of immunoglobulin-like transcript (ILT)3 and PD-L1, 
meaning that MDP is not able to induce a specific phenotype in DCs. Cytokine analysis 
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also showed no differences between immature DCs (iDCs) and DCs stimulated with 
MDP. 
When a DC encounters bacterial stimulation, simultaneous pathways are activated 
through different pattern recognition receptors [154] . Although NOD2 stimulation alone 
was not able to induce phenotypical changes in DCs, it is possible that the sensing of this 
receptor is important in combination with other stimuli, such as TLR4.  
Our data on cytokine production demonstrated an up-regulation on IL-10 secretion upon 
LPS and MDP combination and a decrease in IL-12 production, indicating a possible 
anti-inflammatory role of NOD2. These results are not completely in line with data found 
by Watanabe et al. [155] who pre-incubated DCs with MDP and observed a decrease in 
IL-12p40, IL-10 and IL-6 after stimulation with TLR ligands for all bacterial ligands 
compared to the response without pre-incubation. The synergistic role of TLRs and 
NOD2 seems not to be clear, since studies in mice demonstrated that NOD2 in 
combination with LPS was associated with an increased production of Th1 polarizing 
mediators [156].  
A different study demonstrated that incubation of murine splenic macrophages with MDP 
suppressed IL-12p40 and IL-12p70 secretion induced by stimulation with TLR2 ligands, 
such as peptidoglycan [144]. This suppression was not observed in cells lacking NOD2 
expression. In vivo experiments demonstrated similar results, since systemic 
administration of peptidoglycan to Nod2-/- mice induced more serum IL-12p40 and IL-
12p70 compared to WT mice. Further analysis indicated that increased IL-12p70 
production in peptidoglycan-stimulated NOD2-deficient cells was due to greater c-Rel-
dependent IL-12p35 mRNA expression. Taken together, these data suggest that 
inactivation of NOD2 enhances IL-12 secretion in murine macrophages due to the fact 
that NOD2 normally limits TLR2 agonist-stimulated expression of this cytokine. 
Autophagy is a highly conserved self-degradation system that plays an important role in 
maintaining cellular homeostasis through the elimination of misfolded proteins and 
damaged organelles. Furthermore, autophagy is crucial for host defense against 
bacterial, viral, and parasitic pathogens [157]. In addition, it has been shown that 
autophagy has a major role in antigen presentation, with constitutive fusion of 
autophagosomes with multivesicular MHC class II-loading compartments in antigen-
presenting cells. Simmons et al. [158] demonstrated that NOD2 induces autophagy in 
DCs that is required for NOD2-mediated antigen presentation and bacterial handling and 
is defective in the presence of NOD2 SNPs, demonstrating another mechanism by which 
DC function may be altered in donors bearing NOD2 SNPs. 
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6.2. Role of vitamin D3 on immune regulation  
There is accumulating evidence that vitamin D3 signalling plays a role in the regulation of 
the immune system from several studies [79]. The vitamin D receptor (VDR) is expressed 
in most cells of the immune system, including T cells, neutrophils and APCs such as 
macrophages and DCs [159].  
The main vitamin D metabolite in serum is 25(OH)D3 and it is converted to the active 
form 1,25 dihydroxy vitamin D3 (1,25(OH)2D3) by Cytochrome P450 Family 27 Subfamily 
B Member 1 (CYP27B1). This enzyme is expressed in the kidney but also by activated 
myeloid immune cells. The active form binds to the VDR and regulates several genes 
e.g. the induction of antimicrobial peptides such as cathelicidin and β-defensin. These 
antimicrobial peptides play an important role in clearing infections since they inhibit the 
growth and kill bacteria. In addition, defensins also amplify adaptive immune responses 
resulting in both Th1- and Th2-dependent responses by activation of immature DCs [80].  
It is also known that 1,25(OH)2D3  regulates the expression of pattern recognition 
receptors (PRRs). It has been shown that 1,25(OH)2D3 has the ability repress TLRs and 
inhibits the secretion of pro-inflammatory cytokines [160]. Moreover, Wang et al. showed 
that vitamin D3 has the capability to induce NOD2 expression [161]. However, in the 
present work only a slightly induced expression of NOD2 mRNA was detected upon 
incubation of monocyte with 1,25(OH)2D3. This difference may be due to the fact that 
Wang. et al. used 100 nM of 1,25(OH)2D3, which is a high, non-physiological 
concentration. Given the importance of NOD2 as a signal for the regulation of 
inflammation, it seems plausible that vitamin D3 acts synergistically with the NOD2 
receptor helping to suppress inflammation.  
Furthermore, 1,25(OH)2D3 is capable of inducing tolerogenic DCs [111]. In line, we were 
able to demonstrate that 1,25(OH)2D3 induces ILT3 expression, a known biomarker of 
tolerogenic DCs [111].  
It is known that the active vitamin D metabolite 1,25(OH)2D3 has not only strong effects 
on the generation of tolerogenic DCs but also inhibits T cell function [29, 111]. Here, we 
investigated whether both vitamin D3 forms, 25-hydroxyvitamin D3 (25(OH)D3)  and 
1,25(OH)2D3 , also have direct effects on T cells, independent of DC presence. This 
would implicate that T cells metabolize 25(OH)D3 to 1,25(OH)2D3 on their own.  
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6.2.1. Effect of vitamin D3 on human T cells 
In the present study, the direct effects of the vitamin D3 precursor, 25(OH)D3 or the active 
form of vitamin D3 (1,25(OH)2D3) on CD4
+ T cells was evaluated.  
In humans, serum levels of 25(OH)D3 in a range of 50-100 nM have been defined as 
sufficient levels [162]. Therefore, in the first set of experiments, T cells were incubated 
with a physiological concentration of 50 nM 25(OH)D3 and stimulated with different T cell 
expander bead (TCE) bead: cell ratios. Since it is known that tolerogenic dendritic cells 
have a weaker ability to stimulate T cells, we hypothesised that a weaker stimulation 
level with lower amounts of beads would give rise to higher amounts of regulatory T cells. 
Although this was not the case, 25(OH)D3 was able to induce FOXP3 expression 
independent of the used bead concentration. 
In this first approach, CD4+ T cells isolated from blood were used and this mixed 
population is composed of CD4+CD25+ , which include circulating FOXP3+ cells, and 
naïve CD4+CD25- cells. Therefore, it is difficult to distinguish whether 25(OH)D3 expands 
pre-existing FOXP3+ cells or induces FOXP3+ cells from CD4+CD25- naïve T cells. To 
overcome this, naïve CD4+CD25- T cells were sorted and used to study the impact of 
25(OH)D3 and 1,25(OH)2D on T cells. After flow cytometry analysis, we were able to 
demonstrate that physiological concentrations of both 25(OH)D3 and 1,25(OH)2D3 were 
able to up-regulate FOXP3 expression in naïve T cells. These results prove that 
25(OH)D3 and not only 1,25(OH)2D3 directly modulates T cells.  
There are already some studies showing an effect of 1,25(OH)2D3 on Tregs [118, 163], 
but these studies use high non-physiological concentrations of 1,25(OH)2D3. One study 
compared the effects of 25(OH)D3 and 1,25(OH)2D3 on human T cells and stated that 
25(OH)D3 is not capable to directly act on T cells. The authors state that 25(OH)D3 has to 
be converted to 1,25(OH)2D3  through the action of DCs [116], since it is known that 
APCs are capable of converting the circulation form of 25(OH)D3 to its active form. In 
addition, it has also been shown that 1,25(OH)2D3 induces a tolerogenic phenotype in 
DCs, decreasing IL-12 secretion and increasing IL-10 [111], eventually leading to Treg 
induction. Nevertheless, since T cells also express the VDR and CYP27B1 [164, 165] it 
seems plausible that 25(OH)D3 can be converted to 1,25(OH)2D3 which then has a direct 
effect on T cells. In line with this, we were able to prove that T cells can actively convert 
25(OH)D3 to its active form 1,25(OH)2D3. On the other hand, 25(OH)D3 has been 
reported to bind with low affinity to VDR [166]. Therefore, it remains to be elucidated 
whether the effect of 25(OH)D3 on T cells is a result of its conversion to the active vitamin 
D metabolite and subsequent action of 1,25(OH)2D3 on the cells or whether 25(OH)D3 
exerts direct effects on T cells. 
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Since it is known that TGF-β is a potent inducer of Tregs [117], we included TGF-β in our 
experiments as a control. In addition, we aimed to study its possible synergy with 
25(OH)D3 and 1,25(OH)2D3. The results from the present work demonstrate that the 
addition of both forms of vitamin D3 to TGF-β did not further increase the number of 
FOXP3+ cells analysed by flow cytometry, although we detected a significant increase of 
FOXP3 mRNA in the combined use of TGF-β and 1,25(OH)2D3. In further analyses we 
investigated the functional impact of 25(OH)D3 and 1,25(OH)2D3 on Tregs.  
Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) is a suppressive protein that is 
expressed constitutively by Tregs and is induced on conventional T cells following 
activation. Its main function is to restrain inappropriate activation of autoreactive T cells 
and to restore T cell homeostasis following activation [167]. We detected an increase in 
the alternatively spliced soluble CTLA-4 (sCTLA4) isoform in the culture supernatant of T 
cells in the presence of 1,25(OH)D3 and the highest increase was found in cultures 
stimulated with both TGF-β and 1,25(OH)2D3. In line with this finding, we also found an 
increased IL-10 production in cultures stimulated with a combination of 1,25(OH)2D3 and 
TGF-β, demonstrating an additive effect of these both agents. 
IL-17 is a strong inducer of inflammation and has an important role in protecting the body 
against invading pathogens. It is mainly produced by Th17 cells and this population 
needs to be kept in a strict balance, since it contributes to tissue damage in inflammation 
such as gut GvHD [168]. For this reason, we also measured IL-17 in the culture 
supernatants and found that 1,25(OH)2D3 treatment decreased the secretion of this 
cytokine, demonstrating a possible role for vitamin D3 in the attenuation of Th17 
responses.  
Finally, reduced IFN-γ secretion was found upon 1,25(OH)2D3 addition to the cultures. 
IFN-γ is a classical Th1 cytokine, so this result is in line with the literature that states that 
1,25(OH)2D3 inhibits Th1 responses, favouring Th2 [80]. 
Taken together, the data on vitamin D3 and T cells clearly demonstrates that even 
physiological amounts of both 25(OH)D3 and 1,25(OH)2D3 are able to induce a regulatory 
phenotype in T cells. Although an increase in the percentage of FOXP3+ cells was not 
detected in the combination of 1,25(OH)2D3 and TGF-β, analysis of the culture 
supernatants demonstrated a clear additive effect of both stimuli on extracellular levels of 
sCTLA4, IL17 and IFN. As the cytokine profile is an important mediator of the immune 
response, combination of TGF-β and vitamin D3 could balance anti- and pro-inflammatory 
cytokines, necessary for effective tolerance induction. The protective role of 25(OH)D3 
has already been demonstrated in several diseases. Namely, vitamin D3 supplementation 
was observed to reduce disease activity in patients with CD, as well ameliorated 
experimental models of inflammatory bowel disease (IBD) [169]. Also, vitamin D3 levels 
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have been related with the outcome of hematopoietic stem cell transplantation (HSCT) 
[89]. This could in part be due to effects on Treg induction since in humans Prietl et al. 
demonstrated an association of vitamin D3 supplementation with an increase in 
CD4+Foxp3+ T cells in circulation [170, 171]. 
In a different setting, Hjelte et al. studied the impact of vitamin D3 supplementation in 
Cystic fibrosis patients. This disease is characterized by a persistent lung inflammation 
[172] and the authors found that total 25(OH)D3 dose/kg bodyweight correlated with the 
down-regulation of CD86 on mDCs. Furthermore, they reported a reduced programmed 
cell death protein 1 (PD-1) expression on CD4 and CD8 cells, as well as a decreased 
frequency of CD8+ T cells co-expressing the activation markers CD38 and HLA-DR in a 
dose-dependent fashion. 
The impact of vitamin D3 on human monocytes was also investigated in vivo in donors 
infected with human immunodeficiency virus HIV. Sereti et al. [173] found that patients 
with vitamin D3 deficiency, when compared to those with insufficient or normal vitamin D3 
levels had increased levels of IL-6, TNF-α and higher proportions of CD14dim CD16+ and 
CX3CR1
+monocytes. A decreased frequency of CCR2+ monocytes was also detected in 
this study. In summary, in line with our data, in vivo 25(OH)D3 levels also seem to be 
important for proper immune regulation as vitamin D3 deficiency is often associated with 
more prone inflammatory conditions. 
6.2.2. In vivo effects of vitamin D3 on mice 
The in vivo effects of vitamin D3 have also been studied in different mouse models such 
as VDR-KO or CYP27B1-KO models which demonstrated that defects in the vitamin D 
metabolism are associated with an inhibition of T cell proliferation, inhibition of IFN-γ, IL-
17 and induction of IL-4 [88].  
Koeffler and colleagues [84] demonstrated that VDR-KO mice have normal numbers of T 
and B lymphocytes, but differences in their cytokine responses. The authors found that 
splenocytes from VDR-KO mice secreted less IFNγ and more IL-4 compared with 
splenocytes from WT mice. Moreover, VDR expression seems to be crucial for the 
appropriate development of invariant natural killer (iNKT) cells, a subset of lymphoid cells 
involved in basic immune responses and also restricting autoimmunity [85]. Cantorna et 
al. noted a reduced number of these cells in a VDR-KO mouse model.  
In a model of IBD it was also demonstrated that VDR-KO mice had reduced numbers of 
CD8αα intraepithelial lymphocytes (IEL). In addition, low IL-10 production in the IEL and 
the failure of the VDR-KO T cells to home to the small intestine was detected. 
Besides its impact on T cells, the VDR also influences the number of myeloid cells. Song 
et al. [174] showed that the number of macrophages is markedly reduced in wounds of 
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vitamin D3-deficient mice and mice with macrophage-specific VDR deletion, 
demonstrating that the expression of the VDR in macrophages is essential for the normal 
expansion of tissue-resident macrophages.  
In this thesis we used no VDR-KO mouse model but the more physiological setting of 
different vitamin levels in mice to study the impact of vitamin D levels on immune cell 
composition. Besides blood immune cells we also investigated immune cells in the 
spleen and bone marrow as important sites of immune cell differentiation. Three 
independent experiments, using two different animal models were performed: BALB/c, an 
inbred mouse strain and CD-1, an outbred strain. In two experiments BALB/c mice were 
used. The animals were the same age, in the same animal facility and were purchased 
from the same company. Nevertheless we found great variations between both vitamin 
D3 levels and immune cell composition that were not expected. Even though this animal 
model should provide solid results due to genetic similarities owed to long inbreeding, 
results indicate that yet unidentified variables modulate the immune system of these 
mice. Surprisingly, the outbred strain CD-1 mice showed no significant differences to the 
used BALB/c mice. In the main lymphoid blood cell populations such as B and T cells, no 
significant effects of vitamin D3 were detected in BALB/c mice, with the exception of 
experiment 2 using BALB/c mice where more TCRβ+ cells were detected in the bone 
marrow of animals fed with sufficient levels of vitamin D3. This result was also observed 
in the bone marrow of outbred strain CD-1 and contradicts in part the VDR-KO data 
models were no differences were found in the total number of these cells [84]. 
Furthermore, CD-1 mice fed with sufficient vitamin D3 seem to have less CD19
+ B cells in 
their spleen compared to animals having a deficient vitamin D3 diet. 
When analysing myeloid cell subpopulations, we detected in two experiments an 
increase in myeloid-derived suppressor cells (MDSC) in animals with sufficient levels of 
vitamin D3 in blood and spleen. 
MDSC have been shown to ameliorate GvHD [175] and to mitigate dextran sulfate 
sodium (DSS)-induced colitis [176]. The finding that 25(OH)D3 also positively modulates 
this cell population provides another possible mechanism by which vitamin D3 could be 
beneficial in an inflammatory setting. Furthermore, using a murine IBD model Qin et al. 
[177] made use of the combined properties of MDSC and vitamin D3 in a sophisticated 
monocyte-based adoptive CYP27B1 gene therapy approach where they used the traffic 
capacity of MDSC to inflamed colon to deliver local amounts of vitamin D3. In this system 
the authors used a targeting strategy with CD11b+/Gr1+ monocytes as the cell vehicle 
and a macrophage-specific promoter (Mac1) to control CYP27B1 expression. Local 
amounts of vitamin D3 modulated T cells (switch from Th1 to Th2), cytokine secretion and 
promoted mucosal regeneration via epithelial tight junction protein synthesis. 
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Although we expected an increased amount of CD4+FOXP3+ cells in mice with sufficient 
levels of 25(OH)D3 compared with deficient ones, we were not able to prove this finding 
in our experimental setting. Possibly, Tregs are only modulated by vitamin D under 
inflammatory conditions where TGF-β is present and not under steady state conditions, 
since it is known that TGF-β is a positive regulator of Tregs and we proved a synergistic 
effect of vitamin D3 and TGF-β in vitro. Therefore, in mice with sufficient vitamin D3 
levels, when facing inflammation, vitamin D3 could synergize with TGF-β and other 
cytokines, increasing the number of Tregs. Nevertheless, in one experiment we detected 
that Helios, a transcription factor expressed in thymus-derived Tregs, [122]could also be 
a target for vitamin D3, as more cells expressing Helios were detected in the bone 
marrow of animals fed with sufficient vitamin D3. 
6.3. Impact of vitamin D3 on microbiota 
Several mechanisms have been proposed through which vitamin D3 may influence the 
gut microbiota. Vitamin D3 can affect both immune cells and colonic epithelial cells; 
modulating colon barrier function, and the secretion of antimicrobial peptides, mucins, 
and cytokines, all of which have the potential to modulate gut bacteria [178]. 
In a recent study from Franke et al. [179] the authors identified that variations in the VDR 
influenced the gut microbiome. Additionally, they provided compelling follow-up to the 
finding of Makishima et al. that demonstrated that secondary bile acids (which are 
produced by special bacteria in the gut) serve as ligands for VDR. 
Furthermore, it has been demonstrated that vitamin D3-deficient mice have decreased 
expression of angiogenin-4 (an antimicrobial peptide) within the colon and consequently 
have an increased bacterial load with decreases in Lactobacillus species and increases 
in Clostridium and Bacteroides species within the colon, suggesting that vitamin D3 
deficiency may impair microbial homeostasis [180]. Furthermore, mice lacking the ability 
to respond to vitamin D3 (either due to lack of VDR or CYP27B1) have differences in their 
gut microbiome compared to WT littermates with intact vitamin D3 signalling [181] 
demonstrating that host responses to vitamin D3 impact the microbiome. In this study, 
Cantorna and co-workers found that Firmicutes and Bacteroidetes were the dominant 
phyla in all mice (KO or WT). Bacteroidetes, Proteobacteria, and unclassified bacteria 
were over-represented in the fecal microflora of Cyp-KO and VDR-KO mice relative to 
their WT counterparts. Equally, the Cyp-KO and VDR-KO mice had fewer bacteria from 
the Firmicutes and Deferribacteres phyla compared with their respective WT littermates. 
In our analyses, we detected higher bacterial diversity in mice with deficient vitamin D3 
compared with mice with vitamin D3 sufficiency. Similarly to findings of Cantorna et al., 
the most dominant phyla detected in vitamin D-deficient mice were Bacteroidetes. 
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However, an increased amount of this phylum as well as Firmicutes was detected in mice 
with vitamin D3 deficiency. On the other hand, increased amounts of Verrocomicobia 
were detected in mice with sufficient vitamin D3 levels. 
Akkermansia was the only bacteria genus found in significantly greater amount in the 
stool of vitamin D3 sufficient animals. These results are in line with findings by Han and 
colleagues [182] who observed a marked reduction in Akkermansia in VDR-KO mice. 
Although there are 8 identified species belonging to this genus, most reports concern 
Akkermansia muciniphila. These mucin-degrading bacteria have been reported to be in 
low numbers in patients with IBD [183] compared with healthy individuals, have been 
identified as capable Treg inducers, have proven to be beneficial in colitis and shown to 
induce the expression of antimicrobial peptide Reg3γ in the colon [184]. Taken together, 
the results prove a strong relationship between vitamin D3 status and gut microbiota, and 
how these two factors could shape the immune response.  
6.4. Perspectives 
The importance of the NOD2 status has been acknowledged for some years for several 
inflammatory conditions such as CD and HSCT outcome. Although the possible role of 
NOD2 has been established as a suppressor of inflammation, the exact mechanism by 
which this occurs is not clear. In the present work, we found a decreased amount of 
myeloid cells in healthy donors bearing the studied NOD2 mutations, indicating a 
possible role for NOD2 in haematopoiesis. Furthermore, an increased CD16 expression 
was detected in NOD2 mutants, which can be related with an increase activation of 
myeloid cells, characteristic of inflammatory conditions. Since we also demonstrated the 
capacity of platelets and TGF-β in upregulating CD16, the amount of TGF-β as well as 
the presence of monocyte-platelet aggregates in circulation should be investigated in 
donors bearing the NOD2 mutations in comparison with WT individuals. 
Since neutrophils represent the main myeloid blood cell population, in further studies it 
would be interesting to analyse neutrophils counts in blood. 
The signalling pathways involved with NOD2 activation, such as NF-κB and phospho p38 
also seem to be involved in the NOD2 effects and should be analysed in more detail. 
Although we detected a higher IL-6 secretion in non-stimulated NOD2 SNP-bearing 
donors, we were only able to detect what seems to be constitutive activation of NF-κB in 
one donor, harbouring a SNP8 and a SNP13, meaning that the presence of both 
mutations could constitute a special phenotype. Nevertheless, more donors should be 
included in the analysis. Data on cell differentiation/maturation suggested and increased 
activation of DCs generated from NOD2 mutated donors compared with WT, what goes 
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in line with the CD16 findings. More donors should be included and the T cell stimulatory 
capacity of these cells should also be investigated.  
Regarding the in-vitro T cells studies, we proved that both 25(OH)D3 and 1,25(OH)2D3 
are capable of directly modulate the T cell phenotype, in an additive fashion with TGF-β. 
Although TGF-β is able to induce FOXP3 expression, it is known that this expression is 
not stable. Stable Tregs are characterized by the demethylation of a CpG-rich element 
within the FOXP3 locus, so naturally the next step on evaluating the vitamin D3 effect on 
T regs would be analysing the methylation status of the FOXP3 gene after vitamin D3 
treatment. To access the stability of the phenotype, the cells should be cultured in a first 
period in the presence of vitamin D3 and/or TGF-β and in a second period this stimulus 
should be removed from culture. After this period the cell phenotype should be 
investigated in order to compare with the initial culture period. 
Although due to experimental variability no clear effects were found in the in vivo studies 
regarding vitamin D3, the most interesting finding is possibly the significant relation 
between vitamin D3 status and MDSC. 
Due to the findings relating vitamin D3 and inflammatory conditions such as IBD and 
GvHD, further studies need to be conducted in order to clarify the exact mechanisms 
leading to these observations. After establishment of vitamin D3-sufficient and -deficient 
mice and analysing their respective microbiota, bone marrow transplantation of these 
animals should be performed. Since the effects of vitamin D3 are vast and not restricted 
to one cell population and cover several aspects of the host immune response, two 
approaches can be followed. The first one would be to analyse the impact of the vitamin 
D3 in the host. In this way, one would expect that the vitamin D3 effects were due to its 
impact on intestinal epithelia (main target of GvHD) and microbiota modulation by vitamin 
D3.  
The second approach would be to study the impact of vitamin D3 on immune cells, and 
for this, bone marrow and spleen cells of vitamin D3-sufficient or -deficient donor mice 
should be injected in irradiated recipients. Although it is known that there are several 
cells, especially APCs, resistant to irradiation the mice are then immune-reconstituted 
with cells with different vitamin D3 backgrounds (sufficient and deficient). This would be 
probably the most accurate approach to study the impact of vitamin D on immune cells 
and the outcome of bone marrow transplantation. 
In conclusion, this work demonstrates a new mechanism by which NOD2 mutations 
could lead to a more inflammatory-prone condition, by the increased number of CD16+ 
monocytes, deregulated NF-κB pathway and differences in dendritic cell 
maturation/activation. Furthermore we demonstrate a synergistic effect of vitamin D3 and 
TGF-β for the generation of regulatory T cells. The in vivo effects of vitamin D3 
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demonstrated a positive relation between vitamin D3 and MDSC and the modulation of 
the murine microbiome, with a significant loss of Akkermansia in mice with vitamin D3 
deficiency. A more detailed study on the impact of the gut microbiota and vitamin D3 
should be performed, studying the expression of proteins involved in maintaining the 
epithelial barrier function.  
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7. Summary 
GvHD is still the most common life-threatening complication associated with allogeneic 
hematopoietic stem cell transplantation (HSCT). NOD2/CARD15, an intra-cytoplasmatic 
pathogen-recognition receptor recognizing bacterial muramyl dipeptide (MDP), has 
gained substantial interest, as single nucleotide polymorphisms (SNPs) of this receptor 
have been identified as a risk factor for Crohn´s disease and GvHD. These data suggest 
that MDP sensing by hematopoietic cells is of crucial importance for the immune 
homeostasis in target organs of GvHD, especially in the gastrointestinal tract and/or skin. 
Nevertheless, the exact mechanism by which the mutation in the NOD2 receptor affects 
the outcome of transplantation is not entirely understood. 
In the present work, the impact of NOD2 polymorphisms on the immune cell composition 
in peripheral blood of healthy donors was evaluated. We found that donors with NOD2 
mutations presented differences in their myeloid compartment, with less CD33+ cells (a 
common myeloid marker) and less myeloid dendritic cells (mDCs). A more detailed 
analysis on the monocyte population revealed that donors with SNP12 or SNP13 but not 
SNP8 had increased CD16 expression. CD14+CD16+ monocytes have been identified as 
a major proinflammatory cell population as they exhibit a distinct cytokine secretion 
pattern, with low IL-10 production and high levels of IL-1β, TNF and IL-12. Moreover, it 
has been shown that these monocytes are more efficient antigen-presenting cells than 
their classical counterparts. These results provide a new insight by which NOD2 
polymorphisms can have a modulatory function in the course of inflammation.  
TGF-β is a pleiotropic cytokine with strong regulatory and inflammatory activity. Our 
analysis demonstrated that TGF-β is capable of inducing the expression of CD16 on 
monocytes, independent of the NOD2 status. However, we noticed that the highest 
number of CD14+CD16+ cells was found in donors with SNP12 or 13 mutations. The 
cytokine profile of these cells revealed a decrease in IL-8 secretion by SNP12 or 13 
donors and, although not significant, a strong trend towards an increased IL-6 secretion, 
especially under non-stimulatory conditions. In line with these observations, we analysed 
the expression of iκB and found a constitutive degradation of IκB in one donor with both 
SNP8 and SNP13 mutation, indicating a constitutive activation of the NF-κB pathway. 
The imbalance found in the immune cell composition of the analysed NOD2 SNP donors 
could contribute to the association seen between NOD2 SNPs and HSCT outcome. The 
cellular imbalances reflect at molecular level through pro-inflammatory cytokine 
secretion, and it is believed that a dysregulation on cytokine production provide the first 
mechanism by which NOD2 variants can affect the outcome of HSCT. 
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Beside NOD2 polymorphisms, vitamin D3 receptor gene polymorphisms have also been 
associated with GvHD. Furthermore, it has already been shown that vitamin D3 deficiency 
is a common phenomenon in allogeneic transplant patients and may also be involved in 
the pathogenesis of Crohn’s disease and GvHD. The impact of 1α,25-Dihydroxyvitamin 
D3 (1,25(OH)2D3) on T cells is well documented. It is known that this vitamin is capable of 
inducing FOXP3 expression, a known marker for regulatory T cells. However, the 
majority of the studies make use of high, non-physiological amounts of 1,25(OH)2D3. 
Furthermore, the impact of vitamin D3 on T cells is commonly mediated through the 
action of dendritic cells. In addition, the impact of vitamin D3 precursor, 25(OH)D3 is 
poorly documented.  
In the present work, we demonstrated that T cells are direct targets of vitamin D3. Both 
25(OH)D3 and 1,25 (OH)2D3 were able to upregulate FOXP3 expression on human CD4
+ 
T cells, independent of dendritic cells. Also, we demonstrated a synergistic effect of 
vitamin D3 and TGF-β in the induction of a regulatory phenotype on T cells. Although the 
expression of FOXP3 was not different in cells treated with TGF-β and 1,25(OH)2D3, 
compared with TGF-β alone, cytokine analysis demonstrated an increased IL-10 and 
sCTLA4 in the presence of both stimuli. Furthermore, both 25(OH)D3 and 1,25(OH)2D3 
showed a strong trend in the reduction of IL-17 and IFNγ secretion. 
The use of a vitamin D3 sufficient vs deficient mice model proved to be rather 
inconsistent between the three performed experiments. However, a significant increase 
in the number of myeloid-derived suppressor cells in mice with sufficient levels of vitamin 
D3 was found. Since MDSC were found to ameliorate GvHD and DSS- induced colitis, 
this finding supports the relations found between vitamin D3 status and inflammatory 
conditions.  
The impact of vitamin D3 on microbiome was also analysed and an increased bacterial 
diversity on mice with low levels of vitamin D3 was detected.  Furthermore, a significant 
increase in bacteria from the Akkermansia genus was found in the stool of mice with 
sufficient levels of vitamin D3. These bacteria are known to be capable Treg inducers, 
have proven to be beneficial in colitis and shown to induce the expression of 
antimicrobial peptide Reg3γ in the colon. These data provide further proof on the 
importance of vitamin D3 status on the resolution of inflammatory conditions.
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8. Zusammenfassung 
Die GvHD gilt nach wie vor als die häufigste, lebensbedrohliche Komplikation, die bei 
einer allogenen hämatopoetischen Stammzelltransplantation (HSZT) auftreten kann. 
NOD2/CARD15, ein pathogen-spezifischer Rezeptor im Zytoplasma, der das bakterielle 
Muramyl-Dipeptid (MDP) erkennt, hat zunehmend an Bedeutung gewonnen, da 
Einzelnukleotid-Polymorphismen (SNPs) dieses Rezeptors als Risikofaktor für Morbus 
Crohn und die GvHD gelten. Diese Erkenntnis deutet darauf hin, dass das Erkennen von 
MDP durch hämatopoetische Zellen für die Immunhomeostase in Zielorganen der GvHD, 
wie dem Magen-Darm Trakt und/ oder der Haut, von großer Bedeutung ist. Allerdings ist 
der exakte Mechanismus, auf welche Weise die Mutation im NOD2 Rezeptor den 
Ausgang einer Transplantation beeinflusst, nicht vollständig geklärt. 
In dieser Arbeit wurde deshalb untersucht, wie sich NOD2 Polymorphismen auf die 
Immunzellkomposition im peripheren Blut gesunder Spender auswirken. Spender mit 
einer NOD2 Mutation wiesen Unterschiede in der Zusammensetzung der myeloiden 
Zellen auf, wobei weniger CD33+ Zellen (ein klassischer myeloider Marker) und weniger 
myeloide dendritische Zellen (mDCs) detektiert wurden. Genauere Untersuchungen von 
Spendern mit einer SNP12 oder SNP13, nicht aber mit einer SNP8 Mutation, zeigten 
eine erhöhte CD16 Expression in Monozyten. Aufgrund ihres unterschiedlichen 
Zytokinprofils mit einer geringen IL-10, sowie eine hohe IL-1β, TNF und IL-12 Sekretion, 
gelten CD14+CD16+ Monozyten als die wichtigste proinflammatorische Zellpopulation. Es 
konnte gezeigt werden, dass diese Monozyten im Vergleich zu den klassischen 
Monozyten durch eine effizientere Antigenpräsentation charakterisiert sind. Diese 
Ergebnisse liefern neue Anhaltspunkte, inwieweit NOD2 Polymorphismen modulatorisch 
bei dem Ablauf einer Entzündungsreaktion wirken könnten. 
TGF-β ist ein pleiotropes Zytokin mit stark regulatorischen und inflammatorischen 
Eigenschaften. Analysen im Rahmen dieser Arbeit zeigten, dass TGF-β, unabhängig 
vom NOD2 Status, die CD16 Expression auf Monozyten induzieren kann. In Spendern 
mit einer SNP12 oder SNP13 Mutation war der Effekt jedoch am stärksten und es 
wurden die meisten CD14+CD16+ Zellen detektiert. Das Zytokinprofil von Monozyten 
zeigte eine Reduktion der IL-8 Sekretion in SNP12 oder SNP13 mutierten Spendern und, 
obwohl nicht signifikant, vor allem unter nicht stimulierten Bedingungen trendmäßig eine 
erhöhte IL-6 Sekretion. Aufgrund dieser Beobachtung analysierten wir die Expression 
von iκB und fanden eine starke Reduktion von iκB in einem Spender mit gleichzeitiger 
SNP8 und SNP13 Mutation, was auf eine dauerhafte Aktivierung des NF-κB Signalwegs 
hinweist. 
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Die unterschiedliche Immunzellkomposition in den analysierten NOD2 SNP Spendern 
könnte den beobachteten Zusammenhang zwischen den NOD2 SNPs und dem Ausgang 
einer HSZT erklären, da eine Dysregulation der Zytokinproduktion den ersten Schritt 
darstellt, durch den NOD2-Varianten das Ergebnis einer HSZT beeinflussen könnten. 
Neben dem NOD2 Polymorphismus, wird der Vitamin D3 Rezeptor Polymorphismus 
ebenfalls mit der GvHD in Verbindung gebracht. Es wurde bereits gezeigt, dass ein 
niedriger Vitamin D3 Spiegel in allogen transplantierten Patienten vorherrscht und dass 
dieser eine Rolle in der Pathogenität von Morbus Crohn und der GvHD spielen kann.  
Der Einfluss von 1α,25-Dihydroxyvitamin D3 (1,25(OH)2D3) auf T Zellen wurde in der 
Literatur bereits beschrieben. Es wurde gezeigt, dass dieses Vitamin die Expression von 
FOXP3 induzieren kann, ein klassischer Marker für regulatorische T Zellen. Jedoch 
wurde in einem Großteil der Studien eine sehr hohe, nicht physiologische Konzentration 
an 1,25(OH)2D3 eingesetzt. Zudem wird der Einfluss von Vitamin D3 auf T Zellen oftmals 
indirekt durch die Interaktion mit dendritischen Zellen erklärt. Über den Effekt von 
25(OH)D3, dem Vorläufermolekül von Vitamin D3, ist nur wenig bekannt.  
In dieser Arbeit konnte gezeigt werden, dass Vitamin D3 T Zellen direkt beeinflusst. 
Sowohl 25(OH)D3 als auch 1,25(OH)2D3 waren in der Lage die FOXP3 Expression in 
humanen CD4+ T Zellen zu steigern, unabhängig von der Stimulation durch dendritische 
Zellen. Zudem zeigten wir einen synergistischen Effekt zwischen Vitamin D3 und TGF-β, 
der zur Ausprägung des regulatorischen Phänotyps in T Zellen führte. Obwohl kein 
Unterschied in der FOXP3 Expression in TGF-β und 1,25(OH)2D3 behandelten Zellen im 
Vergleich zu einer Behandlung ausschließlich mit TGF-β bestand, ergab die 
Untersuchung der Zytokine eine erhöhte IL-10 und sCTLA4 Sekretion unter Stimulation 
mit beiden Substanzen. Sowohl 25(OH)D3 als auch 1,25(OH)2D3 führten trendmäßig zu 
einer Reduktion der IL-17 und IFNγ Sekretion.  
Drei Experimente in einem Mausmodell, bei dem eine Diät mit ausreichend viel 
gegenüber zu wenig Vitamin D3 gefüttert wurde, lieferten widersprüchliche Ergebnisse. 
Allerdings nahm die Anzahl der myeloiden Suppressorzellen (MDSC) in Mäusen mit 
ausreichendem Vitamin D3 Spiegel zu. Da MDSCs die Ausprägung einer GvHD und eine 
DSS-induzierte Kolitis abschwächen können, deuten unsere Ergebnisse auf einen 
Zusammenhang zwischen dem Vitamin D3 Status und der Schwere einer Entzündung 
hin. 
Bei der Analyse des Effekts von Vitamin D3 auf das Mikrobiom wurde eine erhöhte 
bakterielle Diversität in Mäusen mit geringem Vitamin D3 Spiegel beobachtet. Außerdem 
wurden signifikant mehr Bakterien der Gattung Akkermansia im Stuhl von Mäusen mit 
ausreichendem Vitamin D3 Spiegel detektiert. Diese Bakterien können die 
Differenzierung von regulatorischen T Zellen auslösen, begünstigen den Ausgang einer 
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Kolitis und steigern die Expression des antimikrobiellen Reg3γ-Peptid im Kolon. Diese 
Ergebnisse deuten auf eine wichtige Rolle des Vitamin D3 Status für die Regulation einer 
Entzündung hin.  
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